#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=White matter changes in treatment refractory schizophrenia: Does cognitive control and myelination matter?
1-1	0-5	White	_	
1-2	6-12	matter	_	
1-3	13-20	changes	_	
1-4	21-23	in	_	
1-5	24-33	treatment	_	
1-6	34-44	refractory	_	
1-7	45-58	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-8	58-59	:	_	
1-9	60-64	Does	_	
1-10	65-74	cognitive	_	
1-11	75-82	control	_	
1-12	83-86	and	_	
1-13	87-98	myelination	_	
1-14	99-105	matter	_	
1-15	105-106	?	_	

#Text=Widespread white matter abnormalities have been reported in schizophrenia, a disorder frequently characterised as a dysconnection syndrome.
2-1	107-117	Widespread	_	
2-2	118-123	white	_	
2-3	124-130	matter	_	
2-4	131-144	abnormalities	_	
2-5	145-149	have	_	
2-6	150-154	been	_	
2-7	155-163	reported	_	
2-8	164-166	in	_	
2-9	167-180	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
2-10	180-181	,	_	
2-11	182-183	a	_	
2-12	184-192	disorder	_	
2-13	193-203	frequently	_	
2-14	204-217	characterised	_	
2-15	218-220	as	_	
2-16	221-222	a	_	
2-17	223-236	dysconnection	_	
2-18	237-245	syndrome	_	
2-19	245-246	.	_	

#Text=White matter connectivity in schizophrenia has been predominantly investigated using diffusion weighted imaging, with reductions in fractional anisotropy throughout the brain often interpreted as an indicator of abnormal myelination.
3-1	247-252	White	_	
3-2	253-259	matter	_	
3-3	260-272	connectivity	_	
3-4	273-275	in	_	
3-5	276-289	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
3-6	290-293	has	_	
3-7	294-298	been	_	
3-8	299-312	predominantly	_	
3-9	313-325	investigated	_	
3-10	326-331	using	_	
3-11	332-341	diffusion	_	
3-12	342-350	weighted	_	
3-13	351-358	imaging	_	
3-14	358-359	,	_	
3-15	360-364	with	_	
3-16	365-375	reductions	_	
3-17	376-378	in	_	
3-18	379-389	fractional	_	
3-19	390-400	anisotropy	_	
3-20	401-411	throughout	_	
3-21	412-415	the	_	
3-22	416-421	brain	_	
3-23	422-427	often	_	
3-24	428-439	interpreted	_	
3-25	440-442	as	_	
3-26	443-445	an	_	
3-27	446-455	indicator	_	
3-28	456-458	of	_	
3-29	459-467	abnormal	_	
3-30	468-479	myelination	_	
3-31	479-480	.	_	

#Text=However, diffusion weighted imaging lacks specificity and as such a number of microstructural factors besides myelin may be contributing to these results.
4-1	481-488	However	_	
4-2	488-489	,	_	
4-3	490-499	diffusion	_	
4-4	500-508	weighted	_	
4-5	509-516	imaging	_	
4-6	517-522	lacks	_	
4-7	523-534	specificity	_	
4-8	535-538	and	_	
4-9	539-541	as	_	
4-10	542-546	such	_	
4-11	547-548	a	_	
4-12	549-555	number	_	
4-13	556-558	of	_	
4-14	559-574	microstructural	_	
4-15	575-582	factors	_	
4-16	583-590	besides	_	
4-17	591-597	myelin	_	
4-18	598-601	may	_	
4-19	602-604	be	_	
4-20	605-617	contributing	_	
4-21	618-620	to	_	
4-22	621-626	these	_	
4-23	627-634	results	_	
4-24	634-635	.	_	

#Text=We utilised multicomponent driven equilibrium single pulse observation of T1 and T2 (mcDESPOT) in medicated patients with chronic schizophrenia, stratified by treatment response status, and healthy controls, in order to assess myelin water fraction (MWF) in these groups.
5-1	636-638	We	_	
5-2	639-647	utilised	_	
5-3	648-662	multicomponent	_	
5-4	663-669	driven	_	
5-5	670-681	equilibrium	_	
5-6	682-688	single	_	
5-7	689-694	pulse	_	
5-8	695-706	observation	_	
5-9	707-709	of	_	
5-10	710-712	T1	_	
5-11	713-716	and	_	
5-12	717-719	T2	_	
5-13	720-721	(	_	
5-14	721-729	mcDESPOT	_	
5-15	729-730	)	_	
5-16	731-733	in	_	
5-17	734-743	medicated	_	
5-18	744-752	patients	_	
5-19	753-757	with	_	
5-20	758-765	chronic	_	
5-21	766-779	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
5-22	779-780	,	_	
5-23	781-791	stratified	_	
5-24	792-794	by	_	
5-25	795-804	treatment	_	
5-26	805-813	response	_	
5-27	814-820	status	_	
5-28	820-821	,	_	
5-29	822-825	and	_	
5-30	826-833	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
5-31	834-842	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
5-32	842-843	,	_	
5-33	844-846	in	_	
5-34	847-852	order	_	
5-35	853-855	to	_	
5-36	856-862	assess	_	
5-37	863-869	myelin	_	
5-38	870-875	water	_	
5-39	876-884	fraction	_	
5-40	885-886	(	_	
5-41	886-889	MWF	_	
5-42	889-890	)	_	
5-43	891-893	in	_	
5-44	894-899	these	_	
5-45	900-906	groups	_	
5-46	906-907	.	_	

#Text=In addition, we assessed cognitive control using the Stroop task to investigate how response inhibition relates to myelination in patients and controls.
6-1	908-910	In	_	
6-2	911-919	addition	_	
6-3	919-920	,	_	
6-4	921-923	we	_	
6-5	924-932	assessed	_	
6-6	933-942	cognitive	_	
6-7	943-950	control	_	
6-8	951-956	using	_	
6-9	957-960	the	_	
6-10	961-967	Stroop	_	
6-11	968-972	task	_	
6-12	973-975	to	_	
6-13	976-987	investigate	_	
6-14	988-991	how	_	
6-15	992-1000	response	_	
6-16	1001-1011	inhibition	_	
6-17	1012-1019	relates	_	
6-18	1020-1022	to	_	
6-19	1023-1034	myelination	_	
6-20	1035-1037	in	_	
6-21	1038-1046	patients	_	
6-22	1047-1050	and	_	
6-23	1051-1059	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
6-24	1059-1060	.	_	

#Text=Both treatment resistant (n = 22) and treatment responsive (n = 21) patients showed reduced MWF compared to healthy controls (n = 24) in bilateral fronto-occipital fasciculi, particularly evident in the vicinity of the striatum und extending to the cerebellum, with no difference between patient groups.
7-1	1061-1065	Both	_	
7-2	1066-1075	treatment	_	
7-3	1076-1085	resistant	_	
7-4	1086-1087	(	_	
7-5	1087-1088	n	_	
7-6	1088-1089	 	_	
7-7	1089-1090	=	_	
7-8	1090-1091	 	_	
7-9	1091-1093	22	_	
7-10	1093-1094	)	_	
7-11	1095-1098	and	_	
7-12	1099-1108	treatment	_	
7-13	1109-1119	responsive	_	
7-14	1120-1121	(	_	
7-15	1121-1122	n	_	
7-16	1122-1123	 	_	
7-17	1123-1124	=	_	
7-18	1124-1125	 	_	
7-19	1125-1127	21	_	
7-20	1127-1128	)	_	
7-21	1129-1137	patients	_	
7-22	1138-1144	showed	_	
7-23	1145-1152	reduced	_	
7-24	1153-1156	MWF	_	
7-25	1157-1165	compared	_	
7-26	1166-1168	to	_	
7-27	1169-1176	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]	
7-28	1177-1185	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]	
7-29	1186-1187	(	_	
7-30	1187-1188	n	_	
7-31	1188-1189	 	_	
7-32	1189-1190	=	_	
7-33	1190-1191	 	_	
7-34	1191-1193	24	_	
7-35	1193-1194	)	_	
7-36	1195-1197	in	_	
7-37	1198-1207	bilateral	_	
7-38	1208-1224	fronto-occipital	_	
7-39	1225-1234	fasciculi	_	
7-40	1234-1235	,	_	
7-41	1236-1248	particularly	_	
7-42	1249-1256	evident	_	
7-43	1257-1259	in	_	
7-44	1260-1263	the	_	
7-45	1264-1272	vicinity	_	
7-46	1273-1275	of	_	
7-47	1276-1279	the	_	
7-48	1280-1288	striatum	_	
7-49	1289-1292	und	_	
7-50	1293-1302	extending	_	
7-51	1303-1305	to	_	
7-52	1306-1309	the	_	
7-53	1310-1320	cerebellum	_	
7-54	1320-1321	,	_	
7-55	1322-1326	with	_	
7-56	1327-1329	no	_	
7-57	1330-1340	difference	_	
7-58	1341-1348	between	_	
7-59	1349-1356	patient	_	
7-60	1357-1363	groups	_	
7-61	1363-1364	.	_	

#Text=Patients showed greater reaction time interference on the Stroop task compared to healthy controls, with no difference between patient groups.
8-1	1365-1373	Patients	_	
8-2	1374-1380	showed	_	
8-3	1381-1388	greater	_	
8-4	1389-1397	reaction	_	
8-5	1398-1402	time	_	
8-6	1403-1415	interference	_	
8-7	1416-1418	on	_	
8-8	1419-1422	the	_	
8-9	1423-1429	Stroop	_	
8-10	1430-1434	task	_	
8-11	1435-1443	compared	_	
8-12	1444-1446	to	_	
8-13	1447-1454	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
8-14	1455-1463	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
8-15	1463-1464	,	_	
8-16	1465-1469	with	_	
8-17	1470-1472	no	_	
8-18	1473-1483	difference	_	
8-19	1484-1491	between	_	
8-20	1492-1499	patient	_	
8-21	1500-1506	groups	_	
8-22	1506-1507	.	_	

#Text=Stroop interference was significantly negatively correlated with MWF in the corpus callosum across groups, and MWF differences in this region mediated the behavioural group effects on the Stroop task.
9-1	1508-1514	Stroop	_	
9-2	1515-1527	interference	_	
9-3	1528-1531	was	_	
9-4	1532-1545	significantly	_	
9-5	1546-1556	negatively	_	
9-6	1557-1567	correlated	_	
9-7	1568-1572	with	_	
9-8	1573-1576	MWF	_	
9-9	1577-1579	in	_	
9-10	1580-1583	the	_	
9-11	1584-1590	corpus	_	
9-12	1591-1599	callosum	_	
9-13	1600-1606	across	_	
9-14	1607-1613	groups	_	
9-15	1613-1614	,	_	
9-16	1615-1618	and	_	
9-17	1619-1622	MWF	_	
9-18	1623-1634	differences	_	
9-19	1635-1637	in	_	
9-20	1638-1642	this	_	
9-21	1643-1649	region	_	
9-22	1650-1658	mediated	_	
9-23	1659-1662	the	_	
9-24	1663-1674	behavioural	_	
9-25	1675-1680	group	_	
9-26	1681-1688	effects	_	
9-27	1689-1691	on	_	
9-28	1692-1695	the	_	
9-29	1696-1702	Stroop	_	
9-30	1703-1707	task	_	
9-31	1707-1708	.	_	

#Text=These findings support the suitability of mcDESPOT as a myelin-specific measure of abnormal connectivity in schizophrenia, and suggest that treatment resistant schizophrenia is not characterised by more severe abnormalities in myelination or cognitive control compared to treatment responsive schizophrenia.
10-1	1709-1714	These	_	
10-2	1715-1723	findings	_	
10-3	1724-1731	support	_	
10-4	1732-1735	the	_	
10-5	1736-1747	suitability	_	
10-6	1748-1750	of	_	
10-7	1751-1759	mcDESPOT	_	
10-8	1760-1762	as	_	
10-9	1763-1764	a	_	
10-10	1765-1780	myelin-specific	_	
10-11	1781-1788	measure	_	
10-12	1789-1791	of	_	
10-13	1792-1800	abnormal	_	
10-14	1801-1813	connectivity	_	
10-15	1814-1816	in	_	
10-16	1817-1830	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
10-17	1830-1831	,	_	
10-18	1832-1835	and	_	
10-19	1836-1843	suggest	_	
10-20	1844-1848	that	_	
10-21	1849-1858	treatment	_	
10-22	1859-1868	resistant	_	
10-23	1869-1882	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
10-24	1883-1885	is	_	
10-25	1886-1889	not	_	
10-26	1890-1903	characterised	_	
10-27	1904-1906	by	_	
10-28	1907-1911	more	_	
10-29	1912-1918	severe	_	
10-30	1919-1932	abnormalities	_	
10-31	1933-1935	in	_	
10-32	1936-1947	myelination	_	
10-33	1948-1950	or	_	
10-34	1951-1960	cognitive	_	
10-35	1961-1968	control	_	
10-36	1969-1977	compared	_	
10-37	1978-1980	to	_	
10-38	1981-1990	treatment	_	
10-39	1991-2001	responsive	_	
10-40	2002-2015	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
10-41	2015-2016	.	_	

#Text=Highlights
#Text=Treatment resistant and responsive schizophrenia patients show reduced myelin water fraction compared to healthy controls
#Text=Myelin water fraction in the corpus callosum is related to performance on a cognitive control task
#Text=Myelin water fraction in the corpus callosum mediates differences in a cognitive control task between patients and controls
#Text=Introduction
#Text=Schizophrenia, a debilitating psychotic disorder, has been widely described in terms of a dysconnection syndrome.
11-1	2017-2027	Highlights	_	
11-2	2028-2037	Treatment	_	
11-3	2038-2047	resistant	_	
11-4	2048-2051	and	_	
11-5	2052-2062	responsive	_	
11-6	2063-2076	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
11-7	2077-2085	patients	_	
11-8	2086-2090	show	_	
11-9	2091-2098	reduced	_	
11-10	2099-2105	myelin	_	
11-11	2106-2111	water	_	
11-12	2112-2120	fraction	_	
11-13	2121-2129	compared	_	
11-14	2130-2132	to	_	
11-15	2133-2140	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]	
11-16	2141-2149	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]	
11-17	2150-2156	Myelin	_	
11-18	2157-2162	water	_	
11-19	2163-2171	fraction	_	
11-20	2172-2174	in	_	
11-21	2175-2178	the	_	
11-22	2179-2185	corpus	_	
11-23	2186-2194	callosum	_	
11-24	2195-2197	is	_	
11-25	2198-2205	related	_	
11-26	2206-2208	to	_	
11-27	2209-2220	performance	_	
11-28	2221-2223	on	_	
11-29	2224-2225	a	_	
11-30	2226-2235	cognitive	_	
11-31	2236-2243	control	_	
11-32	2244-2248	task	_	
11-33	2249-2255	Myelin	_	
11-34	2256-2261	water	_	
11-35	2262-2270	fraction	_	
11-36	2271-2273	in	_	
11-37	2274-2277	the	_	
11-38	2278-2284	corpus	_	
11-39	2285-2293	callosum	_	
11-40	2294-2302	mediates	_	
11-41	2303-2314	differences	_	
11-42	2315-2317	in	_	
11-43	2318-2319	a	_	
11-44	2320-2329	cognitive	_	
11-45	2330-2337	control	_	
11-46	2338-2342	task	_	
11-47	2343-2350	between	_	
11-48	2351-2359	patients	_	
11-49	2360-2363	and	_	
11-50	2364-2372	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
11-51	2373-2385	Introduction	_	
11-52	2386-2399	Schizophrenia	_	
11-53	2399-2400	,	_	
11-54	2401-2402	a	_	
11-55	2403-2415	debilitating	_	
11-56	2416-2425	psychotic	_	
11-57	2426-2434	disorder	_	
11-58	2434-2435	,	_	
11-59	2436-2439	has	_	
11-60	2440-2444	been	_	
11-61	2445-2451	widely	_	
11-62	2452-2461	described	_	
11-63	2462-2464	in	_	
11-64	2465-2470	terms	_	
11-65	2471-2473	of	_	
11-66	2474-2475	a	_	
11-67	2476-2489	dysconnection	_	
11-68	2490-2498	syndrome	_	
11-69	2498-2499	.	_	

#Text=Symptoms of psychosis, including delusions and hallucinations, are in part suggested to emerge as a result of inadequate integration of neural processes in the brain.
12-1	2500-2508	Symptoms	_	
12-2	2509-2511	of	_	
12-3	2512-2521	psychosis	_	
12-4	2521-2522	,	_	
12-5	2523-2532	including	_	
12-6	2533-2542	delusions	_	
12-7	2543-2546	and	_	
12-8	2547-2561	hallucinations	_	
12-9	2561-2562	,	_	
12-10	2563-2566	are	_	
12-11	2567-2569	in	_	
12-12	2570-2574	part	_	
12-13	2575-2584	suggested	_	
12-14	2585-2587	to	_	
12-15	2588-2594	emerge	_	
12-16	2595-2597	as	_	
12-17	2598-2599	a	_	
12-18	2600-2606	result	_	
12-19	2607-2609	of	_	
12-20	2610-2620	inadequate	_	
12-21	2621-2632	integration	_	
12-22	2633-2635	of	_	
12-23	2636-2642	neural	_	
12-24	2643-2652	processes	_	
12-25	2653-2655	in	_	
12-26	2656-2659	the	_	
12-27	2660-2665	brain	_	
12-28	2665-2666	.	_	

#Text=Both functional and structural connectivity dysfunctions have been observed in schizophrenia and it is by now widely established that white matter abnormalities are pervasive in the disorder.
13-1	2667-2671	Both	_	
13-2	2672-2682	functional	_	
13-3	2683-2686	and	_	
13-4	2687-2697	structural	_	
13-5	2698-2710	connectivity	_	
13-6	2711-2723	dysfunctions	_	
13-7	2724-2728	have	_	
13-8	2729-2733	been	_	
13-9	2734-2742	observed	_	
13-10	2743-2745	in	_	
13-11	2746-2759	schizophrenia	_	
13-12	2760-2763	and	_	
13-13	2764-2766	it	_	
13-14	2767-2769	is	_	
13-15	2770-2772	by	_	
13-16	2773-2776	now	_	
13-17	2777-2783	widely	_	
13-18	2784-2795	established	_	
13-19	2796-2800	that	_	
13-20	2801-2806	white	_	
13-21	2807-2813	matter	_	
13-22	2814-2827	abnormalities	_	
13-23	2828-2831	are	_	
13-24	2832-2841	pervasive	_	
13-25	2842-2844	in	_	
13-26	2845-2848	the	_	
13-27	2849-2857	disorder	_	
13-28	2857-2858	.	_	

#Text=These have been shown to be associated with abnormal functional activation and connectivity as well as symptoms.
14-1	2859-2864	These	_	
14-2	2865-2869	have	_	
14-3	2870-2874	been	_	
14-4	2875-2880	shown	_	
14-5	2881-2883	to	_	
14-6	2884-2886	be	_	
14-7	2887-2897	associated	_	
14-8	2898-2902	with	_	
14-9	2903-2911	abnormal	_	
14-10	2912-2922	functional	_	
14-11	2923-2933	activation	_	
14-12	2934-2937	and	_	
14-13	2938-2950	connectivity	_	
14-14	2951-2953	as	_	
14-15	2954-2958	well	_	
14-16	2959-2961	as	_	
14-17	2962-2970	symptoms	_	
14-18	2970-2971	.	_	

#Text=The most consistent findings show white matter changes in frontal and temporal lobes, as well as in the corpus callosum and internal capsule.
15-1	2972-2975	The	_	
15-2	2976-2980	most	_	
15-3	2981-2991	consistent	_	
15-4	2992-3000	findings	_	
15-5	3001-3005	show	_	
15-6	3006-3011	white	_	
15-7	3012-3018	matter	_	
15-8	3019-3026	changes	_	
15-9	3027-3029	in	_	
15-10	3030-3037	frontal	_	
15-11	3038-3041	and	_	
15-12	3042-3050	temporal	_	
15-13	3051-3056	lobes	_	
15-14	3056-3057	,	_	
15-15	3058-3060	as	_	
15-16	3061-3065	well	_	
15-17	3066-3068	as	_	
15-18	3069-3071	in	_	
15-19	3072-3075	the	_	
15-20	3076-3082	corpus	_	
15-21	3083-3091	callosum	_	
15-22	3092-3095	and	_	
15-23	3096-3104	internal	_	
15-24	3105-3112	capsule	_	
15-25	3112-3113	.	_	

#Text=Symptoms of psychosis are treated with antipsychotics which act via subcortical dopamine receptor blockade.
16-1	3114-3122	Symptoms	_	
16-2	3123-3125	of	_	
16-3	3126-3135	psychosis	_	
16-4	3136-3139	are	_	
16-5	3140-3147	treated	_	
16-6	3148-3152	with	_	
16-7	3153-3167	antipsychotics	_	
16-8	3168-3173	which	_	
16-9	3174-3177	act	_	
16-10	3178-3181	via	_	
16-11	3182-3193	subcortical	_	
16-12	3194-3202	dopamine	_	
16-13	3203-3211	receptor	_	
16-14	3212-3220	blockade	_	
16-15	3220-3221	.	_	

#Text=However, symptomatic non-response to treatment remains an area of unmet clinical need, with around 30% of patients with a diagnosis of schizophrenia showing inadequate response despite optimal treatment.
17-1	3222-3229	However	_	
17-2	3229-3230	,	_	
17-3	3231-3242	symptomatic	_	
17-4	3243-3255	non-response	_	
17-5	3256-3258	to	_	
17-6	3259-3268	treatment	_	
17-7	3269-3276	remains	_	
17-8	3277-3279	an	_	
17-9	3280-3284	area	_	
17-10	3285-3287	of	_	
17-11	3288-3293	unmet	_	
17-12	3294-3302	clinical	_	
17-13	3303-3307	need	_	
17-14	3307-3308	,	_	
17-15	3309-3313	with	_	
17-16	3314-3320	around	_	
17-17	3321-3324	30%	_	
17-18	3325-3327	of	_	
17-19	3328-3336	patients	_	
17-20	3337-3341	with	_	
17-21	3342-3343	a	_	
17-22	3344-3353	diagnosis	_	
17-23	3354-3356	of	_	
17-24	3357-3370	schizophrenia	_	
17-25	3371-3378	showing	_	
17-26	3379-3389	inadequate	_	
17-27	3390-3398	response	_	
17-28	3399-3406	despite	_	
17-29	3407-3414	optimal	_	
17-30	3415-3424	treatment	_	
17-31	3424-3425	.	_	

#Text=It is likely that this form of “treatment-resistant” schizophrenia (TRS) differs in terms of its underlying neurobiology from treatment responsive schizophrenia.
18-1	3426-3428	It	_	
18-2	3429-3431	is	_	
18-3	3432-3438	likely	_	
18-4	3439-3443	that	_	
18-5	3444-3448	this	_	
18-6	3449-3453	form	_	
18-7	3454-3456	of	_	
18-8	3457-3458	“	_	
18-9	3458-3477	treatment-resistant	_	
18-10	3477-3478	”	_	
18-11	3479-3492	schizophrenia	_	
18-12	3493-3494	(	_	
18-13	3494-3497	TRS	_	
18-14	3497-3498	)	_	
18-15	3499-3506	differs	_	
18-16	3507-3509	in	_	
18-17	3510-3515	terms	_	
18-18	3516-3518	of	_	
18-19	3519-3522	its	_	
18-20	3523-3533	underlying	_	
18-21	3534-3546	neurobiology	_	
18-22	3547-3551	from	_	
18-23	3552-3561	treatment	_	
18-24	3562-3572	responsive	_	
18-25	3573-3586	schizophrenia	_	
18-26	3586-3587	.	_	

#Text=As a result, antipsychotic medication acting on the dopamine system may not be targeting the underlying cause of psychosis in TRS patients.
19-1	3588-3590	As	_	
19-2	3591-3592	a	_	
19-3	3593-3599	result	_	
19-4	3599-3600	,	_	
19-5	3601-3614	antipsychotic	_	
19-6	3615-3625	medication	_	
19-7	3626-3632	acting	_	
19-8	3633-3635	on	_	
19-9	3636-3639	the	_	
19-10	3640-3648	dopamine	_	
19-11	3649-3655	system	_	
19-12	3656-3659	may	_	
19-13	3660-3663	not	_	
19-14	3664-3666	be	_	
19-15	3667-3676	targeting	_	
19-16	3677-3680	the	_	
19-17	3681-3691	underlying	_	
19-18	3692-3697	cause	_	
19-19	3698-3700	of	_	
19-20	3701-3710	psychosis	_	
19-21	3711-3713	in	_	
19-22	3714-3717	TRS	_	
19-23	3718-3726	patients	_	
19-24	3726-3727	.	_	

#Text=It has been suggested that TRS is characterised by more severe or distinct patterns of structural dysconnectivity compared to treatment responsive schizophrenia, resulting in more severe cognitive deficits and psychotic symptoms.
20-1	3728-3730	It	_	
20-2	3731-3734	has	_	
20-3	3735-3739	been	_	
20-4	3740-3749	suggested	_	
20-5	3750-3754	that	_	
20-6	3755-3758	TRS	_	
20-7	3759-3761	is	_	
20-8	3762-3775	characterised	_	
20-9	3776-3778	by	_	
20-10	3779-3783	more	_	
20-11	3784-3790	severe	_	
20-12	3791-3793	or	_	
20-13	3794-3802	distinct	_	
20-14	3803-3811	patterns	_	
20-15	3812-3814	of	_	
20-16	3815-3825	structural	_	
20-17	3826-3841	dysconnectivity	_	
20-18	3842-3850	compared	_	
20-19	3851-3853	to	_	
20-20	3854-3863	treatment	_	
20-21	3864-3874	responsive	_	
20-22	3875-3888	schizophrenia	_	
20-23	3888-3889	,	_	
20-24	3890-3899	resulting	_	
20-25	3900-3902	in	_	
20-26	3903-3907	more	_	
20-27	3908-3914	severe	_	
20-28	3915-3924	cognitive	_	
20-29	3925-3933	deficits	_	
20-30	3934-3937	and	_	
20-31	3938-3947	psychotic	_	
20-32	3948-3956	symptoms	_	
20-33	3956-3957	.	_	

#Text=An association between good treatment response and improved white matter integrity has been previously shown, however it is unclear how myelination specifically relates to cognitive performance in schizophrenia as a function of treatment response.
21-1	3958-3960	An	_	
21-2	3961-3972	association	_	
21-3	3973-3980	between	_	
21-4	3981-3985	good	_	
21-5	3986-3995	treatment	_	
21-6	3996-4004	response	_	
21-7	4005-4008	and	_	
21-8	4009-4017	improved	_	
21-9	4018-4023	white	_	
21-10	4024-4030	matter	_	
21-11	4031-4040	integrity	_	
21-12	4041-4044	has	_	
21-13	4045-4049	been	_	
21-14	4050-4060	previously	_	
21-15	4061-4066	shown	_	
21-16	4066-4067	,	_	
21-17	4068-4075	however	_	
21-18	4076-4078	it	_	
21-19	4079-4081	is	_	
21-20	4082-4089	unclear	_	
21-21	4090-4093	how	_	
21-22	4094-4105	myelination	_	
21-23	4106-4118	specifically	_	
21-24	4119-4126	relates	_	
21-25	4127-4129	to	_	
21-26	4130-4139	cognitive	_	
21-27	4140-4151	performance	_	
21-28	4152-4154	in	_	
21-29	4155-4168	schizophrenia	_	
21-30	4169-4171	as	_	
21-31	4172-4173	a	_	
21-32	4174-4182	function	_	
21-33	4183-4185	of	_	
21-34	4186-4195	treatment	_	
21-35	4196-4204	response	_	
21-36	4204-4205	.	_	

#Text=Overall there is a large body of evidence suggesting that patients with schizophrenia show widespread decreases in white matter integrity, usually on the basis of diffusion weighted imaging.
22-1	4206-4213	Overall	_	
22-2	4214-4219	there	_	
22-3	4220-4222	is	_	
22-4	4223-4224	a	_	
22-5	4225-4230	large	_	
22-6	4231-4235	body	_	
22-7	4236-4238	of	_	
22-8	4239-4247	evidence	_	
22-9	4248-4258	suggesting	_	
22-10	4259-4263	that	_	
22-11	4264-4272	patients	_	
22-12	4273-4277	with	_	
22-13	4278-4291	schizophrenia	_	
22-14	4292-4296	show	_	
22-15	4297-4307	widespread	_	
22-16	4308-4317	decreases	_	
22-17	4318-4320	in	_	
22-18	4321-4326	white	_	
22-19	4327-4333	matter	_	
22-20	4334-4343	integrity	_	
22-21	4343-4344	,	_	
22-22	4345-4352	usually	_	
22-23	4353-4355	on	_	
22-24	4356-4359	the	_	
22-25	4360-4365	basis	_	
22-26	4366-4368	of	_	
22-27	4369-4378	diffusion	_	
22-28	4379-4387	weighted	_	
22-29	4388-4395	imaging	_	
22-30	4395-4396	.	_	

#Text=The most commonly reported measure is fractional anisotropy (FA), which indexes the degree of directionality of diffusing water molecules.
23-1	4397-4400	The	_	
23-2	4401-4405	most	_	
23-3	4406-4414	commonly	_	
23-4	4415-4423	reported	_	
23-5	4424-4431	measure	_	
23-6	4432-4434	is	_	
23-7	4435-4445	fractional	_	
23-8	4446-4456	anisotropy	_	
23-9	4457-4458	(	_	
23-10	4458-4460	FA	_	
23-11	4460-4461	)	_	
23-12	4461-4462	,	_	
23-13	4463-4468	which	_	
23-14	4469-4476	indexes	_	
23-15	4477-4480	the	_	
23-16	4481-4487	degree	_	
23-17	4488-4490	of	_	
23-18	4491-4505	directionality	_	
23-19	4506-4508	of	_	
23-20	4509-4518	diffusing	_	
23-21	4519-4524	water	_	
23-22	4525-4534	molecules	_	
23-23	4534-4535	.	_	

#Text=Changes in FA are attributed to changes in the microstructure of white matter tracts; however, these could in effect be indicators of numerous underlying features such as myelination, axon diameter, fibre density, axon number, or axonal membrane integrity.
24-1	4536-4543	Changes	_	
24-2	4544-4546	in	_	
24-3	4547-4549	FA	_	
24-4	4550-4553	are	_	
24-5	4554-4564	attributed	_	
24-6	4565-4567	to	_	
24-7	4568-4575	changes	_	
24-8	4576-4578	in	_	
24-9	4579-4582	the	_	
24-10	4583-4597	microstructure	_	
24-11	4598-4600	of	_	
24-12	4601-4606	white	_	
24-13	4607-4613	matter	_	
24-14	4614-4620	tracts	_	
24-15	4620-4621	;	_	
24-16	4622-4629	however	_	
24-17	4629-4630	,	_	
24-18	4631-4636	these	_	
24-19	4637-4642	could	_	
24-20	4643-4645	in	_	
24-21	4646-4652	effect	_	
24-22	4653-4655	be	_	
24-23	4656-4666	indicators	_	
24-24	4667-4669	of	_	
24-25	4670-4678	numerous	_	
24-26	4679-4689	underlying	_	
24-27	4690-4698	features	_	
24-28	4699-4703	such	_	
24-29	4704-4706	as	_	
24-30	4707-4718	myelination	_	
24-31	4718-4719	,	_	
24-32	4720-4724	axon	_	
24-33	4725-4733	diameter	_	
24-34	4733-4734	,	_	
24-35	4735-4740	fibre	_	
24-36	4741-4748	density	_	
24-37	4748-4749	,	_	
24-38	4750-4754	axon	_	
24-39	4755-4761	number	_	
24-40	4761-4762	,	_	
24-41	4763-4765	or	_	
24-42	4766-4772	axonal	_	
24-43	4773-4781	membrane	_	
24-44	4782-4791	integrity	_	
24-45	4791-4792	.	_	

#Text=Multicomponent driven equilibrium single pulse observation of T1 and T2 (mcDESPOT) is a recently developed imaging technique which allows for the derivation of a whole-brain myelin water fraction (MWF) map with rapid acquisition times.
25-1	4793-4807	Multicomponent	_	
25-2	4808-4814	driven	_	
25-3	4815-4826	equilibrium	_	
25-4	4827-4833	single	_	
25-5	4834-4839	pulse	_	
25-6	4840-4851	observation	_	
25-7	4852-4854	of	_	
25-8	4855-4857	T1	_	
25-9	4858-4861	and	_	
25-10	4862-4864	T2	_	
25-11	4865-4866	(	_	
25-12	4866-4874	mcDESPOT	_	
25-13	4874-4875	)	_	
25-14	4876-4878	is	_	
25-15	4879-4880	a	_	
25-16	4881-4889	recently	_	
25-17	4890-4899	developed	_	
25-18	4900-4907	imaging	_	
25-19	4908-4917	technique	_	
25-20	4918-4923	which	_	
25-21	4924-4930	allows	_	
25-22	4931-4934	for	_	
25-23	4935-4938	the	_	
25-24	4939-4949	derivation	_	
25-25	4950-4952	of	_	
25-26	4953-4954	a	_	
25-27	4955-4966	whole-brain	_	
25-28	4967-4973	myelin	_	
25-29	4974-4979	water	_	
25-30	4980-4988	fraction	_	
25-31	4989-4990	(	_	
25-32	4990-4993	MWF	_	
25-33	4993-4994	)	_	
25-34	4995-4998	map	_	
25-35	4999-5003	with	_	
25-36	5004-5009	rapid	_	
25-37	5010-5021	acquisition	_	
25-38	5022-5027	times	_	
25-39	5027-5028	.	_	

#Text=As a metric for the fraction of water trapped between the myelin sheaths around the neuronal axons, MWF has been shown to correlate strongly with histological measures of myelin content, and to provide higher specificity to myelin content as compared with diffusion measures.
26-1	5029-5031	As	_	
26-2	5032-5033	a	_	
26-3	5034-5040	metric	_	
26-4	5041-5044	for	_	
26-5	5045-5048	the	_	
26-6	5049-5057	fraction	_	
26-7	5058-5060	of	_	
26-8	5061-5066	water	_	
26-9	5067-5074	trapped	_	
26-10	5075-5082	between	_	
26-11	5083-5086	the	_	
26-12	5087-5093	myelin	_	
26-13	5094-5101	sheaths	_	
26-14	5102-5108	around	_	
26-15	5109-5112	the	_	
26-16	5113-5121	neuronal	_	
26-17	5122-5127	axons	_	
26-18	5127-5128	,	_	
26-19	5129-5132	MWF	_	
26-20	5133-5136	has	_	
26-21	5137-5141	been	_	
26-22	5142-5147	shown	_	
26-23	5148-5150	to	_	
26-24	5151-5160	correlate	_	
26-25	5161-5169	strongly	_	
26-26	5170-5174	with	_	
26-27	5175-5187	histological	_	
26-28	5188-5196	measures	_	
26-29	5197-5199	of	_	
26-30	5200-5206	myelin	_	
26-31	5207-5214	content	_	
26-32	5214-5215	,	_	
26-33	5216-5219	and	_	
26-34	5220-5222	to	_	
26-35	5223-5230	provide	_	
26-36	5231-5237	higher	_	
26-37	5238-5249	specificity	_	
26-38	5250-5252	to	_	
26-39	5253-5259	myelin	_	
26-40	5260-5267	content	_	
26-41	5268-5270	as	_	
26-42	5271-5279	compared	_	
26-43	5280-5284	with	_	
26-44	5285-5294	diffusion	_	
26-45	5295-5303	measures	_	
26-46	5303-5304	.	_	

#Text=Here we report the first study utilising mcDESPOT in a sample of patients with a diagnosis of schizophrenia, stratified by treatment response status, and a healthy control sample.
27-1	5305-5309	Here	_	
27-2	5310-5312	we	_	
27-3	5313-5319	report	_	
27-4	5320-5323	the	_	
27-5	5324-5329	first	_	
27-6	5330-5335	study	_	
27-7	5336-5345	utilising	_	
27-8	5346-5354	mcDESPOT	_	
27-9	5355-5357	in	_	
27-10	5358-5359	a	_	
27-11	5360-5366	sample	_	
27-12	5367-5369	of	_	
27-13	5370-5378	patients	_	
27-14	5379-5383	with	_	
27-15	5384-5385	a	_	
27-16	5386-5395	diagnosis	_	
27-17	5396-5398	of	_	
27-18	5399-5412	schizophrenia	_	
27-19	5412-5413	,	_	
27-20	5414-5424	stratified	_	
27-21	5425-5427	by	_	
27-22	5428-5437	treatment	_	
27-23	5438-5446	response	_	
27-24	5447-5453	status	_	
27-25	5453-5454	,	_	
27-26	5455-5458	and	_	
27-27	5459-5460	a	_	
27-28	5461-5468	healthy	_	
27-29	5469-5476	control	_	
27-30	5477-5483	sample	_	
27-31	5483-5484	.	_	

#Text=In order to assess the relationship between myelination, treatment response, and cognitive function, we included a basic measure of executive control, the Stroop task.
28-1	5485-5487	In	_	
28-2	5488-5493	order	_	
28-3	5494-5496	to	_	
28-4	5497-5503	assess	_	
28-5	5504-5507	the	_	
28-6	5508-5520	relationship	_	
28-7	5521-5528	between	_	
28-8	5529-5540	myelination	_	
28-9	5540-5541	,	_	
28-10	5542-5551	treatment	_	
28-11	5552-5560	response	_	
28-12	5560-5561	,	_	
28-13	5562-5565	and	_	
28-14	5566-5575	cognitive	_	
28-15	5576-5584	function	_	
28-16	5584-5585	,	_	
28-17	5586-5588	we	_	
28-18	5589-5597	included	_	
28-19	5598-5599	a	_	
28-20	5600-5605	basic	_	
28-21	5606-5613	measure	_	
28-22	5614-5616	of	_	
28-23	5617-5626	executive	_	
28-24	5627-5634	control	_	
28-25	5634-5635	,	_	
28-26	5636-5639	the	_	
28-27	5640-5646	Stroop	_	
28-28	5647-5651	task	_	
28-29	5651-5652	.	_	

#Text=The task was chosen as it represents a widely used measure of executive control, which is known to be impaired in schizophrenia and has been shown to be related to functional outcome.
29-1	5653-5656	The	_	
29-2	5657-5661	task	_	
29-3	5662-5665	was	_	
29-4	5666-5672	chosen	_	
29-5	5673-5675	as	_	
29-6	5676-5678	it	_	
29-7	5679-5689	represents	_	
29-8	5690-5691	a	_	
29-9	5692-5698	widely	_	
29-10	5699-5703	used	_	
29-11	5704-5711	measure	_	
29-12	5712-5714	of	_	
29-13	5715-5724	executive	_	
29-14	5725-5732	control	_	
29-15	5732-5733	,	_	
29-16	5734-5739	which	_	
29-17	5740-5742	is	_	
29-18	5743-5748	known	_	
29-19	5749-5751	to	_	
29-20	5752-5754	be	_	
29-21	5755-5763	impaired	_	
29-22	5764-5766	in	_	
29-23	5767-5780	schizophrenia	_	
29-24	5781-5784	and	_	
29-25	5785-5788	has	_	
29-26	5789-5793	been	_	
29-27	5794-5799	shown	_	
29-28	5800-5802	to	_	
29-29	5803-5805	be	_	
29-30	5806-5813	related	_	
29-31	5814-5816	to	_	
29-32	5817-5827	functional	_	
29-33	5828-5835	outcome	_	
29-34	5835-5836	.	_	

#Text=Impaired performance on the Stroop task in patients with schizophrenia was confirmed in a recent meta-analysis.
30-1	5837-5845	Impaired	_	
30-2	5846-5857	performance	_	
30-3	5858-5860	on	_	
30-4	5861-5864	the	_	
30-5	5865-5871	Stroop	_	
30-6	5872-5876	task	_	
30-7	5877-5879	in	_	
30-8	5880-5888	patients	_	
30-9	5889-5893	with	_	
30-10	5894-5907	schizophrenia	_	
30-11	5908-5911	was	_	
30-12	5912-5921	confirmed	_	
30-13	5922-5924	in	_	
30-14	5925-5926	a	_	
30-15	5927-5933	recent	_	
30-16	5934-5947	meta-analysis	_	
30-17	5947-5948	.	_	

#Text=The aims of this study were 1) to test the utility of mcDESPOT in detecting differences in myelination between patients with schizophrenia and healthy controls, 2) to investigate whether differences in myelination may account for differences in response to antipsychotic treatment, 3) to explore whether myelin content as measured by mcDESPOT modulates behavioural performance on a cognitive control task and 4) if this is differentially impacted across treatment refractory and treatment responsive patients with schizophrenia.
31-1	5949-5952	The	_	
31-2	5953-5957	aims	_	
31-3	5958-5960	of	_	
31-4	5961-5965	this	_	
31-5	5966-5971	study	_	
31-6	5972-5976	were	_	
31-7	5977-5978	1	_	
31-8	5978-5979	)	_	
31-9	5980-5982	to	_	
31-10	5983-5987	test	_	
31-11	5988-5991	the	_	
31-12	5992-5999	utility	_	
31-13	6000-6002	of	_	
31-14	6003-6011	mcDESPOT	_	
31-15	6012-6014	in	_	
31-16	6015-6024	detecting	_	
31-17	6025-6036	differences	_	
31-18	6037-6039	in	_	
31-19	6040-6051	myelination	_	
31-20	6052-6059	between	_	
31-21	6060-6068	patients	_	
31-22	6069-6073	with	_	
31-23	6074-6087	schizophrenia	_	
31-24	6088-6091	and	_	
31-25	6092-6099	healthy	_	
31-26	6100-6108	controls	_	
31-27	6108-6109	,	_	
31-28	6110-6111	2	_	
31-29	6111-6112	)	_	
31-30	6113-6115	to	_	
31-31	6116-6127	investigate	_	
31-32	6128-6135	whether	_	
31-33	6136-6147	differences	_	
31-34	6148-6150	in	_	
31-35	6151-6162	myelination	_	
31-36	6163-6166	may	_	
31-37	6167-6174	account	_	
31-38	6175-6178	for	_	
31-39	6179-6190	differences	_	
31-40	6191-6193	in	_	
31-41	6194-6202	response	_	
31-42	6203-6205	to	_	
31-43	6206-6219	antipsychotic	_	
31-44	6220-6229	treatment	_	
31-45	6229-6230	,	_	
31-46	6231-6232	3	_	
31-47	6232-6233	)	_	
31-48	6234-6236	to	_	
31-49	6237-6244	explore	_	
31-50	6245-6252	whether	_	
31-51	6253-6259	myelin	_	
31-52	6260-6267	content	_	
31-53	6268-6270	as	_	
31-54	6271-6279	measured	_	
31-55	6280-6282	by	_	
31-56	6283-6291	mcDESPOT	_	
31-57	6292-6301	modulates	_	
31-58	6302-6313	behavioural	_	
31-59	6314-6325	performance	_	
31-60	6326-6328	on	_	
31-61	6329-6330	a	_	
31-62	6331-6340	cognitive	_	
31-63	6341-6348	control	_	
31-64	6349-6353	task	_	
31-65	6354-6357	and	_	
31-66	6358-6359	4	_	
31-67	6359-6360	)	_	
31-68	6361-6363	if	_	
31-69	6364-6368	this	_	
31-70	6369-6371	is	_	
31-71	6372-6386	differentially	_	
31-72	6387-6395	impacted	_	
31-73	6396-6402	across	_	
31-74	6403-6412	treatment	_	
31-75	6413-6423	refractory	_	
31-76	6424-6427	and	_	
31-77	6428-6437	treatment	_	
31-78	6438-6448	responsive	_	
31-79	6449-6457	patients	_	
31-80	6458-6462	with	_	
31-81	6463-6476	schizophrenia	_	
31-82	6476-6477	.	_	

#Text=Material and methods
#Text=Participants
#Text=Means and standard deviations of histogram data per group.
32-1	6478-6486	Material	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]	
32-2	6487-6490	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]	
32-3	6491-6498	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]	
32-4	6499-6511	Participants	_	
32-5	6512-6517	Means	_	
32-6	6518-6521	and	_	
32-7	6522-6530	standard	_	
32-8	6531-6541	deviations	_	
32-9	6542-6544	of	_	
32-10	6545-6554	histogram	_	
32-11	6555-6559	data	_	
32-12	6560-6563	per	_	
32-13	6564-6569	group	_	
32-14	6569-6570	.	_	

#Text=Table 1\t \t
#Text=\tHC\tNTR\tTRS\t\t \t\tM\tSD\tM\tSD\tM\tSD\tχ2(2)\tP\t \tMean\t24.19\t0.98\t23.33\t1.30\t23.31\t1.24\t7.61\t0.022\t \tVariance\t24.02\t4.57\t28.93\t4.71\t27.90\t5.00\t13.49\t0.001\t \tMode (peak position)\t27.46\t1.18\t27.15\t1.39\t26.89\t1.33\t2.23\t> 0.05\t \tMode frequency (peak height)\t0.17\t0.04\t0.14\t0.03\t0.14\t0.03\t6.98\t0.031\t \t
#Text=HC: healthy controls.
33-1	6571-6576	Table	_	
33-2	6577-6578	1	_	
33-3	6583-6585	HC	_	
33-4	6586-6589	NTR	_	
33-5	6590-6593	TRS	_	
33-6	6598-6599	M	_	
33-7	6600-6602	SD	_	
33-8	6603-6604	M	_	
33-9	6605-6607	SD	_	
33-10	6608-6609	M	_	
33-11	6610-6612	SD	_	
33-12	6613-6615	χ2	_	
33-13	6615-6616	(	_	
33-14	6616-6617	2	_	
33-15	6617-6618	)	_	
33-16	6619-6620	P	_	
33-17	6623-6627	Mean	_	
33-18	6628-6633	24.19	_	
33-19	6634-6638	0.98	_	
33-20	6639-6644	23.33	_	
33-21	6645-6649	1.30	_	
33-22	6650-6655	23.31	_	
33-23	6656-6660	1.24	_	
33-24	6661-6665	7.61	_	
33-25	6666-6671	0.022	_	
33-26	6674-6682	Variance	_	
33-27	6683-6688	24.02	_	
33-28	6689-6693	4.57	_	
33-29	6694-6699	28.93	_	
33-30	6700-6704	4.71	_	
33-31	6705-6710	27.90	_	
33-32	6711-6715	5.00	_	
33-33	6716-6721	13.49	_	
33-34	6722-6727	0.001	_	
33-35	6730-6734	Mode	_	
33-36	6735-6736	(	_	
33-37	6736-6740	peak	_	
33-38	6741-6749	position	_	
33-39	6749-6750	)	_	
33-40	6751-6756	27.46	_	
33-41	6757-6761	1.18	_	
33-42	6762-6767	27.15	_	
33-43	6768-6772	1.39	_	
33-44	6773-6778	26.89	_	
33-45	6779-6783	1.33	_	
33-46	6784-6788	2.23	_	
33-47	6789-6790	>	_	
33-48	6791-6795	0.05	_	
33-49	6798-6802	Mode	_	
33-50	6803-6812	frequency	_	
33-51	6813-6814	(	_	
33-52	6814-6818	peak	_	
33-53	6819-6825	height	_	
33-54	6825-6826	)	_	
33-55	6827-6831	0.17	_	
33-56	6832-6836	0.04	_	
33-57	6837-6841	0.14	_	
33-58	6842-6846	0.03	_	
33-59	6847-6851	0.14	_	
33-60	6852-6856	0.03	_	
33-61	6857-6861	6.98	_	
33-62	6862-6867	0.031	_	
33-63	6871-6873	HC	_	
33-64	6873-6874	:	_	
33-65	6875-6882	healthy	_	
33-66	6883-6891	controls	_	
33-67	6891-6892	.	_	

#Text=NTR: non-treatment resistant schizophrenia.
34-1	6893-6896	NTR	_	
34-2	6896-6897	:	_	
34-3	6898-6911	non-treatment	_	
34-4	6912-6921	resistant	_	
34-5	6922-6935	schizophrenia	_	
34-6	6935-6936	.	_	

#Text=TRS: treatment resistant schizophrenia. χ2: Kruskall-Wallis Chi squared test statistic.
35-1	6937-6940	TRS	_	
35-2	6940-6941	:	_	
35-3	6942-6951	treatment	_	
35-4	6952-6961	resistant	_	
35-5	6962-6975	schizophrenia	_	
35-6	6975-6976	.	_	
35-7	6977-6979	χ2	_	
35-8	6979-6980	:	_	
35-9	6981-6996	Kruskall-Wallis	_	
35-10	6997-7000	Chi	_	
35-11	7001-7008	squared	_	
35-12	7009-7013	test	_	
35-13	7014-7023	statistic	_	
35-14	7023-7024	.	_	

#Text=The study included 43 individuals with a diagnosis of schizophrenia (according to ICD-10 criteria) and 24 healthy controls matched for age, sex, and socioeconomic background.
36-1	7025-7028	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-2	7029-7034	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-3	7035-7043	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-4	7044-7046	43	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-5	7047-7058	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-6	7059-7063	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-7	7064-7065	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-8	7066-7075	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-9	7076-7078	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-10	7079-7092	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]	
36-11	7093-7094	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-12	7094-7103	according	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-13	7104-7106	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-14	7107-7110	ICD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-15	7110-7111	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-16	7111-7113	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-17	7114-7122	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-18	7122-7123	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-19	7124-7127	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-20	7128-7130	24	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-21	7131-7138	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]	
36-22	7139-7147	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]	
36-23	7148-7155	matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-24	7156-7159	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-25	7160-7163	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-26	7163-7164	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-27	7165-7168	sex	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-28	7168-7169	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-29	7170-7173	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-30	7174-7187	socioeconomic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-31	7188-7198	background	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
36-32	7198-7199	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	

#Text=The patient sample included 22 patients who fulfilled criteria for treatment resistance (TRS), based on at least two prior drug trials of 4–6 weeks duration with no clinical improvement, persistence of illness for longer than five years with no period of good social or occupational functioning, and persistent psychotic symptoms as defined as a score of at least 4 (moderate) on at least two positive symptom items of the Positive and Negative Syndrome Scale (PANSS).
37-1	7200-7203	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-2	7204-7211	patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-3	7212-7218	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-4	7219-7227	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-5	7228-7230	22	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-6	7231-7239	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-7	7240-7243	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-8	7244-7253	fulfilled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-9	7254-7262	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-10	7263-7266	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-11	7267-7276	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[9]	
37-12	7277-7287	resistance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[9]	
37-13	7288-7289	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[9]	
37-14	7289-7292	TRS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[9]	
37-15	7292-7293	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[9]	
37-16	7293-7294	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-17	7295-7300	based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-18	7301-7303	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-19	7304-7306	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-20	7307-7312	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-21	7313-7316	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-22	7317-7322	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-23	7323-7327	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-24	7328-7334	trials	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-25	7335-7337	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-26	7338-7339	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-27	7339-7340	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-28	7340-7341	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-29	7341-7342	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-30	7342-7347	weeks	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-31	7348-7356	duration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-32	7357-7361	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-33	7362-7364	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-34	7365-7373	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-35	7374-7385	improvement	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-36	7385-7386	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-37	7387-7398	persistence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-38	7399-7401	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-39	7402-7409	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-40	7410-7413	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-41	7414-7420	longer	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-42	7421-7425	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-43	7426-7430	five	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-44	7431-7436	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-45	7437-7441	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-46	7442-7444	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-47	7445-7451	period	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-48	7452-7454	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-49	7455-7459	good	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-50	7460-7466	social	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-51	7467-7469	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-52	7470-7482	occupational	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-53	7483-7494	functioning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-54	7494-7495	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-55	7496-7499	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-56	7500-7510	persistent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-57	7511-7520	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-58	7521-7529	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-59	7530-7532	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-60	7533-7540	defined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-61	7541-7543	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-62	7544-7545	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-63	7546-7551	score	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-64	7552-7554	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-65	7555-7557	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-66	7558-7563	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-67	7564-7565	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-68	7566-7567	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-69	7567-7575	moderate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-70	7575-7576	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-71	7577-7579	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-72	7580-7582	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-73	7583-7588	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-74	7589-7592	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-75	7593-7601	positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-76	7602-7609	symptom	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-77	7610-7615	items	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-78	7616-7618	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-79	7619-7622	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
37-80	7623-7631	Positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[10]	
37-81	7632-7635	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[10]	
37-82	7636-7644	Negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[10]	
37-83	7645-7653	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[10]	
37-84	7654-7659	Scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[10]	
37-85	7660-7661	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[10]	
37-86	7661-7666	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[10]	
37-87	7666-7667	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[10]	
37-88	7667-7668	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	

#Text=The remaining 21 patients fulfilled criteria for being in symptomatic remission (non-treatment resistant; NTR), as defined by a score of 3 or less on all items of the PANSS, and these symptoms having been stable for at least 6 months.
38-1	7669-7672	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-2	7673-7682	remaining	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-3	7683-7685	21	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-4	7686-7694	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-5	7695-7704	fulfilled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-6	7705-7713	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-7	7714-7717	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-8	7718-7723	being	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-9	7724-7726	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-10	7727-7738	symptomatic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]	
38-11	7739-7748	remission	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]	
38-12	7749-7750	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]	
38-13	7750-7763	non-treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]	
38-14	7764-7773	resistant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]	
38-15	7773-7774	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]	
38-16	7775-7778	NTR	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]	
38-17	7778-7779	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-18	7779-7780	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-19	7781-7783	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-20	7784-7791	defined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-21	7792-7794	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-22	7795-7796	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-23	7797-7802	score	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-24	7803-7805	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-25	7806-7807	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-26	7808-7810	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-27	7811-7815	less	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-28	7816-7818	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-29	7819-7822	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-30	7823-7828	items	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-31	7829-7831	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-32	7832-7835	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-33	7836-7841	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[12]	
38-34	7841-7842	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-35	7843-7846	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-36	7847-7852	these	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-37	7853-7861	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-38	7862-7868	having	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-39	7869-7873	been	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-40	7874-7880	stable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-41	7881-7884	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-42	7885-7887	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-43	7888-7893	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-44	7894-7895	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-45	7895-7896	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-46	7896-7902	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-47	7902-7903	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	

#Text=The two patient groups were matched for age, sex, duration of illness, medication type and dosage.
39-1	7904-7907	The	_	
39-2	7908-7911	two	_	
39-3	7912-7919	patient	_	
39-4	7920-7926	groups	_	
39-5	7927-7931	were	_	
39-6	7932-7939	matched	_	
39-7	7940-7943	for	_	
39-8	7944-7947	age	_	
39-9	7947-7948	,	_	
39-10	7949-7952	sex	_	
39-11	7952-7953	,	_	
39-12	7954-7962	duration	_	
39-13	7963-7965	of	_	
39-14	7966-7973	illness	_	
39-15	7973-7974	,	_	
39-16	7975-7985	medication	_	
39-17	7986-7990	type	_	
39-18	7991-7994	and	_	
39-19	7995-8001	dosage	_	
39-20	8001-8002	.	_	

#Text=Current clozapine use was an exclusion criterion for all patients; this was to maintain the homogeneity of the patient sample - fulfilling the standard criteria for treatment resistance - avoiding the introduction of sub-groups of patients refractory to clozapine (super-resistant patients).
40-1	8003-8010	Current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-2	8011-8020	clozapine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-3	8021-8024	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-4	8025-8028	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-5	8029-8031	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-6	8032-8041	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-7	8042-8051	criterion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-8	8052-8055	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-9	8056-8059	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-10	8060-8068	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-11	8068-8069	;	_	
40-12	8070-8074	this	_	
40-13	8075-8078	was	_	
40-14	8079-8081	to	_	
40-15	8082-8090	maintain	_	
40-16	8091-8094	the	_	
40-17	8095-8106	homogeneity	_	
40-18	8107-8109	of	_	
40-19	8110-8113	the	_	
40-20	8114-8121	patient	_	
40-21	8122-8128	sample	_	
40-22	8129-8130	-	_	
40-23	8131-8141	fulfilling	_	
40-24	8142-8145	the	_	
40-25	8146-8154	standard	_	
40-26	8155-8163	criteria	_	
40-27	8164-8167	for	_	
40-28	8168-8177	treatment	_	
40-29	8178-8188	resistance	_	
40-30	8189-8190	-	_	
40-31	8191-8199	avoiding	_	
40-32	8200-8203	the	_	
40-33	8204-8216	introduction	_	
40-34	8217-8219	of	_	
40-35	8220-8230	sub-groups	_	
40-36	8231-8233	of	_	
40-37	8234-8242	patients	_	
40-38	8243-8253	refractory	_	
40-39	8254-8256	to	_	
40-40	8257-8266	clozapine	_	
40-41	8267-8268	(	_	
40-42	8268-8283	super-resistant	_	
40-43	8284-8292	patients	_	
40-44	8292-8293	)	_	
40-45	8293-8294	.	_	

#Text=Chlorpromazine (CPZ) equivalent doses of medications were calculated using conversion tables.
41-1	8295-8309	Chlorpromazine	_	
41-2	8310-8311	(	_	
41-3	8311-8314	CPZ	_	
41-4	8314-8315	)	_	
41-5	8316-8326	equivalent	_	
41-6	8327-8332	doses	_	
41-7	8333-8335	of	_	
41-8	8336-8347	medications	_	
41-9	8348-8352	were	_	
41-10	8353-8363	calculated	_	
41-11	8364-8369	using	_	
41-12	8370-8380	conversion	_	
41-13	8381-8387	tables	_	
41-14	8387-8388	.	_	

#Text=Exclusion criteria for all subjects were a history of neurological illness, current major physical illness, and drug dependency over the last six months.
42-1	8389-8398	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-2	8399-8407	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-3	8408-8411	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-4	8412-8415	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-5	8416-8424	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-6	8425-8429	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-7	8430-8431	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-8	8432-8439	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-9	8440-8442	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-10	8443-8455	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-11	8456-8463	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-12	8463-8464	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-13	8465-8472	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-14	8473-8478	major	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-15	8479-8487	physical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-16	8488-8495	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-17	8495-8496	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-18	8497-8500	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-19	8501-8505	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-20	8506-8516	dependency	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-21	8517-8521	over	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-22	8522-8525	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-23	8526-8530	last	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-24	8531-8534	six	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-25	8535-8541	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-26	8541-8542	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	

#Text=Exclusion criteria for HC were a history of psychiatric illness and a first-degree relative currently or previously suffering from a psychotic illness.
43-1	8543-8552	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-2	8553-8561	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-3	8562-8565	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-4	8566-8568	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[16]	
43-5	8569-8573	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-6	8574-8575	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-7	8576-8583	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-8	8584-8586	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-9	8587-8598	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-10	8599-8606	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-11	8607-8610	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-12	8611-8612	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-13	8613-8625	first-degree	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-14	8626-8634	relative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-15	8635-8644	currently	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-16	8645-8647	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-17	8648-8658	previously	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-18	8659-8668	suffering	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-19	8669-8673	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-20	8674-8675	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-21	8676-8685	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-22	8686-8693	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-23	8693-8694	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	

#Text=All subjects had normal hearing and normal or corrected-to-normal vision.
44-1	8695-8698	All	_	
44-2	8699-8707	subjects	_	
44-3	8708-8711	had	_	
44-4	8712-8718	normal	_	
44-5	8719-8726	hearing	_	
44-6	8727-8730	and	_	
44-7	8731-8737	normal	_	
44-8	8738-8740	or	_	
44-9	8741-8760	corrected-to-normal	_	
44-10	8761-8767	vision	_	
44-11	8767-8768	.	_	

#Text=Demographic characteristics and clinical data are presented in Table 1.
45-1	8769-8780	Demographic	_	
45-2	8781-8796	characteristics	_	
45-3	8797-8800	and	_	
45-4	8801-8809	clinical	_	
45-5	8810-8814	data	_	
45-6	8815-8818	are	_	
45-7	8819-8828	presented	_	
45-8	8829-8831	in	_	
45-9	8832-8837	Table	_	
45-10	8838-8839	1	_	
45-11	8839-8840	.	_	

#Text=Ethical approval was provided by the London Camberwell St Giles Research and Ethics Committee.
46-1	8841-8848	Ethical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-2	8849-8857	approval	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-3	8858-8861	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-4	8862-8870	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-5	8871-8873	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-6	8874-8877	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-7	8878-8884	London	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-8	8885-8895	Camberwell	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-9	8896-8898	St	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-10	8899-8904	Giles	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-11	8905-8913	Research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-12	8914-8917	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-13	8918-8924	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-14	8925-8934	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-15	8934-8935	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	

#Text=All participants provided informed written consent and were compensated for their time and travel.
47-1	8936-8939	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
47-2	8940-8952	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
47-3	8953-8961	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
47-4	8962-8970	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
47-5	8971-8978	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
47-6	8979-8986	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
47-7	8987-8990	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
47-8	8991-8995	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
47-9	8996-9007	compensated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
47-10	9008-9011	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
47-11	9012-9017	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
47-12	9018-9022	time	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
47-13	9023-9026	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
47-14	9027-9033	travel	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
47-15	9033-9034	.	_	

#Text=MRI acquisition and processing
#Text=Scans were acquired on a 3T GE Excite II MR scanner (GE Healthcare, USA) with an 8-channel head coil.
48-1	9035-9038	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
48-2	9039-9050	acquisition	_	
48-3	9051-9054	and	_	
48-4	9055-9065	processing	_	
48-5	9066-9071	Scans	_	
48-6	9072-9076	were	_	
48-7	9077-9085	acquired	_	
48-8	9086-9088	on	_	
48-9	9089-9090	a	_	
48-10	9091-9093	3T	_	
48-11	9094-9096	GE	_	
48-12	9097-9103	Excite	_	
48-13	9104-9106	II	_	
48-14	9107-9109	MR	_	
48-15	9110-9117	scanner	_	
48-16	9118-9119	(	_	
48-17	9119-9121	GE	_	
48-18	9122-9132	Healthcare	_	
48-19	9132-9133	,	_	
48-20	9134-9137	USA	_	
48-21	9137-9138	)	_	
48-22	9139-9143	with	_	
48-23	9144-9146	an	_	
48-24	9147-9148	8	_	
48-25	9148-9149	-	_	
48-26	9149-9156	channel	_	
48-27	9157-9161	head	_	
48-28	9162-9166	coil	_	
48-29	9166-9167	.	_	

#Text=The mcDESPOT protocol consisted of a spoiled gradient recalled echo (SPGR) sequence across nine flip angles α (TR = 8.0 ms; TE = 3.6 ms; α = [2, 3, 4, 5, 6, 7, 9, 13, 18]°; matrix = 128 × 128), and a balanced steady-state free procession (bSSFP) sequence across eight flip angles, acquired at radiofrequency phase cycling patterns of 0° and 180° to correct for off-resonance effects (TR = 3.8 ms; TE = 1.9 ms; α = [12, 16, 21, 27, 33, 40, 51, 68]; matrix = 128 × 128).
49-1	9168-9171	The	_	
49-2	9172-9180	mcDESPOT	_	
49-3	9181-9189	protocol	_	
49-4	9190-9199	consisted	_	
49-5	9200-9202	of	_	
49-6	9203-9204	a	_	
49-7	9205-9212	spoiled	_	
49-8	9213-9221	gradient	_	
49-9	9222-9230	recalled	_	
49-10	9231-9235	echo	_	
49-11	9236-9237	(	_	
49-12	9237-9241	SPGR	_	
49-13	9241-9242	)	_	
49-14	9243-9251	sequence	_	
49-15	9252-9258	across	_	
49-16	9259-9263	nine	_	
49-17	9264-9268	flip	_	
49-18	9269-9275	angles	_	
49-19	9276-9277	α	_	
49-20	9278-9279	(	_	
49-21	9279-9281	TR	_	
49-22	9281-9282	 	_	
49-23	9282-9283	=	_	
49-24	9283-9284	 	_	
49-25	9284-9287	8.0	_	
49-26	9287-9288	 	_	
49-27	9288-9290	ms	_	
49-28	9290-9291	;	_	
49-29	9292-9294	TE	_	
49-30	9294-9295	 	_	
49-31	9295-9296	=	_	
49-32	9296-9297	 	_	
49-33	9297-9300	3.6	_	
49-34	9300-9301	 	_	
49-35	9301-9303	ms	_	
49-36	9303-9304	;	_	
49-37	9305-9306	α	_	
49-38	9306-9307	 	_	
49-39	9307-9308	=	_	
49-40	9308-9309	 	_	
49-41	9309-9310	[	_	
49-42	9310-9311	2	_	
49-43	9311-9312	,	_	
49-44	9313-9314	3	_	
49-45	9314-9315	,	_	
49-46	9316-9317	4	_	
49-47	9317-9318	,	_	
49-48	9319-9320	5	_	
49-49	9320-9321	,	_	
49-50	9322-9323	6	_	
49-51	9323-9324	,	_	
49-52	9325-9326	7	_	
49-53	9326-9327	,	_	
49-54	9328-9329	9	_	
49-55	9329-9330	,	_	
49-56	9331-9333	13	_	
49-57	9333-9334	,	_	
49-58	9335-9337	18	_	
49-59	9337-9338	]	_	
49-60	9338-9339	°	_	
49-61	9339-9340	;	_	
49-62	9341-9347	matrix	_	
49-63	9347-9348	 	_	
49-64	9348-9349	=	_	
49-65	9349-9350	 	_	
49-66	9350-9353	128	_	
49-67	9353-9354	 	_	
49-68	9354-9355	×	_	
49-69	9355-9356	 	_	
49-70	9356-9359	128	_	
49-71	9359-9360	)	_	
49-72	9360-9361	,	_	
49-73	9362-9365	and	_	
49-74	9366-9367	a	_	
49-75	9368-9376	balanced	_	
49-76	9377-9389	steady-state	_	
49-77	9390-9394	free	_	
49-78	9395-9405	procession	_	
49-79	9406-9407	(	_	
49-80	9407-9412	bSSFP	_	
49-81	9412-9413	)	_	
49-82	9414-9422	sequence	_	
49-83	9423-9429	across	_	
49-84	9430-9435	eight	_	
49-85	9436-9440	flip	_	
49-86	9441-9447	angles	_	
49-87	9447-9448	,	_	
49-88	9449-9457	acquired	_	
49-89	9458-9460	at	_	
49-90	9461-9475	radiofrequency	_	
49-91	9476-9481	phase	_	
49-92	9482-9489	cycling	_	
49-93	9490-9498	patterns	_	
49-94	9499-9501	of	_	
49-95	9502-9503	0	_	
49-96	9503-9504	°	_	
49-97	9505-9508	and	_	
49-98	9509-9512	180	_	
49-99	9512-9513	°	_	
49-100	9514-9516	to	_	
49-101	9517-9524	correct	_	
49-102	9525-9528	for	_	
49-103	9529-9542	off-resonance	_	
49-104	9543-9550	effects	_	
49-105	9551-9552	(	_	
49-106	9552-9554	TR	_	
49-107	9554-9555	 	_	
49-108	9555-9556	=	_	
49-109	9556-9557	 	_	
49-110	9557-9560	3.8	_	
49-111	9560-9561	 	_	
49-112	9561-9563	ms	_	
49-113	9563-9564	;	_	
49-114	9565-9567	TE	_	
49-115	9567-9568	 	_	
49-116	9568-9569	=	_	
49-117	9569-9570	 	_	
49-118	9570-9573	1.9	_	
49-119	9573-9574	 	_	
49-120	9574-9576	ms	_	
49-121	9576-9577	;	_	
49-122	9578-9579	α	_	
49-123	9579-9580	 	_	
49-124	9580-9581	=	_	
49-125	9581-9582	 	_	
49-126	9582-9583	[	_	
49-127	9583-9585	12	_	
49-128	9585-9586	,	_	
49-129	9587-9589	16	_	
49-130	9589-9590	,	_	
49-131	9591-9593	21	_	
49-132	9593-9594	,	_	
49-133	9595-9597	27	_	
49-134	9597-9598	,	_	
49-135	9599-9601	33	_	
49-136	9601-9602	,	_	
49-137	9603-9605	40	_	
49-138	9605-9606	,	_	
49-139	9607-9609	51	_	
49-140	9609-9610	,	_	
49-141	9611-9613	68	_	
49-142	9613-9614	]	_	
49-143	9614-9615	;	_	
49-144	9616-9622	matrix	_	
49-145	9622-9623	 	_	
49-146	9623-9624	=	_	
49-147	9624-9625	 	_	
49-148	9625-9628	128	_	
49-149	9628-9629	 	_	
49-150	9629-9630	×	_	
49-151	9630-9631	 	_	
49-152	9631-9634	128	_	
49-153	9634-9635	)	_	
49-154	9635-9636	.	_	

#Text=In addition an inversion recovery SPGR was acquired for estimating the flip angle error caused by transmitting B1 field inhomogeneity (TR = 8.0 ms; TE = 3.6 ms; α = 5°; matrix = 220 × 110).
50-1	9637-9639	In	_	
50-2	9640-9648	addition	_	
50-3	9649-9651	an	_	
50-4	9652-9661	inversion	_	
50-5	9662-9670	recovery	_	
50-6	9671-9675	SPGR	_	
50-7	9676-9679	was	_	
50-8	9680-9688	acquired	_	
50-9	9689-9692	for	_	
50-10	9693-9703	estimating	_	
50-11	9704-9707	the	_	
50-12	9708-9712	flip	_	
50-13	9713-9718	angle	_	
50-14	9719-9724	error	_	
50-15	9725-9731	caused	_	
50-16	9732-9734	by	_	
50-17	9735-9747	transmitting	_	
50-18	9748-9750	B1	_	
50-19	9751-9756	field	_	
50-20	9757-9770	inhomogeneity	_	
50-21	9771-9772	(	_	
50-22	9772-9774	TR	_	
50-23	9774-9775	 	_	
50-24	9775-9776	=	_	
50-25	9776-9777	 	_	
50-26	9777-9780	8.0	_	
50-27	9780-9781	 	_	
50-28	9781-9783	ms	_	
50-29	9783-9784	;	_	
50-30	9785-9787	TE	_	
50-31	9787-9788	 	_	
50-32	9788-9789	=	_	
50-33	9789-9790	 	_	
50-34	9790-9793	3.6	_	
50-35	9793-9794	 	_	
50-36	9794-9796	ms	_	
50-37	9796-9797	;	_	
50-38	9798-9799	α	_	
50-39	9799-9800	 	_	
50-40	9800-9801	=	_	
50-41	9801-9802	 	_	
50-42	9802-9803	5	_	
50-43	9803-9804	°	_	
50-44	9804-9805	;	_	
50-45	9806-9812	matrix	_	
50-46	9812-9813	 	_	
50-47	9813-9814	=	_	
50-48	9814-9815	 	_	
50-49	9815-9818	220	_	
50-50	9818-9819	 	_	
50-51	9819-9820	×	_	
50-52	9820-9821	 	_	
50-53	9821-9824	110	_	
50-54	9824-9825	)	_	
50-55	9825-9826	.	_	

#Text=The field of view was 220 × 220 cm and the voxel size was 1.7 mm isotropic.
51-1	9827-9830	The	_	
51-2	9831-9836	field	_	
51-3	9837-9839	of	_	
51-4	9840-9844	view	_	
51-5	9845-9848	was	_	
51-6	9849-9852	220	_	
51-7	9852-9853	 	_	
51-8	9853-9854	×	_	
51-9	9854-9855	 	_	
51-10	9855-9858	220	_	
51-11	9858-9859	 	_	
51-12	9859-9861	cm	_	
51-13	9862-9865	and	_	
51-14	9866-9869	the	_	
51-15	9870-9875	voxel	_	
51-16	9876-9880	size	_	
51-17	9881-9884	was	_	
51-18	9885-9888	1.7	_	
51-19	9888-9889	 	_	
51-20	9889-9891	mm	_	
51-21	9892-9901	isotropic	_	
51-22	9901-9902	.	_	

#Text=The full mcDESPOT sequence lasted approximately 13 min.
52-1	9903-9906	The	_	
52-2	9907-9911	full	_	
52-3	9912-9920	mcDESPOT	_	
52-4	9921-9929	sequence	_	
52-5	9930-9936	lasted	_	
52-6	9937-9950	approximately	_	
52-7	9951-9953	13	_	
52-8	9953-9954	 	_	
52-9	9954-9957	min	_	
52-10	9957-9958	.	_	

#Text=All raw images were visually inspected for motion artefacts.
53-1	9959-9962	All	_	
53-2	9963-9966	raw	_	
53-3	9967-9973	images	_	
53-4	9974-9978	were	_	
53-5	9979-9987	visually	_	
53-6	9988-9997	inspected	_	
53-7	9998-10001	for	_	
53-8	10002-10008	motion	_	
53-9	10009-10018	artefacts	_	
53-10	10018-10019	.	_	

#Text=Participants with missing scans or excessive motion were re-scanned either immediately or at their earliest convenience, resulting in a complete dataset.
54-1	10020-10032	Participants	_	
54-2	10033-10037	with	_	
54-3	10038-10045	missing	_	
54-4	10046-10051	scans	_	
54-5	10052-10054	or	_	
54-6	10055-10064	excessive	_	
54-7	10065-10071	motion	_	
54-8	10072-10076	were	_	
54-9	10077-10087	re-scanned	_	
54-10	10088-10094	either	_	
54-11	10095-10106	immediately	_	
54-12	10107-10109	or	_	
54-13	10110-10112	at	_	
54-14	10113-10118	their	_	
54-15	10119-10127	earliest	_	
54-16	10128-10139	convenience	_	
54-17	10139-10140	,	_	
54-18	10141-10150	resulting	_	
54-19	10151-10153	in	_	
54-20	10154-10155	a	_	
54-21	10156-10164	complete	_	
54-22	10165-10172	dataset	_	
54-23	10172-10173	.	_	

#Text=Each subject's scans were linearly coregistered, and non-brain parenchyma signal removed using BET (FMRIB Software Library, www.fmrib.ox.ac.uk/fsl). mcDESPOT maps were processed using our previously described open-source software.
55-1	10174-10178	Each	_	
55-2	10179-10188	subject's	_	
55-3	10189-10194	scans	_	
55-4	10195-10199	were	_	
55-5	10200-10208	linearly	_	
55-6	10209-10221	coregistered	_	
55-7	10221-10222	,	_	
55-8	10223-10226	and	_	
55-9	10227-10236	non-brain	_	
55-10	10237-10247	parenchyma	_	
55-11	10248-10254	signal	_	
55-12	10255-10262	removed	_	
55-13	10263-10268	using	_	
55-14	10269-10272	BET	_	
55-15	10273-10274	(	_	
55-16	10274-10279	FMRIB	_	
55-17	10280-10288	Software	_	
55-18	10289-10296	Library	_	
55-19	10296-10297	,	_	
55-20	10298-10316	www.fmrib.ox.ac.uk	_	
55-21	10316-10317	/	_	
55-22	10317-10320	fsl	_	
55-23	10320-10321	)	_	
55-24	10321-10322	.	_	
55-25	10323-10331	mcDESPOT	_	
55-26	10332-10336	maps	_	
55-27	10337-10341	were	_	
55-28	10342-10351	processed	_	
55-29	10352-10357	using	_	
55-30	10358-10361	our	_	
55-31	10362-10372	previously	_	
55-32	10373-10382	described	_	
55-33	10383-10394	open-source	_	
55-34	10395-10403	software	_	
55-35	10403-10404	.	_	

#Text=Briefly, first T1 & B1 maps were calculated from the data, then T2 & off-resonance maps, and then finally Myelin Water Fraction maps using a three component model and Gaussian Region Contraction.
56-1	10405-10412	Briefly	_	
56-2	10412-10413	,	_	
56-3	10414-10419	first	_	
56-4	10420-10422	T1	_	
56-5	10423-10424	&	_	
56-6	10425-10427	B1	_	
56-7	10428-10432	maps	_	
56-8	10433-10437	were	_	
56-9	10438-10448	calculated	_	
56-10	10449-10453	from	_	
56-11	10454-10457	the	_	
56-12	10458-10462	data	_	
56-13	10462-10463	,	_	
56-14	10464-10468	then	_	
56-15	10469-10471	T2	_	
56-16	10472-10473	&	_	
56-17	10474-10487	off-resonance	_	
56-18	10488-10492	maps	_	
56-19	10492-10493	,	_	
56-20	10494-10497	and	_	
56-21	10498-10502	then	_	
56-22	10503-10510	finally	_	
56-23	10511-10517	Myelin	_	
56-24	10518-10523	Water	_	
56-25	10524-10532	Fraction	_	
56-26	10533-10537	maps	_	
56-27	10538-10543	using	_	
56-28	10544-10545	a	_	
56-29	10546-10551	three	_	
56-30	10552-10561	component	_	
56-31	10562-10567	model	_	
56-32	10568-10571	and	_	
56-33	10572-10580	Gaussian	_	
56-34	10581-10587	Region	_	
56-35	10588-10599	Contraction	_	
56-36	10599-10600	.	_	

#Text=MWF maps were non-linearly registered to the MNI152 2 mm isotropic standard brain, and smoothed using a Gaussian kernel at 5 mm FWHM.
57-1	10601-10604	MWF	_	
57-2	10605-10609	maps	_	
57-3	10610-10614	were	_	
57-4	10615-10627	non-linearly	_	
57-5	10628-10638	registered	_	
57-6	10639-10641	to	_	
57-7	10642-10645	the	_	
57-8	10646-10652	MNI152	_	
57-9	10653-10654	2	_	
57-10	10654-10655	 	_	
57-11	10655-10657	mm	_	
57-12	10658-10667	isotropic	_	
57-13	10668-10676	standard	_	
57-14	10677-10682	brain	_	
57-15	10682-10683	,	_	
57-16	10684-10687	and	_	
57-17	10688-10696	smoothed	_	
57-18	10697-10702	using	_	
57-19	10703-10704	a	_	
57-20	10705-10713	Gaussian	_	
57-21	10714-10720	kernel	_	
57-22	10721-10723	at	_	
57-23	10724-10725	5	_	
57-24	10725-10726	 	_	
57-25	10726-10728	mm	_	
57-26	10729-10733	FWHM	_	
57-27	10733-10734	.	_	

#Text=Statistical analysis
#Text=Whole-brain group comparisons
#Text=Whole-brain normalised MWF maps were subjected to non-parametric permutation tests using FSL's randomise (with 10,000 permutations), and significance values were corrected for multiple comparisons using threshold-free cluster enhancement (TFCE).
58-1	10735-10746	Statistical	_	
58-2	10747-10755	analysis	_	
58-3	10756-10767	Whole-brain	_	
58-4	10768-10773	group	_	
58-5	10774-10785	comparisons	_	
58-6	10786-10797	Whole-brain	_	
58-7	10798-10808	normalised	_	
58-8	10809-10812	MWF	_	
58-9	10813-10817	maps	_	
58-10	10818-10822	were	_	
58-11	10823-10832	subjected	_	
58-12	10833-10835	to	_	
58-13	10836-10850	non-parametric	_	
58-14	10851-10862	permutation	_	
58-15	10863-10868	tests	_	
58-16	10869-10874	using	_	
58-17	10875-10880	FSL's	_	
58-18	10881-10890	randomise	_	
58-19	10891-10892	(	_	
58-20	10892-10896	with	_	
58-21	10897-10903	10,000	_	
58-22	10904-10916	permutations	_	
58-23	10916-10917	)	_	
58-24	10917-10918	,	_	
58-25	10919-10922	and	_	
58-26	10923-10935	significance	_	
58-27	10936-10942	values	_	
58-28	10943-10947	were	_	
58-29	10948-10957	corrected	_	
58-30	10958-10961	for	_	
58-31	10962-10970	multiple	_	
58-32	10971-10982	comparisons	_	
58-33	10983-10988	using	_	
58-34	10989-11003	threshold-free	_	
58-35	11004-11011	cluster	_	
58-36	11012-11023	enhancement	_	
58-37	11024-11025	(	_	
58-38	11025-11029	TFCE	_	
58-39	11029-11030	)	_	
58-40	11030-11031	.	_	

#Text=Clusters were defined with an extent threshold of 50 voxels.
59-1	11032-11040	Clusters	_	
59-2	11041-11045	were	_	
59-3	11046-11053	defined	_	
59-4	11054-11058	with	_	
59-5	11059-11061	an	_	
59-6	11062-11068	extent	_	
59-7	11069-11078	threshold	_	
59-8	11079-11081	of	_	
59-9	11082-11084	50	_	
59-10	11084-11085	 	_	
59-11	11085-11091	voxels	_	
59-12	11091-11092	.	_	

#Text=We tested the effect of group (HC vs.
60-1	11093-11095	We	_	
60-2	11096-11102	tested	_	
60-3	11103-11106	the	_	
60-4	11107-11113	effect	_	
60-5	11114-11116	of	_	
60-6	11117-11122	group	_	
60-7	11123-11124	(	_	
60-8	11124-11126	HC	_	
60-9	11127-11129	vs	_	
60-10	11129-11130	.	_	

#Text=NTR vs.
61-1	11131-11134	NTR	_	
61-2	11135-11137	vs	_	
61-3	11137-11138	.	_	

#Text=TRS), adjusting for effects of age and sex.
62-1	11139-11142	TRS	_	
62-2	11142-11143	)	_	
62-3	11143-11144	,	_	
62-4	11145-11154	adjusting	_	
62-5	11155-11158	for	_	
62-6	11159-11166	effects	_	
62-7	11167-11169	of	_	
62-8	11170-11173	age	_	
62-9	11174-11177	and	_	
62-10	11178-11181	sex	_	
62-11	11181-11182	.	_	

#Text=White matter histogram analysis
#Text=In order to analyse the distribution of WMF values within the white matter specifically, we overlaid MWF maps with a white matter mask obtained from the Johns Hopkins University White Matter Atlas.
63-1	11183-11188	White	_	
63-2	11189-11195	matter	_	
63-3	11196-11205	histogram	_	
63-4	11206-11214	analysis	_	
63-5	11215-11217	In	_	
63-6	11218-11223	order	_	
63-7	11224-11226	to	_	
63-8	11227-11234	analyse	_	
63-9	11235-11238	the	_	
63-10	11239-11251	distribution	_	
63-11	11252-11254	of	_	
63-12	11255-11258	WMF	_	
63-13	11259-11265	values	_	
63-14	11266-11272	within	_	
63-15	11273-11276	the	_	
63-16	11277-11282	white	_	
63-17	11283-11289	matter	_	
63-18	11290-11302	specifically	_	
63-19	11302-11303	,	_	
63-20	11304-11306	we	_	
63-21	11307-11315	overlaid	_	
63-22	11316-11319	MWF	_	
63-23	11320-11324	maps	_	
63-24	11325-11329	with	_	
63-25	11330-11331	a	_	
63-26	11332-11337	white	_	
63-27	11338-11344	matter	_	
63-28	11345-11349	mask	_	
63-29	11350-11358	obtained	_	
63-30	11359-11363	from	_	
63-31	11364-11367	the	_	
63-32	11368-11373	Johns	_	
63-33	11374-11381	Hopkins	_	
63-34	11382-11392	University	_	
63-35	11393-11398	White	_	
63-36	11399-11405	Matter	_	
63-37	11406-11411	Atlas	_	
63-38	11411-11412	.	_	

#Text=Histogram analyses of white matter MWF were conducted by summing the number of voxels for 100 uniform bins between 0% and 30%.
64-1	11413-11422	Histogram	_	
64-2	11423-11431	analyses	_	
64-3	11432-11434	of	_	
64-4	11435-11440	white	_	
64-5	11441-11447	matter	_	
64-6	11448-11451	MWF	_	
64-7	11452-11456	were	_	
64-8	11457-11466	conducted	_	
64-9	11467-11469	by	_	
64-10	11470-11477	summing	_	
64-11	11478-11481	the	_	
64-12	11482-11488	number	_	
64-13	11489-11491	of	_	
64-14	11492-11498	voxels	_	
64-15	11499-11502	for	_	
64-16	11503-11506	100	_	
64-17	11507-11514	uniform	_	
64-18	11515-11519	bins	_	
64-19	11520-11527	between	_	
64-20	11528-11530	0%	_	
64-21	11531-11534	and	_	
64-22	11535-11538	30%	_	
64-23	11538-11539	.	_	

#Text=Each individual's histogram was normalised with respect to the area of the histogram.
65-1	11540-11544	Each	_	
65-2	11545-11557	individual's	_	
65-3	11558-11567	histogram	_	
65-4	11568-11571	was	_	
65-5	11572-11582	normalised	_	
65-6	11583-11587	with	_	
65-7	11588-11595	respect	_	
65-8	11596-11598	to	_	
65-9	11599-11602	the	_	
65-10	11603-11607	area	_	
65-11	11608-11610	of	_	
65-12	11611-11614	the	_	
65-13	11615-11624	histogram	_	
65-14	11624-11625	.	_	

#Text=For each subject, the mean (first moment), variance (second moment), peak position (mode), and peak height (frequency of voxels in the modal bin) of the histogram were calculated and subsequently compared between groups using non-parametric Kruskal Wallis tests.
66-1	11626-11629	For	_	
66-2	11630-11634	each	_	
66-3	11635-11642	subject	_	
66-4	11642-11643	,	_	
66-5	11644-11647	the	_	
66-6	11648-11652	mean	_	
66-7	11653-11654	(	_	
66-8	11654-11659	first	_	
66-9	11660-11666	moment	_	
66-10	11666-11667	)	_	
66-11	11667-11668	,	_	
66-12	11669-11677	variance	_	
66-13	11678-11679	(	_	
66-14	11679-11685	second	_	
66-15	11686-11692	moment	_	
66-16	11692-11693	)	_	
66-17	11693-11694	,	_	
66-18	11695-11699	peak	_	
66-19	11700-11708	position	_	
66-20	11709-11710	(	_	
66-21	11710-11714	mode	_	
66-22	11714-11715	)	_	
66-23	11715-11716	,	_	
66-24	11717-11720	and	_	
66-25	11721-11725	peak	_	
66-26	11726-11732	height	_	
66-27	11733-11734	(	_	
66-28	11734-11743	frequency	_	
66-29	11744-11746	of	_	
66-30	11747-11753	voxels	_	
66-31	11754-11756	in	_	
66-32	11757-11760	the	_	
66-33	11761-11766	modal	_	
66-34	11767-11770	bin	_	
66-35	11770-11771	)	_	
66-36	11772-11774	of	_	
66-37	11775-11778	the	_	
66-38	11779-11788	histogram	_	
66-39	11789-11793	were	_	
66-40	11794-11804	calculated	_	
66-41	11805-11808	and	_	
66-42	11809-11821	subsequently	_	
66-43	11822-11830	compared	_	
66-44	11831-11838	between	_	
66-45	11839-11845	groups	_	
66-46	11846-11851	using	_	
66-47	11852-11866	non-parametric	_	
66-48	11867-11874	Kruskal	_	
66-49	11875-11881	Wallis	_	
66-50	11882-11887	tests	_	
66-51	11887-11888	.	_	

#Text=MWF and the Stroop effect
#Text=Stroop task
#Text=Subjects performed a standard verbal Stroop task inside the MRI scanner.
67-1	11889-11892	MWF	_	
67-2	11893-11896	and	_	
67-3	11897-11900	the	_	
67-4	11901-11907	Stroop	_	
67-5	11908-11914	effect	_	
67-6	11915-11921	Stroop	_	
67-7	11922-11926	task	_	
67-8	11927-11935	Subjects	_	
67-9	11936-11945	performed	_	
67-10	11946-11947	a	_	
67-11	11948-11956	standard	_	
67-12	11957-11963	verbal	_	
67-13	11964-11970	Stroop	_	
67-14	11971-11975	task	_	
67-15	11976-11982	inside	_	
67-16	11983-11986	the	_	
67-17	11987-11990	MRI	_	
67-18	11991-11998	scanner	_	
67-19	11998-11999	.	_	

#Text=The task consisted of naming the font colour of colour words that were either congruent (e.g. the word “yellow” printed in yellow) or incongruent (e.g. the word ‘yellow’ printed in blue).
68-1	12000-12003	The	_	
68-2	12004-12008	task	_	
68-3	12009-12018	consisted	_	
68-4	12019-12021	of	_	
68-5	12022-12028	naming	_	
68-6	12029-12032	the	_	
68-7	12033-12037	font	_	
68-8	12038-12044	colour	_	
68-9	12045-12047	of	_	
68-10	12048-12054	colour	_	
68-11	12055-12060	words	_	
68-12	12061-12065	that	_	
68-13	12066-12070	were	_	
68-14	12071-12077	either	_	
68-15	12078-12087	congruent	_	
68-16	12088-12089	(	_	
68-17	12089-12092	e.g	_	
68-18	12092-12093	.	_	
68-19	12094-12097	the	_	
68-20	12098-12102	word	_	
68-21	12103-12104	“	_	
68-22	12104-12110	yellow	_	
68-23	12110-12111	”	_	
68-24	12112-12119	printed	_	
68-25	12120-12122	in	_	
68-26	12123-12129	yellow	_	
68-27	12129-12130	)	_	
68-28	12131-12133	or	_	
68-29	12134-12145	incongruent	_	
68-30	12146-12147	(	_	
68-31	12147-12150	e.g	_	
68-32	12150-12151	.	_	
68-33	12152-12155	the	_	
68-34	12156-12160	word	_	
68-35	12161-12162	‘	_	
68-36	12162-12168	yellow	_	
68-37	12168-12169	’	_	
68-38	12170-12177	printed	_	
68-39	12178-12180	in	_	
68-40	12181-12185	blue	_	
68-41	12185-12186	)	_	
68-42	12186-12187	.	_	

#Text=Thirty-three congruent, 33 incongruent, and 34 fixation trials were presented in randomised order, each with a duration of 700 ms and inter-stimulus-interval of 2300 ms.
69-1	12188-12200	Thirty-three	_	
69-2	12201-12210	congruent	_	
69-3	12210-12211	,	_	
69-4	12212-12214	33	_	
69-5	12215-12226	incongruent	_	
69-6	12226-12227	,	_	
69-7	12228-12231	and	_	
69-8	12232-12234	34	_	
69-9	12235-12243	fixation	_	
69-10	12244-12250	trials	_	
69-11	12251-12255	were	_	
69-12	12256-12265	presented	_	
69-13	12266-12268	in	_	
69-14	12269-12279	randomised	_	
69-15	12280-12285	order	_	
69-16	12285-12286	,	_	
69-17	12287-12291	each	_	
69-18	12292-12296	with	_	
69-19	12297-12298	a	_	
69-20	12299-12307	duration	_	
69-21	12308-12310	of	_	
69-22	12311-12314	700	_	
69-23	12314-12315	 	_	
69-24	12315-12317	ms	_	
69-25	12318-12321	and	_	
69-26	12322-12345	inter-stimulus-interval	_	
69-27	12346-12348	of	_	
69-28	12349-12353	2300	_	
69-29	12353-12354	 	_	
69-30	12354-12356	ms	_	
69-31	12356-12357	.	_	

#Text=This preceded the mcDESPOT scanning protocol.
70-1	12358-12362	This	_	
70-2	12363-12371	preceded	_	
70-3	12372-12375	the	_	
70-4	12376-12384	mcDESPOT	_	
70-5	12385-12393	scanning	_	
70-6	12394-12402	protocol	_	
70-7	12402-12403	.	_	

#Text=Each subject's Stroop effect was defined as the difference between their mean reaction time (RT) on incongruent trials and their mean RT on congruent trials.
71-1	12404-12408	Each	_	
71-2	12409-12418	subject's	_	
71-3	12419-12425	Stroop	_	
71-4	12426-12432	effect	_	
71-5	12433-12436	was	_	
71-6	12437-12444	defined	_	
71-7	12445-12447	as	_	
71-8	12448-12451	the	_	
71-9	12452-12462	difference	_	
71-10	12463-12470	between	_	
71-11	12471-12476	their	_	
71-12	12477-12481	mean	_	
71-13	12482-12490	reaction	_	
71-14	12491-12495	time	_	
71-15	12496-12497	(	_	
71-16	12497-12499	RT	_	
71-17	12499-12500	)	_	
71-18	12501-12503	on	_	
71-19	12504-12515	incongruent	_	
71-20	12516-12522	trials	_	
71-21	12523-12526	and	_	
71-22	12527-12532	their	_	
71-23	12533-12537	mean	_	
71-24	12538-12540	RT	_	
71-25	12541-12543	on	_	
71-26	12544-12553	congruent	_	
71-27	12554-12560	trials	_	
71-28	12560-12561	.	_	

#Text=The Stroop effect was compared between groups using one-way ANOVA.
72-1	12562-12565	The	_	
72-2	12566-12572	Stroop	_	
72-3	12573-12579	effect	_	
72-4	12580-12583	was	_	
72-5	12584-12592	compared	_	
72-6	12593-12600	between	_	
72-7	12601-12607	groups	_	
72-8	12608-12613	using	_	
72-9	12614-12621	one-way	_	
72-10	12622-12627	ANOVA	_	
72-11	12627-12628	.	_	

#Text=We tested for correlations between whole-brain MWF and the RT Stroop effect across all subjects using randomise.
73-1	12629-12631	We	_	
73-2	12632-12638	tested	_	
73-3	12639-12642	for	_	
73-4	12643-12655	correlations	_	
73-5	12656-12663	between	_	
73-6	12664-12675	whole-brain	_	
73-7	12676-12679	MWF	_	
73-8	12680-12683	and	_	
73-9	12684-12687	the	_	
73-10	12688-12690	RT	_	
73-11	12691-12697	Stroop	_	
73-12	12698-12704	effect	_	
73-13	12705-12711	across	_	
73-14	12712-12715	all	_	
73-15	12716-12724	subjects	_	
73-16	12725-12730	using	_	
73-17	12731-12740	randomise	_	
73-18	12740-12741	.	_	

#Text=For the resulting significant cluster, we extracted each subject's mean MWF and compared these between groups.
74-1	12742-12745	For	_	
74-2	12746-12749	the	_	
74-3	12750-12759	resulting	_	
74-4	12760-12771	significant	_	
74-5	12772-12779	cluster	_	
74-6	12779-12780	,	_	
74-7	12781-12783	we	_	
74-8	12784-12793	extracted	_	
74-9	12794-12798	each	_	
74-10	12799-12808	subject's	_	
74-11	12809-12813	mean	_	
74-12	12814-12817	MWF	_	
74-13	12818-12821	and	_	
74-14	12822-12830	compared	_	
74-15	12831-12836	these	_	
74-16	12837-12844	between	_	
74-17	12845-12851	groups	_	
74-18	12851-12852	.	_	

#Text=We then conducted a mediation analysis to test whether MWF in this region mediated group differences in the RT Stroop effect.
75-1	12853-12855	We	_	
75-2	12856-12860	then	_	
75-3	12861-12870	conducted	_	
75-4	12871-12872	a	_	
75-5	12873-12882	mediation	_	
75-6	12883-12891	analysis	_	
75-7	12892-12894	to	_	
75-8	12895-12899	test	_	
75-9	12900-12907	whether	_	
75-10	12908-12911	MWF	_	
75-11	12912-12914	in	_	
75-12	12915-12919	this	_	
75-13	12920-12926	region	_	
75-14	12927-12935	mediated	_	
75-15	12936-12941	group	_	
75-16	12942-12953	differences	_	
75-17	12954-12956	in	_	
75-18	12957-12960	the	_	
75-19	12961-12963	RT	_	
75-20	12964-12970	Stroop	_	
75-21	12971-12977	effect	_	
75-22	12977-12978	.	_	

#Text=We used a bootstrap approach proposed by in order to test for significance of the indirect effect of group on RT Stroop effect.
76-1	12979-12981	We	_	
76-2	12982-12986	used	_	
76-3	12987-12988	a	_	
76-4	12989-12998	bootstrap	_	
76-5	12999-13007	approach	_	
76-6	13008-13016	proposed	_	
76-7	13017-13019	by	_	
76-8	13020-13022	in	_	
76-9	13023-13028	order	_	
76-10	13029-13031	to	_	
76-11	13032-13036	test	_	
76-12	13037-13040	for	_	
76-13	13041-13053	significance	_	
76-14	13054-13056	of	_	
76-15	13057-13060	the	_	
76-16	13061-13069	indirect	_	
76-17	13070-13076	effect	_	
76-18	13077-13079	of	_	
76-19	13080-13085	group	_	
76-20	13086-13088	on	_	
76-21	13089-13091	RT	_	
76-22	13092-13098	Stroop	_	
76-23	13099-13105	effect	_	
76-24	13105-13106	.	_	

#Text=Results
#Text=mcDESPOT group effects
#Text=Main effect of group on myelin water fraction.
77-1	13107-13114	Results	_	
77-2	13115-13123	mcDESPOT	_	
77-3	13124-13129	group	_	
77-4	13130-13137	effects	_	
77-5	13138-13142	Main	_	
77-6	13143-13149	effect	_	
77-7	13150-13152	of	_	
77-8	13153-13158	group	_	
77-9	13159-13161	on	_	
77-10	13162-13168	myelin	_	
77-11	13169-13174	water	_	
77-12	13175-13183	fraction	_	
77-13	13183-13184	.	_	

#Text=Fig. 1
#Text=At whole-brain level, controlling for sex and age, there was a significant effect of group in four clusters (Fig. 1): two large clusters covering much of the right (MNI: x = 44, y = −68, z = −36, p = 0.016) and left (MNI: x = −32, y = −18, z = −2, p = 0.010) subcortical white matter including the inferior fronto-occipital fasciculi, particularly in the vicinity of the striatum and extending to the cerebellum, one cluster containing the left putamen (MNI: x = −26, y = 6, z = −6, p = 0.035), and a small cluster in the right subcallosal cortex (MNI: x = 8, y = 18, z = −24, p = 0.026).
78-1	13185-13188	Fig	_	
78-2	13188-13189	.	_	
78-3	13190-13191	1	_	
78-4	13192-13194	At	_	
78-5	13195-13206	whole-brain	_	
78-6	13207-13212	level	_	
78-7	13212-13213	,	_	
78-8	13214-13225	controlling	_	
78-9	13226-13229	for	_	
78-10	13230-13233	sex	_	
78-11	13234-13237	and	_	
78-12	13238-13241	age	_	
78-13	13241-13242	,	_	
78-14	13243-13248	there	_	
78-15	13249-13252	was	_	
78-16	13253-13254	a	_	
78-17	13255-13266	significant	_	
78-18	13267-13273	effect	_	
78-19	13274-13276	of	_	
78-20	13277-13282	group	_	
78-21	13283-13285	in	_	
78-22	13286-13290	four	_	
78-23	13291-13299	clusters	_	
78-24	13300-13301	(	_	
78-25	13301-13304	Fig	_	
78-26	13304-13305	.	_	
78-27	13306-13307	1	_	
78-28	13307-13308	)	_	
78-29	13308-13309	:	_	
78-30	13310-13313	two	_	
78-31	13314-13319	large	_	
78-32	13320-13328	clusters	_	
78-33	13329-13337	covering	_	
78-34	13338-13342	much	_	
78-35	13343-13345	of	_	
78-36	13346-13349	the	_	
78-37	13350-13355	right	_	
78-38	13356-13357	(	_	
78-39	13357-13360	MNI	_	
78-40	13360-13361	:	_	
78-41	13362-13363	x	_	
78-42	13363-13364	 	_	
78-43	13364-13365	=	_	
78-44	13365-13366	 	_	
78-45	13366-13368	44	_	
78-46	13368-13369	,	_	
78-47	13370-13371	y	_	
78-48	13371-13372	 	_	
78-49	13372-13373	=	_	
78-50	13373-13374	 	_	
78-51	13374-13375	−	_	
78-52	13375-13377	68	_	
78-53	13377-13378	,	_	
78-54	13379-13380	z	_	
78-55	13380-13381	 	_	
78-56	13381-13382	=	_	
78-57	13382-13383	 	_	
78-58	13383-13384	−	_	
78-59	13384-13386	36	_	
78-60	13386-13387	,	_	
78-61	13388-13389	p	_	
78-62	13389-13390	 	_	
78-63	13390-13391	=	_	
78-64	13391-13392	 	_	
78-65	13392-13397	0.016	_	
78-66	13397-13398	)	_	
78-67	13399-13402	and	_	
78-68	13403-13407	left	_	
78-69	13408-13409	(	_	
78-70	13409-13412	MNI	_	
78-71	13412-13413	:	_	
78-72	13414-13415	x	_	
78-73	13415-13416	 	_	
78-74	13416-13417	=	_	
78-75	13417-13418	 	_	
78-76	13418-13419	−	_	
78-77	13419-13421	32	_	
78-78	13421-13422	,	_	
78-79	13423-13424	y	_	
78-80	13424-13425	 	_	
78-81	13425-13426	=	_	
78-82	13426-13427	 	_	
78-83	13427-13428	−	_	
78-84	13428-13430	18	_	
78-85	13430-13431	,	_	
78-86	13432-13433	z	_	
78-87	13433-13434	 	_	
78-88	13434-13435	=	_	
78-89	13435-13436	 	_	
78-90	13436-13437	−	_	
78-91	13437-13438	2	_	
78-92	13438-13439	,	_	
78-93	13440-13441	p	_	
78-94	13441-13442	 	_	
78-95	13442-13443	=	_	
78-96	13443-13444	 	_	
78-97	13444-13449	0.010	_	
78-98	13449-13450	)	_	
78-99	13451-13462	subcortical	_	
78-100	13463-13468	white	_	
78-101	13469-13475	matter	_	
78-102	13476-13485	including	_	
78-103	13486-13489	the	_	
78-104	13490-13498	inferior	_	
78-105	13499-13515	fronto-occipital	_	
78-106	13516-13525	fasciculi	_	
78-107	13525-13526	,	_	
78-108	13527-13539	particularly	_	
78-109	13540-13542	in	_	
78-110	13543-13546	the	_	
78-111	13547-13555	vicinity	_	
78-112	13556-13558	of	_	
78-113	13559-13562	the	_	
78-114	13563-13571	striatum	_	
78-115	13572-13575	and	_	
78-116	13576-13585	extending	_	
78-117	13586-13588	to	_	
78-118	13589-13592	the	_	
78-119	13593-13603	cerebellum	_	
78-120	13603-13604	,	_	
78-121	13605-13608	one	_	
78-122	13609-13616	cluster	_	
78-123	13617-13627	containing	_	
78-124	13628-13631	the	_	
78-125	13632-13636	left	_	
78-126	13637-13644	putamen	_	
78-127	13645-13646	(	_	
78-128	13646-13649	MNI	_	
78-129	13649-13650	:	_	
78-130	13651-13652	x	_	
78-131	13652-13653	 	_	
78-132	13653-13654	=	_	
78-133	13654-13655	 	_	
78-134	13655-13656	−	_	
78-135	13656-13658	26	_	
78-136	13658-13659	,	_	
78-137	13660-13661	y	_	
78-138	13661-13662	 	_	
78-139	13662-13663	=	_	
78-140	13663-13664	 	_	
78-141	13664-13665	6	_	
78-142	13665-13666	,	_	
78-143	13667-13668	z	_	
78-144	13668-13669	 	_	
78-145	13669-13670	=	_	
78-146	13670-13671	 	_	
78-147	13671-13672	−	_	
78-148	13672-13673	6	_	
78-149	13673-13674	,	_	
78-150	13675-13676	p	_	
78-151	13676-13677	 	_	
78-152	13677-13678	=	_	
78-153	13678-13679	 	_	
78-154	13679-13684	0.035	_	
78-155	13684-13685	)	_	
78-156	13685-13686	,	_	
78-157	13687-13690	and	_	
78-158	13691-13692	a	_	
78-159	13693-13698	small	_	
78-160	13699-13706	cluster	_	
78-161	13707-13709	in	_	
78-162	13710-13713	the	_	
78-163	13714-13719	right	_	
78-164	13720-13731	subcallosal	_	
78-165	13732-13738	cortex	_	
78-166	13739-13740	(	_	
78-167	13740-13743	MNI	_	
78-168	13743-13744	:	_	
78-169	13745-13746	x	_	
78-170	13746-13747	 	_	
78-171	13747-13748	=	_	
78-172	13748-13749	 	_	
78-173	13749-13750	8	_	
78-174	13750-13751	,	_	
78-175	13752-13753	y	_	
78-176	13753-13754	 	_	
78-177	13754-13755	=	_	
78-178	13755-13756	 	_	
78-179	13756-13758	18	_	
78-180	13758-13759	,	_	
78-181	13760-13761	z	_	
78-182	13761-13762	 	_	
78-183	13762-13763	=	_	
78-184	13763-13764	 	_	
78-185	13764-13765	−	_	
78-186	13765-13767	24	_	
78-187	13767-13768	,	_	
78-188	13769-13770	p	_	
78-189	13770-13771	 	_	
78-190	13771-13772	=	_	
78-191	13772-13773	 	_	
78-192	13773-13778	0.026	_	
78-193	13778-13779	)	_	
78-194	13779-13780	.	_	

#Text=In each of these clusters, post-hoc t-tests revealed that both NTR and TRS patients showed reductions compared to HC, all ps < 0.05, with no difference detected between the two patient groups, all ps > 0.05.
79-1	13781-13783	In	_	
79-2	13784-13788	each	_	
79-3	13789-13791	of	_	
79-4	13792-13797	these	_	
79-5	13798-13806	clusters	_	
79-6	13806-13807	,	_	
79-7	13808-13816	post-hoc	_	
79-8	13817-13824	t-tests	_	
79-9	13825-13833	revealed	_	
79-10	13834-13838	that	_	
79-11	13839-13843	both	_	
79-12	13844-13847	NTR	_	
79-13	13848-13851	and	_	
79-14	13852-13855	TRS	_	
79-15	13856-13864	patients	_	
79-16	13865-13871	showed	_	
79-17	13872-13882	reductions	_	
79-18	13883-13891	compared	_	
79-19	13892-13894	to	_	
79-20	13895-13897	HC	_	
79-21	13897-13898	,	_	
79-22	13899-13902	all	_	
79-23	13903-13905	ps	_	
79-24	13905-13906	 	_	
79-25	13906-13907	<	_	
79-26	13907-13908	 	_	
79-27	13908-13912	0.05	_	
79-28	13912-13913	,	_	
79-29	13914-13918	with	_	
79-30	13919-13921	no	_	
79-31	13922-13932	difference	_	
79-32	13933-13941	detected	_	
79-33	13942-13949	between	_	
79-34	13950-13953	the	_	
79-35	13954-13957	two	_	
79-36	13958-13965	patient	_	
79-37	13966-13972	groups	_	
79-38	13972-13973	,	_	
79-39	13974-13977	all	_	
79-40	13978-13980	ps	_	
79-41	13980-13981	 	_	
79-42	13981-13982	>	_	
79-43	13982-13983	 	_	
79-44	13983-13987	0.05	_	
79-45	13987-13988	.	_	

#Text=Mean MWF within these clusters ranged from 6% to 19% - lower than the expected range for white matter - indicating that group differences may extend to grey matter regions.
80-1	13989-13993	Mean	_	
80-2	13994-13997	MWF	_	
80-3	13998-14004	within	_	
80-4	14005-14010	these	_	
80-5	14011-14019	clusters	_	
80-6	14020-14026	ranged	_	
80-7	14027-14031	from	_	
80-8	14032-14034	6%	_	
80-9	14035-14037	to	_	
80-10	14038-14041	19%	_	
80-11	14042-14043	-	_	
80-12	14044-14049	lower	_	
80-13	14050-14054	than	_	
80-14	14055-14058	the	_	
80-15	14059-14067	expected	_	
80-16	14068-14073	range	_	
80-17	14074-14077	for	_	
80-18	14078-14083	white	_	
80-19	14084-14090	matter	_	
80-20	14091-14092	-	_	
80-21	14093-14103	indicating	_	
80-22	14104-14108	that	_	
80-23	14109-14114	group	_	
80-24	14115-14126	differences	_	
80-25	14127-14130	may	_	
80-26	14131-14137	extend	_	
80-27	14138-14140	to	_	
80-28	14141-14145	grey	_	
80-29	14146-14152	matter	_	
80-30	14153-14160	regions	_	
80-31	14160-14161	.	_	

#Text=White matter histogram analysis
#Text=Normalised histograms of white matter myelin water fraction by group.
81-1	14162-14167	White	_	
81-2	14168-14174	matter	_	
81-3	14175-14184	histogram	_	
81-4	14185-14193	analysis	_	
81-5	14194-14204	Normalised	_	
81-6	14205-14215	histograms	_	
81-7	14216-14218	of	_	
81-8	14219-14224	white	_	
81-9	14225-14231	matter	_	
81-10	14232-14238	myelin	_	
81-11	14239-14244	water	_	
81-12	14245-14253	fraction	_	
81-13	14254-14256	by	_	
81-14	14257-14262	group	_	
81-15	14262-14263	.	_	

#Text=Fig. 2
#Text=Group histograms (depicted in Fig. 2) show that voxel count peaks in the expected range for white matter (25–30%), consistent with previous mcDESPOT reports.
82-1	14264-14267	Fig	_	
82-2	14267-14268	.	_	
82-3	14269-14270	2	_	
82-4	14271-14276	Group	_	
82-5	14277-14287	histograms	_	
82-6	14288-14289	(	_	
82-7	14289-14297	depicted	_	
82-8	14298-14300	in	_	
82-9	14301-14304	Fig	_	
82-10	14304-14305	.	_	
82-11	14306-14307	2	_	
82-12	14307-14308	)	_	
82-13	14309-14313	show	_	
82-14	14314-14318	that	_	
82-15	14319-14324	voxel	_	
82-16	14325-14330	count	_	
82-17	14331-14336	peaks	_	
82-18	14337-14339	in	_	
82-19	14340-14343	the	_	
82-20	14344-14352	expected	_	
82-21	14353-14358	range	_	
82-22	14359-14362	for	_	
82-23	14363-14368	white	_	
82-24	14369-14375	matter	_	
82-25	14376-14377	(	_	
82-26	14377-14379	25	_	
82-27	14379-14380	–	_	
82-28	14380-14383	30%	_	
82-29	14383-14384	)	_	
82-30	14384-14385	,	_	
82-31	14386-14396	consistent	_	
82-32	14397-14401	with	_	
82-33	14402-14410	previous	_	
82-34	14411-14419	mcDESPOT	_	
82-35	14420-14427	reports	_	
82-36	14427-14428	.	_	

#Text=Both patient groups show shifts slightly downwards and to the left, suggesting that less voxels within the white matter fall into the normal region of MWF values.
83-1	14429-14433	Both	_	
83-2	14434-14441	patient	_	
83-3	14442-14448	groups	_	
83-4	14449-14453	show	_	
83-5	14454-14460	shifts	_	
83-6	14461-14469	slightly	_	
83-7	14470-14479	downwards	_	
83-8	14480-14483	and	_	
83-9	14484-14486	to	_	
83-10	14487-14490	the	_	
83-11	14491-14495	left	_	
83-12	14495-14496	,	_	
83-13	14497-14507	suggesting	_	
83-14	14508-14512	that	_	
83-15	14513-14517	less	_	
83-16	14518-14524	voxels	_	
83-17	14525-14531	within	_	
83-18	14532-14535	the	_	
83-19	14536-14541	white	_	
83-20	14542-14548	matter	_	
83-21	14549-14553	fall	_	
83-22	14554-14558	into	_	
83-23	14559-14562	the	_	
83-24	14563-14569	normal	_	
83-25	14570-14576	region	_	
83-26	14577-14579	of	_	
83-27	14580-14583	MWF	_	
83-28	14584-14590	values	_	
83-29	14590-14591	.	_	

#Text=Post-hoc Mann-Whitney tests (Bonferroni corrected for multiple comparisons) showed that histogram means were significantly lower in TRS compared to HC (W = 374, p = 0.045), and marginally lower in NTR compared to HC (W = 353, p = 0.064).
84-1	14592-14600	Post-hoc	_	
84-2	14601-14613	Mann-Whitney	_	
84-3	14614-14619	tests	_	
84-4	14620-14621	(	_	
84-5	14621-14631	Bonferroni	_	
84-6	14632-14641	corrected	_	
84-7	14642-14645	for	_	
84-8	14646-14654	multiple	_	
84-9	14655-14666	comparisons	_	
84-10	14666-14667	)	_	
84-11	14668-14674	showed	_	
84-12	14675-14679	that	_	
84-13	14680-14689	histogram	_	
84-14	14690-14695	means	_	
84-15	14696-14700	were	_	
84-16	14701-14714	significantly	_	
84-17	14715-14720	lower	_	
84-18	14721-14723	in	_	
84-19	14724-14727	TRS	_	
84-20	14728-14736	compared	_	
84-21	14737-14739	to	_	
84-22	14740-14742	HC	_	
84-23	14743-14744	(	_	
84-24	14744-14745	W	_	
84-25	14745-14746	 	_	
84-26	14746-14747	=	_	
84-27	14747-14748	 	_	
84-28	14748-14751	374	_	
84-29	14751-14752	,	_	
84-30	14753-14754	p	_	
84-31	14754-14755	 	_	
84-32	14755-14756	=	_	
84-33	14756-14757	 	_	
84-34	14757-14762	0.045	_	
84-35	14762-14763	)	_	
84-36	14763-14764	,	_	
84-37	14765-14768	and	_	
84-38	14769-14779	marginally	_	
84-39	14780-14785	lower	_	
84-40	14786-14788	in	_	
84-41	14789-14792	NTR	_	
84-42	14793-14801	compared	_	
84-43	14802-14804	to	_	
84-44	14805-14807	HC	_	
84-45	14808-14809	(	_	
84-46	14809-14810	W	_	
84-47	14810-14811	 	_	
84-48	14811-14812	=	_	
84-49	14812-14813	 	_	
84-50	14813-14816	353	_	
84-51	14816-14817	,	_	
84-52	14818-14819	p	_	
84-53	14819-14820	 	_	
84-54	14820-14821	=	_	
84-55	14821-14822	 	_	
84-56	14822-14827	0.064	_	
84-57	14827-14828	)	_	
84-58	14828-14829	.	_	

#Text=The variance was greater in both NTR and TRS compared to HC, all ps < 0.05.
85-1	14830-14833	The	_	
85-2	14834-14842	variance	_	
85-3	14843-14846	was	_	
85-4	14847-14854	greater	_	
85-5	14855-14857	in	_	
85-6	14858-14862	both	_	
85-7	14863-14866	NTR	_	
85-8	14867-14870	and	_	
85-9	14871-14874	TRS	_	
85-10	14875-14883	compared	_	
85-11	14884-14886	to	_	
85-12	14887-14889	HC	_	
85-13	14889-14890	,	_	
85-14	14891-14894	all	_	
85-15	14895-14897	ps	_	
85-16	14897-14898	 	_	
85-17	14898-14899	<	_	
85-18	14899-14900	 	_	
85-19	14900-14904	0.05	_	
85-20	14904-14905	.	_	

#Text=Peak height was reduced in both patient groups compared to HC, although these tests did not survive corrections for multiple comparisons.
86-1	14906-14910	Peak	_	
86-2	14911-14917	height	_	
86-3	14918-14921	was	_	
86-4	14922-14929	reduced	_	
86-5	14930-14932	in	_	
86-6	14933-14937	both	_	
86-7	14938-14945	patient	_	
86-8	14946-14952	groups	_	
86-9	14953-14961	compared	_	
86-10	14962-14964	to	_	
86-11	14965-14967	HC	_	
86-12	14967-14968	,	_	
86-13	14969-14977	although	_	
86-14	14978-14983	these	_	
86-15	14984-14989	tests	_	
86-16	14990-14993	did	_	
86-17	14994-14997	not	_	
86-18	14998-15005	survive	_	
86-19	15006-15017	corrections	_	
86-20	15018-15021	for	_	
86-21	15022-15030	multiple	_	
86-22	15031-15042	comparisons	_	
86-23	15042-15043	.	_	

#Text=There were no differences between NTR and TRS groups on any of the histogram measures (Table 1).
87-1	15044-15049	There	_	
87-2	15050-15054	were	_	
87-3	15055-15057	no	_	
87-4	15058-15069	differences	_	
87-5	15070-15077	between	_	
87-6	15078-15081	NTR	_	
87-7	15082-15085	and	_	
87-8	15086-15089	TRS	_	
87-9	15090-15096	groups	_	
87-10	15097-15099	on	_	
87-11	15100-15103	any	_	
87-12	15104-15106	of	_	
87-13	15107-15110	the	_	
87-14	15111-15120	histogram	_	
87-15	15121-15129	measures	_	
87-16	15130-15131	(	_	
87-17	15131-15136	Table	_	
87-18	15137-15138	1	_	
87-19	15138-15139	)	_	
87-20	15139-15140	.	_	

#Text=MWF and the Stroop effect
#Text=Stroop data from one HC and one TRS subject were not available due to technical issues.
88-1	15141-15144	MWF	_	
88-2	15145-15148	and	_	
88-3	15149-15152	the	_	
88-4	15153-15159	Stroop	_	
88-5	15160-15166	effect	_	
88-6	15167-15173	Stroop	_	
88-7	15174-15178	data	_	
88-8	15179-15183	from	_	
88-9	15184-15187	one	_	
88-10	15188-15190	HC	_	
88-11	15191-15194	and	_	
88-12	15195-15198	one	_	
88-13	15199-15202	TRS	_	
88-14	15203-15210	subject	_	
88-15	15211-15215	were	_	
88-16	15216-15219	not	_	
88-17	15220-15229	available	_	
88-18	15230-15233	due	_	
88-19	15234-15236	to	_	
88-20	15237-15246	technical	_	
88-21	15247-15253	issues	_	
88-22	15253-15254	.	_	

#Text=There was a main effect of group on RT Stroop effect.
89-1	15255-15260	There	_	
89-2	15261-15264	was	_	
89-3	15265-15266	a	_	
89-4	15267-15271	main	_	
89-5	15272-15278	effect	_	
89-6	15279-15281	of	_	
89-7	15282-15287	group	_	
89-8	15288-15290	on	_	
89-9	15291-15293	RT	_	
89-10	15294-15300	Stroop	_	
89-11	15301-15307	effect	_	
89-12	15307-15308	.	_	

#Text=Pairwise comparisons revealed that both TRS (M = 186.66 ms; SD = 128.26 ms) and NTR (M = 169.78 ms; SD = 129.95 ms) showed a greater Stroop effect than HC (M = 85.14 ms; SD = 71.87), all ps < 0.05 (Bonferroni corrected), with no difference between the two patient groups, p = 0.627.
90-1	15309-15317	Pairwise	_	
90-2	15318-15329	comparisons	_	
90-3	15330-15338	revealed	_	
90-4	15339-15343	that	_	
90-5	15344-15348	both	_	
90-6	15349-15352	TRS	_	
90-7	15353-15354	(	_	
90-8	15354-15355	M	_	
90-9	15355-15356	 	_	
90-10	15356-15357	=	_	
90-11	15357-15358	 	_	
90-12	15358-15364	186.66	_	
90-13	15364-15365	 	_	
90-14	15365-15367	ms	_	
90-15	15367-15368	;	_	
90-16	15369-15371	SD	_	
90-17	15371-15372	 	_	
90-18	15372-15373	=	_	
90-19	15373-15374	 	_	
90-20	15374-15380	128.26	_	
90-21	15380-15381	 	_	
90-22	15381-15383	ms	_	
90-23	15383-15384	)	_	
90-24	15385-15388	and	_	
90-25	15389-15392	NTR	_	
90-26	15393-15394	(	_	
90-27	15394-15395	M	_	
90-28	15395-15396	 	_	
90-29	15396-15397	=	_	
90-30	15397-15398	 	_	
90-31	15398-15404	169.78	_	
90-32	15404-15405	 	_	
90-33	15405-15407	ms	_	
90-34	15407-15408	;	_	
90-35	15409-15411	SD	_	
90-36	15411-15412	 	_	
90-37	15412-15413	=	_	
90-38	15413-15414	 	_	
90-39	15414-15420	129.95	_	
90-40	15420-15421	 	_	
90-41	15421-15423	ms	_	
90-42	15423-15424	)	_	
90-43	15425-15431	showed	_	
90-44	15432-15433	a	_	
90-45	15434-15441	greater	_	
90-46	15442-15448	Stroop	_	
90-47	15449-15455	effect	_	
90-48	15456-15460	than	_	
90-49	15461-15463	HC	_	
90-50	15464-15465	(	_	
90-51	15465-15466	M	_	
90-52	15466-15467	 	_	
90-53	15467-15468	=	_	
90-54	15468-15469	 	_	
90-55	15469-15474	85.14	_	
90-56	15474-15475	 	_	
90-57	15475-15477	ms	_	
90-58	15477-15478	;	_	
90-59	15479-15481	SD	_	
90-60	15481-15482	 	_	
90-61	15482-15483	=	_	
90-62	15483-15484	 	_	
90-63	15484-15489	71.87	_	
90-64	15489-15490	)	_	
90-65	15490-15491	,	_	
90-66	15492-15495	all	_	
90-67	15496-15498	ps	_	
90-68	15498-15499	 	_	
90-69	15499-15500	<	_	
90-70	15500-15501	 	_	
90-71	15501-15505	0.05	_	
90-72	15506-15507	(	_	
90-73	15507-15517	Bonferroni	_	
90-74	15518-15527	corrected	_	
90-75	15527-15528	)	_	
90-76	15528-15529	,	_	
90-77	15530-15534	with	_	
90-78	15535-15537	no	_	
90-79	15538-15548	difference	_	
90-80	15549-15556	between	_	
90-81	15557-15560	the	_	
90-82	15561-15564	two	_	
90-83	15565-15572	patient	_	
90-84	15573-15579	groups	_	
90-85	15579-15580	,	_	
90-86	15581-15582	p	_	
90-87	15582-15583	 	_	
90-88	15583-15584	=	_	
90-89	15584-15585	 	_	
90-90	15585-15590	0.627	_	
90-91	15590-15591	.	_	

#Text=Significant correlation between Stroop effect and myelin water fraction.
91-1	15592-15603	Significant	_	
91-2	15604-15615	correlation	_	
91-3	15616-15623	between	_	
91-4	15624-15630	Stroop	_	
91-5	15631-15637	effect	_	
91-6	15638-15641	and	_	
91-7	15642-15648	myelin	_	
91-8	15649-15654	water	_	
91-9	15655-15663	fraction	_	
91-10	15663-15664	.	_	

#Text=Fig. 3
#Text=Mediation diagram of the association between group, Stroop effect, and callosal myelin water fraction.
92-1	15665-15668	Fig	_	
92-2	15668-15669	.	_	
92-3	15670-15671	3	_	
92-4	15672-15681	Mediation	_	
92-5	15682-15689	diagram	_	
92-6	15690-15692	of	_	
92-7	15693-15696	the	_	
92-8	15697-15708	association	_	
92-9	15709-15716	between	_	
92-10	15717-15722	group	_	
92-11	15722-15723	,	_	
92-12	15724-15730	Stroop	_	
92-13	15731-15737	effect	_	
92-14	15737-15738	,	_	
92-15	15739-15742	and	_	
92-16	15743-15751	callosal	_	
92-17	15752-15758	myelin	_	
92-18	15759-15764	water	_	
92-19	15765-15773	fraction	_	
92-20	15773-15774	.	_	

#Text=Fig. 4
#Text=A large cluster consisting of the corpus callosum (genu, body, and splenium) was negatively related with RT Stroop effect across all subjects, such that higher MWF values were associated with a smaller Stroop effect (Fig. 3).
93-1	15775-15778	Fig	_	
93-2	15778-15779	.	_	
93-3	15780-15781	4	_	
93-4	15782-15783	A	_	
93-5	15784-15789	large	_	
93-6	15790-15797	cluster	_	
93-7	15798-15808	consisting	_	
93-8	15809-15811	of	_	
93-9	15812-15815	the	_	
93-10	15816-15822	corpus	_	
93-11	15823-15831	callosum	_	
93-12	15832-15833	(	_	
93-13	15833-15837	genu	_	
93-14	15837-15838	,	_	
93-15	15839-15843	body	_	
93-16	15843-15844	,	_	
93-17	15845-15848	and	_	
93-18	15849-15857	splenium	_	
93-19	15857-15858	)	_	
93-20	15859-15862	was	_	
93-21	15863-15873	negatively	_	
93-22	15874-15881	related	_	
93-23	15882-15886	with	_	
93-24	15887-15889	RT	_	
93-25	15890-15896	Stroop	_	
93-26	15897-15903	effect	_	
93-27	15904-15910	across	_	
93-28	15911-15914	all	_	
93-29	15915-15923	subjects	_	
93-30	15923-15924	,	_	
93-31	15925-15929	such	_	
93-32	15930-15934	that	_	
93-33	15935-15941	higher	_	
93-34	15942-15945	MWF	_	
93-35	15946-15952	values	_	
93-36	15953-15957	were	_	
93-37	15958-15968	associated	_	
93-38	15969-15973	with	_	
93-39	15974-15975	a	_	
93-40	15976-15983	smaller	_	
93-41	15984-15990	Stroop	_	
93-42	15991-15997	effect	_	
93-43	15998-15999	(	_	
93-44	15999-16002	Fig	_	
93-45	16002-16003	.	_	
93-46	16004-16005	3	_	
93-47	16005-16006	)	_	
93-48	16006-16007	.	_	

#Text=We extracted mean MWF from within this cluster for each subject for further analyses.
94-1	16008-16010	We	_	
94-2	16011-16020	extracted	_	
94-3	16021-16025	mean	_	
94-4	16026-16029	MWF	_	
94-5	16030-16034	from	_	
94-6	16035-16041	within	_	
94-7	16042-16046	this	_	
94-8	16047-16054	cluster	_	
94-9	16055-16058	for	_	
94-10	16059-16063	each	_	
94-11	16064-16071	subject	_	
94-12	16072-16075	for	_	
94-13	16076-16083	further	_	
94-14	16084-16092	analyses	_	
94-15	16092-16093	.	_	

#Text=The negative correlation was evident within each group separately (HC: R = −0.35, p = 0.09; NTR: R = −0.50, p = 0.021; TRS: R = −0.59, p = 0.005).
95-1	16094-16097	The	_	
95-2	16098-16106	negative	_	
95-3	16107-16118	correlation	_	
95-4	16119-16122	was	_	
95-5	16123-16130	evident	_	
95-6	16131-16137	within	_	
95-7	16138-16142	each	_	
95-8	16143-16148	group	_	
95-9	16149-16159	separately	_	
95-10	16160-16161	(	_	
95-11	16161-16163	HC	_	
95-12	16163-16164	:	_	
95-13	16165-16166	R	_	
95-14	16166-16167	 	_	
95-15	16167-16168	=	_	
95-16	16168-16169	 	_	
95-17	16169-16170	−	_	
95-18	16170-16174	0.35	_	
95-19	16174-16175	,	_	
95-20	16176-16177	p	_	
95-21	16177-16178	 	_	
95-22	16178-16179	=	_	
95-23	16179-16180	 	_	
95-24	16180-16184	0.09	_	
95-25	16184-16185	;	_	
95-26	16186-16189	NTR	_	
95-27	16189-16190	:	_	
95-28	16191-16192	R	_	
95-29	16192-16193	 	_	
95-30	16193-16194	=	_	
95-31	16194-16195	 	_	
95-32	16195-16196	−	_	
95-33	16196-16200	0.50	_	
95-34	16200-16201	,	_	
95-35	16202-16203	p	_	
95-36	16203-16204	 	_	
95-37	16204-16205	=	_	
95-38	16205-16206	 	_	
95-39	16206-16211	0.021	_	
95-40	16211-16212	;	_	
95-41	16213-16216	TRS	_	
95-42	16216-16217	:	_	
95-43	16218-16219	R	_	
95-44	16219-16220	 	_	
95-45	16220-16221	=	_	
95-46	16221-16222	 	_	
95-47	16222-16223	−	_	
95-48	16223-16227	0.59	_	
95-49	16227-16228	,	_	
95-50	16229-16230	p	_	
95-51	16230-16231	 	_	
95-52	16231-16232	=	_	
95-53	16232-16233	 	_	
95-54	16233-16238	0.005	_	
95-55	16238-16239	)	_	
95-56	16239-16240	.	_	

#Text=Pairwise comparisons of mean MWF in the corpus callosum between HC and the two patient subgroups did not survive Bonferroni corrections for multiple comparisons; hence NTR and TRS patients were pooled into a single schizophrenia (SZ) group for the mediation analysis.
96-1	16241-16249	Pairwise	_	
96-2	16250-16261	comparisons	_	
96-3	16262-16264	of	_	
96-4	16265-16269	mean	_	
96-5	16270-16273	MWF	_	
96-6	16274-16276	in	_	
96-7	16277-16280	the	_	
96-8	16281-16287	corpus	_	
96-9	16288-16296	callosum	_	
96-10	16297-16304	between	_	
96-11	16305-16307	HC	_	
96-12	16308-16311	and	_	
96-13	16312-16315	the	_	
96-14	16316-16319	two	_	
96-15	16320-16327	patient	_	
96-16	16328-16337	subgroups	_	
96-17	16338-16341	did	_	
96-18	16342-16345	not	_	
96-19	16346-16353	survive	_	
96-20	16354-16364	Bonferroni	_	
96-21	16365-16376	corrections	_	
96-22	16377-16380	for	_	
96-23	16381-16389	multiple	_	
96-24	16390-16401	comparisons	_	
96-25	16401-16402	;	_	
96-26	16403-16408	hence	_	
96-27	16409-16412	NTR	_	
96-28	16413-16416	and	_	
96-29	16417-16420	TRS	_	
96-30	16421-16429	patients	_	
96-31	16430-16434	were	_	
96-32	16435-16441	pooled	_	
96-33	16442-16446	into	_	
96-34	16447-16448	a	_	
96-35	16449-16455	single	_	
96-36	16456-16469	schizophrenia	_	
96-37	16470-16471	(	_	
96-38	16471-16473	SZ	_	
96-39	16473-16474	)	_	
96-40	16475-16480	group	_	
96-41	16481-16484	for	_	
96-42	16485-16488	the	_	
96-43	16489-16498	mediation	_	
96-44	16499-16507	analysis	_	
96-45	16507-16508	.	_	

#Text=We tested whether corpus callosum MWF mediated group differences in the Stroop effect following the Baron and Kenny approach (; Fig. 4).
97-1	16509-16511	We	_	
97-2	16512-16518	tested	_	
97-3	16519-16526	whether	_	
97-4	16527-16533	corpus	_	
97-5	16534-16542	callosum	_	
97-6	16543-16546	MWF	_	
97-7	16547-16555	mediated	_	
97-8	16556-16561	group	_	
97-9	16562-16573	differences	_	
97-10	16574-16576	in	_	
97-11	16577-16580	the	_	
97-12	16581-16587	Stroop	_	
97-13	16588-16594	effect	_	
97-14	16595-16604	following	_	
97-15	16605-16608	the	_	
97-16	16609-16614	Baron	_	
97-17	16615-16618	and	_	
97-18	16619-16624	Kenny	_	
97-19	16625-16633	approach	_	
97-20	16634-16635	(	_	
97-21	16635-16636	;	_	
97-22	16637-16640	Fig	_	
97-23	16640-16641	.	_	
97-24	16642-16643	4	_	
97-25	16643-16644	)	_	
97-26	16644-16645	.	_	

#Text=Regressing the Stroop effect on group (HC vs.
98-1	16646-16656	Regressing	_	
98-2	16657-16660	the	_	
98-3	16661-16667	Stroop	_	
98-4	16668-16674	effect	_	
98-5	16675-16677	on	_	
98-6	16678-16683	group	_	
98-7	16684-16685	(	_	
98-8	16685-16687	HC	_	
98-9	16688-16690	vs	_	
98-10	16690-16691	.	_	

#Text=SZ) showed a significant effect of group (beta = 93.08, sd = 28.93, p = 0.002).
99-1	16692-16694	SZ	_	
99-2	16694-16695	)	_	
99-3	16696-16702	showed	_	
99-4	16703-16704	a	_	
99-5	16705-16716	significant	_	
99-6	16717-16723	effect	_	
99-7	16724-16726	of	_	
99-8	16727-16732	group	_	
99-9	16733-16734	(	_	
99-10	16734-16738	beta	_	
99-11	16738-16739	 	_	
99-12	16739-16740	=	_	
99-13	16740-16741	 	_	
99-14	16741-16746	93.08	_	
99-15	16746-16747	,	_	
99-16	16748-16750	sd	_	
99-17	16750-16751	 	_	
99-18	16751-16752	=	_	
99-19	16752-16753	 	_	
99-20	16753-16758	28.93	_	
99-21	16758-16759	,	_	
99-22	16760-16761	p	_	
99-23	16761-16762	 	_	
99-24	16762-16763	=	_	
99-25	16763-16764	 	_	
99-26	16764-16769	0.002	_	
99-27	16769-16770	)	_	
99-28	16770-16771	.	_	

#Text=Regressing corpus callosum MWF on group showed a significant effect of group, (beta = −0.01, sd = 0.01, p = 0.019), with higher MWF in HC (M = 0.20, SD = 0.1) compared to SZ (M = 0.19, SD = 0.17).
100-1	16772-16782	Regressing	_	
100-2	16783-16789	corpus	_	
100-3	16790-16798	callosum	_	
100-4	16799-16802	MWF	_	
100-5	16803-16805	on	_	
100-6	16806-16811	group	_	
100-7	16812-16818	showed	_	
100-8	16819-16820	a	_	
100-9	16821-16832	significant	_	
100-10	16833-16839	effect	_	
100-11	16840-16842	of	_	
100-12	16843-16848	group	_	
100-13	16848-16849	,	_	
100-14	16850-16851	(	_	
100-15	16851-16855	beta	_	
100-16	16855-16856	 	_	
100-17	16856-16857	=	_	
100-18	16857-16858	 	_	
100-19	16858-16859	−	_	
100-20	16859-16863	0.01	_	
100-21	16863-16864	,	_	
100-22	16865-16867	sd	_	
100-23	16867-16868	 	_	
100-24	16868-16869	=	_	
100-25	16869-16870	 	_	
100-26	16870-16874	0.01	_	
100-27	16874-16875	,	_	
100-28	16876-16877	p	_	
100-29	16877-16878	 	_	
100-30	16878-16879	=	_	
100-31	16879-16880	 	_	
100-32	16880-16885	0.019	_	
100-33	16885-16886	)	_	
100-34	16886-16887	,	_	
100-35	16888-16892	with	_	
100-36	16893-16899	higher	_	
100-37	16900-16903	MWF	_	
100-38	16904-16906	in	_	
100-39	16907-16909	HC	_	
100-40	16910-16911	(	_	
100-41	16911-16912	M	_	
100-42	16912-16913	 	_	
100-43	16913-16914	=	_	
100-44	16914-16915	 	_	
100-45	16915-16919	0.20	_	
100-46	16919-16920	,	_	
100-47	16921-16923	SD	_	
100-48	16923-16924	 	_	
100-49	16924-16925	=	_	
100-50	16925-16926	 	_	
100-51	16926-16929	0.1	_	
100-52	16929-16930	)	_	
100-53	16931-16939	compared	_	
100-54	16940-16942	to	_	
100-55	16943-16945	SZ	_	
100-56	16946-16947	(	_	
100-57	16947-16948	M	_	
100-58	16948-16949	 	_	
100-59	16949-16950	=	_	
100-60	16950-16951	 	_	
100-61	16951-16955	0.19	_	
100-62	16955-16956	,	_	
100-63	16957-16959	SD	_	
100-64	16959-16960	 	_	
100-65	16960-16961	=	_	
100-66	16961-16962	 	_	
100-67	16962-16966	0.17	_	
100-68	16966-16967	)	_	
100-69	16967-16968	.	_	

#Text=Finally, regressing the Stroop effect on both group and corpus callosum MWF revealed a significant effect of MWF (beta = −3534.33, sd = 765.24, p < 0.001).
101-1	16969-16976	Finally	_	
101-2	16976-16977	,	_	
101-3	16978-16988	regressing	_	
101-4	16989-16992	the	_	
101-5	16993-16999	Stroop	_	
101-6	17000-17006	effect	_	
101-7	17007-17009	on	_	
101-8	17010-17014	both	_	
101-9	17015-17020	group	_	
101-10	17021-17024	and	_	
101-11	17025-17031	corpus	_	
101-12	17032-17040	callosum	_	
101-13	17041-17044	MWF	_	
101-14	17045-17053	revealed	_	
101-15	17054-17055	a	_	
101-16	17056-17067	significant	_	
101-17	17068-17074	effect	_	
101-18	17075-17077	of	_	
101-19	17078-17081	MWF	_	
101-20	17082-17083	(	_	
101-21	17083-17087	beta	_	
101-22	17087-17088	 	_	
101-23	17088-17089	=	_	
101-24	17089-17090	 	_	
101-25	17090-17091	−	_	
101-26	17091-17098	3534.33	_	
101-27	17098-17099	,	_	
101-28	17100-17102	sd	_	
101-29	17102-17103	 	_	
101-30	17103-17104	=	_	
101-31	17104-17105	 	_	
101-32	17105-17111	765.24	_	
101-33	17111-17112	,	_	
101-34	17113-17114	p	_	
101-35	17114-17115	 	_	
101-36	17115-17116	<	_	
101-37	17116-17117	 	_	
101-38	17117-17122	0.001	_	
101-39	17122-17123	)	_	
101-40	17123-17124	.	_	

#Text=The effect of group (beta = 60.42, sd = 26.13, p = 0.02), though significant, was reduced compared to the simple model regressing the Stroop effect on group alone.
102-1	17125-17128	The	_	
102-2	17129-17135	effect	_	
102-3	17136-17138	of	_	
102-4	17139-17144	group	_	
102-5	17145-17146	(	_	
102-6	17146-17150	beta	_	
102-7	17150-17151	 	_	
102-8	17151-17152	=	_	
102-9	17152-17153	 	_	
102-10	17153-17158	60.42	_	
102-11	17158-17159	,	_	
102-12	17160-17162	sd	_	
102-13	17162-17163	 	_	
102-14	17163-17164	=	_	
102-15	17164-17165	 	_	
102-16	17165-17170	26.13	_	
102-17	17170-17171	,	_	
102-18	17172-17173	p	_	
102-19	17173-17174	 	_	
102-20	17174-17175	=	_	
102-21	17175-17176	 	_	
102-22	17176-17180	0.02	_	
102-23	17180-17181	)	_	
102-24	17181-17182	,	_	
102-25	17183-17189	though	_	
102-26	17190-17201	significant	_	
102-27	17201-17202	,	_	
102-28	17203-17206	was	_	
102-29	17207-17214	reduced	_	
102-30	17215-17223	compared	_	
102-31	17224-17226	to	_	
102-32	17227-17230	the	_	
102-33	17231-17237	simple	_	
102-34	17238-17243	model	_	
102-35	17244-17254	regressing	_	
102-36	17255-17258	the	_	
102-37	17259-17265	Stroop	_	
102-38	17266-17272	effect	_	
102-39	17273-17275	on	_	
102-40	17276-17281	group	_	
102-41	17282-17287	alone	_	
102-42	17287-17288	.	_	

#Text=An analysis of the indirect effect (defined as the product between the effect of group on MWF and the effect of MWF on RT Stroop, controlling for group) was performed with non-parametric bootstrapping of the sampling distribution using 5000 bootstrap samples.
103-1	17289-17291	An	_	
103-2	17292-17300	analysis	_	
103-3	17301-17303	of	_	
103-4	17304-17307	the	_	
103-5	17308-17316	indirect	_	
103-6	17317-17323	effect	_	
103-7	17324-17325	(	_	
103-8	17325-17332	defined	_	
103-9	17333-17335	as	_	
103-10	17336-17339	the	_	
103-11	17340-17347	product	_	
103-12	17348-17355	between	_	
103-13	17356-17359	the	_	
103-14	17360-17366	effect	_	
103-15	17367-17369	of	_	
103-16	17370-17375	group	_	
103-17	17376-17378	on	_	
103-18	17379-17382	MWF	_	
103-19	17383-17386	and	_	
103-20	17387-17390	the	_	
103-21	17391-17397	effect	_	
103-22	17398-17400	of	_	
103-23	17401-17404	MWF	_	
103-24	17405-17407	on	_	
103-25	17408-17410	RT	_	
103-26	17411-17417	Stroop	_	
103-27	17417-17418	,	_	
103-28	17419-17430	controlling	_	
103-29	17431-17434	for	_	
103-30	17435-17440	group	_	
103-31	17440-17441	)	_	
103-32	17442-17445	was	_	
103-33	17446-17455	performed	_	
103-34	17456-17460	with	_	
103-35	17461-17475	non-parametric	_	
103-36	17476-17489	bootstrapping	_	
103-37	17490-17492	of	_	
103-38	17493-17496	the	_	
103-39	17497-17505	sampling	_	
103-40	17506-17518	distribution	_	
103-41	17519-17524	using	_	
103-42	17525-17529	5000	_	
103-43	17530-17539	bootstrap	_	
103-44	17540-17547	samples	_	
103-45	17547-17548	.	_	

#Text=This revealed a significant indirect effect (95% confidence interval [4.69, 67.50]); suggesting that there was a partial mediation of the effect of group on Stroop effect by corpus callosum MWF.
104-1	17549-17553	This	_	
104-2	17554-17562	revealed	_	
104-3	17563-17564	a	_	
104-4	17565-17576	significant	_	
104-5	17577-17585	indirect	_	
104-6	17586-17592	effect	_	
104-7	17593-17594	(	_	
104-8	17594-17597	95%	_	
104-9	17598-17608	confidence	_	
104-10	17609-17617	interval	_	
104-11	17618-17619	[	_	
104-12	17619-17623	4.69	_	
104-13	17623-17624	,	_	
104-14	17625-17630	67.50	_	
104-15	17630-17631	]	_	
104-16	17631-17632	)	_	
104-17	17632-17633	;	_	
104-18	17634-17644	suggesting	_	
104-19	17645-17649	that	_	
104-20	17650-17655	there	_	
104-21	17656-17659	was	_	
104-22	17660-17661	a	_	
104-23	17662-17669	partial	_	
104-24	17670-17679	mediation	_	
104-25	17680-17682	of	_	
104-26	17683-17686	the	_	
104-27	17687-17693	effect	_	
104-28	17694-17696	of	_	
104-29	17697-17702	group	_	
104-30	17703-17705	on	_	
104-31	17706-17712	Stroop	_	
104-32	17713-17719	effect	_	
104-33	17720-17722	by	_	
104-34	17723-17729	corpus	_	
104-35	17730-17738	callosum	_	
104-36	17739-17742	MWF	_	
104-37	17742-17743	.	_	

#Text=Relationship with clinical variables
#Text=For each of the four significant clusters from the whole-brain MWF group analysis as well as the corpus callosum cluster from the Stroop analysis, we performed an exploratory analysis of correlations of MWF with PANSS positive symptom score, PANSS negative symptom score, illness duration, and CPZ equivalent medication dosages, both across all patients as well as within the two patient groups separately.
105-1	17744-17756	Relationship	_	
105-2	17757-17761	with	_	
105-3	17762-17770	clinical	_	
105-4	17771-17780	variables	_	
105-5	17781-17784	For	_	
105-6	17785-17789	each	_	
105-7	17790-17792	of	_	
105-8	17793-17796	the	_	
105-9	17797-17801	four	_	
105-10	17802-17813	significant	_	
105-11	17814-17822	clusters	_	
105-12	17823-17827	from	_	
105-13	17828-17831	the	_	
105-14	17832-17843	whole-brain	_	
105-15	17844-17847	MWF	_	
105-16	17848-17853	group	_	
105-17	17854-17862	analysis	_	
105-18	17863-17865	as	_	
105-19	17866-17870	well	_	
105-20	17871-17873	as	_	
105-21	17874-17877	the	_	
105-22	17878-17884	corpus	_	
105-23	17885-17893	callosum	_	
105-24	17894-17901	cluster	_	
105-25	17902-17906	from	_	
105-26	17907-17910	the	_	
105-27	17911-17917	Stroop	_	
105-28	17918-17926	analysis	_	
105-29	17926-17927	,	_	
105-30	17928-17930	we	_	
105-31	17931-17940	performed	_	
105-32	17941-17943	an	_	
105-33	17944-17955	exploratory	_	
105-34	17956-17964	analysis	_	
105-35	17965-17967	of	_	
105-36	17968-17980	correlations	_	
105-37	17981-17983	of	_	
105-38	17984-17987	MWF	_	
105-39	17988-17992	with	_	
105-40	17993-17998	PANSS	_	
105-41	17999-18007	positive	_	
105-42	18008-18015	symptom	_	
105-43	18016-18021	score	_	
105-44	18021-18022	,	_	
105-45	18023-18028	PANSS	_	
105-46	18029-18037	negative	_	
105-47	18038-18045	symptom	_	
105-48	18046-18051	score	_	
105-49	18051-18052	,	_	
105-50	18053-18060	illness	_	
105-51	18061-18069	duration	_	
105-52	18069-18070	,	_	
105-53	18071-18074	and	_	
105-54	18075-18078	CPZ	_	
105-55	18079-18089	equivalent	_	
105-56	18090-18100	medication	_	
105-57	18101-18108	dosages	_	
105-58	18108-18109	,	_	
105-59	18110-18114	both	_	
105-60	18115-18121	across	_	
105-61	18122-18125	all	_	
105-62	18126-18134	patients	_	
105-63	18135-18137	as	_	
105-64	18138-18142	well	_	
105-65	18143-18145	as	_	
105-66	18146-18152	within	_	
105-67	18153-18156	the	_	
105-68	18157-18160	two	_	
105-69	18161-18168	patient	_	
105-70	18169-18175	groups	_	
105-71	18176-18186	separately	_	
105-72	18186-18187	.	_	

#Text=No correlation was significant, all ps > 0.05 (uncorrected for multiple comparisons).
106-1	18188-18190	No	_	
106-2	18191-18202	correlation	_	
106-3	18203-18206	was	_	
106-4	18207-18218	significant	_	
106-5	18218-18219	,	_	
106-6	18220-18223	all	_	
106-7	18224-18226	ps	_	
106-8	18226-18227	 	_	
106-9	18227-18228	>	_	
106-10	18228-18229	 	_	
106-11	18229-18233	0.05	_	
106-12	18234-18235	(	_	
106-13	18235-18246	uncorrected	_	
106-14	18247-18250	for	_	
106-15	18251-18259	multiple	_	
106-16	18260-18271	comparisons	_	
106-17	18271-18272	)	_	
106-18	18272-18273	.	_	

#Text=Discussion
#Text=In this study we report the application of mcDESPOT to a sample of patients with a diagnosis of schizophrenia, stratified by treatment response, and healthy controls.
107-1	18274-18284	Discussion	_	
107-2	18285-18287	In	_	
107-3	18288-18292	this	_	
107-4	18293-18298	study	_	
107-5	18299-18301	we	_	
107-6	18302-18308	report	_	
107-7	18309-18312	the	_	
107-8	18313-18324	application	_	
107-9	18325-18327	of	_	
107-10	18328-18336	mcDESPOT	_	
107-11	18337-18339	to	_	
107-12	18340-18341	a	_	
107-13	18342-18348	sample	_	
107-14	18349-18351	of	_	
107-15	18352-18360	patients	_	
107-16	18361-18365	with	_	
107-17	18366-18367	a	_	
107-18	18368-18377	diagnosis	_	
107-19	18378-18380	of	_	
107-20	18381-18394	schizophrenia	_	
107-21	18394-18395	,	_	
107-22	18396-18406	stratified	_	
107-23	18407-18409	by	_	
107-24	18410-18419	treatment	_	
107-25	18420-18428	response	_	
107-26	18428-18429	,	_	
107-27	18430-18433	and	_	
107-28	18434-18441	healthy	_	
107-29	18442-18450	controls	_	
107-30	18450-18451	.	_	

#Text=We show that this method is sensitive to reductions in myelin water fraction (MWF) in schizophrenia compared to healthy controls, with the greatest effect evident in areas surrounding bilateral striatum, particularly the inferior fronto-occipital fasciculus, as well as the cerebellum.
108-1	18452-18454	We	_	
108-2	18455-18459	show	_	
108-3	18460-18464	that	_	
108-4	18465-18469	this	_	
108-5	18470-18476	method	_	
108-6	18477-18479	is	_	
108-7	18480-18489	sensitive	_	
108-8	18490-18492	to	_	
108-9	18493-18503	reductions	_	
108-10	18504-18506	in	_	
108-11	18507-18513	myelin	_	
108-12	18514-18519	water	_	
108-13	18520-18528	fraction	_	
108-14	18529-18530	(	_	
108-15	18530-18533	MWF	_	
108-16	18533-18534	)	_	
108-17	18535-18537	in	_	
108-18	18538-18551	schizophrenia	_	
108-19	18552-18560	compared	_	
108-20	18561-18563	to	_	
108-21	18564-18571	healthy	_	
108-22	18572-18580	controls	_	
108-23	18580-18581	,	_	
108-24	18582-18586	with	_	
108-25	18587-18590	the	_	
108-26	18591-18599	greatest	_	
108-27	18600-18606	effect	_	
108-28	18607-18614	evident	_	
108-29	18615-18617	in	_	
108-30	18618-18623	areas	_	
108-31	18624-18635	surrounding	_	
108-32	18636-18645	bilateral	_	
108-33	18646-18654	striatum	_	
108-34	18654-18655	,	_	
108-35	18656-18668	particularly	_	
108-36	18669-18672	the	_	
108-37	18673-18681	inferior	_	
108-38	18682-18698	fronto-occipital	_	
108-39	18699-18709	fasciculus	_	
108-40	18709-18710	,	_	
108-41	18711-18713	as	_	
108-42	18714-18718	well	_	
108-43	18719-18721	as	_	
108-44	18722-18725	the	_	
108-45	18726-18736	cerebellum	_	
108-46	18736-18737	.	_	

#Text=Reductions in the patient groups were bilateral but with larger clusters observed within the left cerebral hemisphere.
109-1	18738-18748	Reductions	_	
109-2	18749-18751	in	_	
109-3	18752-18755	the	_	
109-4	18756-18763	patient	_	
109-5	18764-18770	groups	_	
109-6	18771-18775	were	_	
109-7	18776-18785	bilateral	_	
109-8	18786-18789	but	_	
109-9	18790-18794	with	_	
109-10	18795-18801	larger	_	
109-11	18802-18810	clusters	_	
109-12	18811-18819	observed	_	
109-13	18820-18826	within	_	
109-14	18827-18830	the	_	
109-15	18831-18835	left	_	
109-16	18836-18844	cerebral	_	
109-17	18845-18855	hemisphere	_	
109-18	18855-18856	.	_	

#Text=Mean MWF in the significant areas were below the expected range for white matter, thus suggesting that the reductions included both white and grey matter voxels.
110-1	18857-18861	Mean	_	
110-2	18862-18865	MWF	_	
110-3	18866-18868	in	_	
110-4	18869-18872	the	_	
110-5	18873-18884	significant	_	
110-6	18885-18890	areas	_	
110-7	18891-18895	were	_	
110-8	18896-18901	below	_	
110-9	18902-18905	the	_	
110-10	18906-18914	expected	_	
110-11	18915-18920	range	_	
110-12	18921-18924	for	_	
110-13	18925-18930	white	_	
110-14	18931-18937	matter	_	
110-15	18937-18938	,	_	
110-16	18939-18943	thus	_	
110-17	18944-18954	suggesting	_	
110-18	18955-18959	that	_	
110-19	18960-18963	the	_	
110-20	18964-18974	reductions	_	
110-21	18975-18983	included	_	
110-22	18984-18988	both	_	
110-23	18989-18994	white	_	
110-24	18995-18998	and	_	
110-25	18999-19003	grey	_	
110-26	19004-19010	matter	_	
110-27	19011-19017	voxels	_	
110-28	19017-19018	.	_	

#Text=Histograms of MWF restricted to the white matter tracts allowed us to more closely compare the distribution of values specifically in the white matter between the three groups, confirming that patients' histograms were shifted towards lower MWF values, with a greater variance compared to healthy controls.
111-1	19019-19029	Histograms	_	
111-2	19030-19032	of	_	
111-3	19033-19036	MWF	_	
111-4	19037-19047	restricted	_	
111-5	19048-19050	to	_	
111-6	19051-19054	the	_	
111-7	19055-19060	white	_	
111-8	19061-19067	matter	_	
111-9	19068-19074	tracts	_	
111-10	19075-19082	allowed	_	
111-11	19083-19085	us	_	
111-12	19086-19088	to	_	
111-13	19089-19093	more	_	
111-14	19094-19101	closely	_	
111-15	19102-19109	compare	_	
111-16	19110-19113	the	_	
111-17	19114-19126	distribution	_	
111-18	19127-19129	of	_	
111-19	19130-19136	values	_	
111-20	19137-19149	specifically	_	
111-21	19150-19152	in	_	
111-22	19153-19156	the	_	
111-23	19157-19162	white	_	
111-24	19163-19169	matter	_	
111-25	19170-19177	between	_	
111-26	19178-19181	the	_	
111-27	19182-19187	three	_	
111-28	19188-19194	groups	_	
111-29	19194-19195	,	_	
111-30	19196-19206	confirming	_	
111-31	19207-19211	that	_	
111-32	19212-19220	patients	_	
111-33	19220-19221	'	_	
111-34	19222-19232	histograms	_	
111-35	19233-19237	were	_	
111-36	19238-19245	shifted	_	
111-37	19246-19253	towards	_	
111-38	19254-19259	lower	_	
111-39	19260-19263	MWF	_	
111-40	19264-19270	values	_	
111-41	19270-19271	,	_	
111-42	19272-19276	with	_	
111-43	19277-19278	a	_	
111-44	19279-19286	greater	_	
111-45	19287-19295	variance	_	
111-46	19296-19304	compared	_	
111-47	19305-19307	to	_	
111-48	19308-19315	healthy	_	
111-49	19316-19324	controls	_	
111-50	19324-19325	.	_	

#Text=MWF did not, however, distinguish between the two patient subgroups, consisting of treatment resistant (TRS) and treatment responsive (NTR) schizophrenia patients.
112-1	19326-19329	MWF	_	
112-2	19330-19333	did	_	
112-3	19334-19337	not	_	
112-4	19337-19338	,	_	
112-5	19339-19346	however	_	
112-6	19346-19347	,	_	
112-7	19348-19359	distinguish	_	
112-8	19360-19367	between	_	
112-9	19368-19371	the	_	
112-10	19372-19375	two	_	
112-11	19376-19383	patient	_	
112-12	19384-19393	subgroups	_	
112-13	19393-19394	,	_	
112-14	19395-19405	consisting	_	
112-15	19406-19408	of	_	
112-16	19409-19418	treatment	_	
112-17	19419-19428	resistant	_	
112-18	19429-19430	(	_	
112-19	19430-19433	TRS	_	
112-20	19433-19434	)	_	
112-21	19435-19438	and	_	
112-22	19439-19448	treatment	_	
112-23	19449-19459	responsive	_	
112-24	19460-19461	(	_	
112-25	19461-19464	NTR	_	
112-26	19464-19465	)	_	
112-27	19466-19479	schizophrenia	_	
112-28	19480-19488	patients	_	
112-29	19488-19489	.	_	

#Text=This suggests that underlying abnormal myelination is not a driving force behind antipsychotic treatment resistance at the chronic stage of the illness.
113-1	19490-19494	This	_	
113-2	19495-19503	suggests	_	
113-3	19504-19508	that	_	
113-4	19509-19519	underlying	_	
113-5	19520-19528	abnormal	_	
113-6	19529-19540	myelination	_	
113-7	19541-19543	is	_	
113-8	19544-19547	not	_	
113-9	19548-19549	a	_	
113-10	19550-19557	driving	_	
113-11	19558-19563	force	_	
113-12	19564-19570	behind	_	
113-13	19571-19584	antipsychotic	_	
113-14	19585-19594	treatment	_	
113-15	19595-19605	resistance	_	
113-16	19606-19608	at	_	
113-17	19609-19612	the	_	
113-18	19613-19620	chronic	_	
113-19	19621-19626	stage	_	
113-20	19627-19629	of	_	
113-21	19630-19633	the	_	
113-22	19634-19641	illness	_	
113-23	19641-19642	.	_	

#Text=We used a standard Stroop task as a measure of executive control and found a correlation with corpus callosum MWF, whereby greater MWF values were associated with a smaller reaction time interference effect.
114-1	19643-19645	We	_	
114-2	19646-19650	used	_	
114-3	19651-19652	a	_	
114-4	19653-19661	standard	_	
114-5	19662-19668	Stroop	_	
114-6	19669-19673	task	_	
114-7	19674-19676	as	_	
114-8	19677-19678	a	_	
114-9	19679-19686	measure	_	
114-10	19687-19689	of	_	
114-11	19690-19699	executive	_	
114-12	19700-19707	control	_	
114-13	19708-19711	and	_	
114-14	19712-19717	found	_	
114-15	19718-19719	a	_	
114-16	19720-19731	correlation	_	
114-17	19732-19736	with	_	
114-18	19737-19743	corpus	_	
114-19	19744-19752	callosum	_	
114-20	19753-19756	MWF	_	
114-21	19756-19757	,	_	
114-22	19758-19765	whereby	_	
114-23	19766-19773	greater	_	
114-24	19774-19777	MWF	_	
114-25	19778-19784	values	_	
114-26	19785-19789	were	_	
114-27	19790-19800	associated	_	
114-28	19801-19805	with	_	
114-29	19806-19807	a	_	
114-30	19808-19815	smaller	_	
114-31	19816-19824	reaction	_	
114-32	19825-19829	time	_	
114-33	19830-19842	interference	_	
114-34	19843-19849	effect	_	
114-35	19849-19850	.	_	

#Text=This association was observable both across all subjects and within all groups separately.
115-1	19851-19855	This	_	
115-2	19856-19867	association	_	
115-3	19868-19871	was	_	
115-4	19872-19882	observable	_	
115-5	19883-19887	both	_	
115-6	19888-19894	across	_	
115-7	19895-19898	all	_	
115-8	19899-19907	subjects	_	
115-9	19908-19911	and	_	
115-10	19912-19918	within	_	
115-11	19919-19922	all	_	
115-12	19923-19929	groups	_	
115-13	19930-19940	separately	_	
115-14	19940-19941	.	_	

#Text=A mediation analysis showed that MWF in the corpus callosum partially mediated the group difference on the Stroop task, such that lower MWF in patients accounted in part for the greater interference effects seen in this sample compared to controls.
116-1	19942-19943	A	_	
116-2	19944-19953	mediation	_	
116-3	19954-19962	analysis	_	
116-4	19963-19969	showed	_	
116-5	19970-19974	that	_	
116-6	19975-19978	MWF	_	
116-7	19979-19981	in	_	
116-8	19982-19985	the	_	
116-9	19986-19992	corpus	_	
116-10	19993-20001	callosum	_	
116-11	20002-20011	partially	_	
116-12	20012-20020	mediated	_	
116-13	20021-20024	the	_	
116-14	20025-20030	group	_	
116-15	20031-20041	difference	_	
116-16	20042-20044	on	_	
116-17	20045-20048	the	_	
116-18	20049-20055	Stroop	_	
116-19	20056-20060	task	_	
116-20	20060-20061	,	_	
116-21	20062-20066	such	_	
116-22	20067-20071	that	_	
116-23	20072-20077	lower	_	
116-24	20078-20081	MWF	_	
116-25	20082-20084	in	_	
116-26	20085-20093	patients	_	
116-27	20094-20103	accounted	_	
116-28	20104-20106	in	_	
116-29	20107-20111	part	_	
116-30	20112-20115	for	_	
116-31	20116-20119	the	_	
116-32	20120-20127	greater	_	
116-33	20128-20140	interference	_	
116-34	20141-20148	effects	_	
116-35	20149-20153	seen	_	
116-36	20154-20156	in	_	
116-37	20157-20161	this	_	
116-38	20162-20168	sample	_	
116-39	20169-20177	compared	_	
116-40	20178-20180	to	_	
116-41	20181-20189	controls	_	
116-42	20189-20190	.	_	

#Text=The findings of reduced MWF in patients with schizophrenia compared to healthy controls are in line with a large body of evidence suggesting impaired white matter integrity in the illness.
117-1	20191-20194	The	_	
117-2	20195-20203	findings	_	
117-3	20204-20206	of	_	
117-4	20207-20214	reduced	_	
117-5	20215-20218	MWF	_	
117-6	20219-20221	in	_	
117-7	20222-20230	patients	_	
117-8	20231-20235	with	_	
117-9	20236-20249	schizophrenia	_	
117-10	20250-20258	compared	_	
117-11	20259-20261	to	_	
117-12	20262-20269	healthy	_	
117-13	20270-20278	controls	_	
117-14	20279-20282	are	_	
117-15	20283-20285	in	_	
117-16	20286-20290	line	_	
117-17	20291-20295	with	_	
117-18	20296-20297	a	_	
117-19	20298-20303	large	_	
117-20	20304-20308	body	_	
117-21	20309-20311	of	_	
117-22	20312-20320	evidence	_	
117-23	20321-20331	suggesting	_	
117-24	20332-20340	impaired	_	
117-25	20341-20346	white	_	
117-26	20347-20353	matter	_	
117-27	20354-20363	integrity	_	
117-28	20364-20366	in	_	
117-29	20367-20370	the	_	
117-30	20371-20378	illness	_	
117-31	20378-20379	.	_	

#Text=The proliferation of diffusion weighted imaging reports in recent years has shed enormous light on disturbances of white matter in psychosis and schizophrenia on a whole-brain basis, yet a remaining disadvantage of the technique is the large number of microstructural factors which could contribute to the signal.
118-1	20380-20383	The	_	
118-2	20384-20397	proliferation	_	
118-3	20398-20400	of	_	
118-4	20401-20410	diffusion	_	
118-5	20411-20419	weighted	_	
118-6	20420-20427	imaging	_	
118-7	20428-20435	reports	_	
118-8	20436-20438	in	_	
118-9	20439-20445	recent	_	
118-10	20446-20451	years	_	
118-11	20452-20455	has	_	
118-12	20456-20460	shed	_	
118-13	20461-20469	enormous	_	
118-14	20470-20475	light	_	
118-15	20476-20478	on	_	
118-16	20479-20491	disturbances	_	
118-17	20492-20494	of	_	
118-18	20495-20500	white	_	
118-19	20501-20507	matter	_	
118-20	20508-20510	in	_	
118-21	20511-20520	psychosis	_	
118-22	20521-20524	and	_	
118-23	20525-20538	schizophrenia	_	
118-24	20539-20541	on	_	
118-25	20542-20543	a	_	
118-26	20544-20555	whole-brain	_	
118-27	20556-20561	basis	_	
118-28	20561-20562	,	_	
118-29	20563-20566	yet	_	
118-30	20567-20568	a	_	
118-31	20569-20578	remaining	_	
118-32	20579-20591	disadvantage	_	
118-33	20592-20594	of	_	
118-34	20595-20598	the	_	
118-35	20599-20608	technique	_	
118-36	20609-20611	is	_	
118-37	20612-20615	the	_	
118-38	20616-20621	large	_	
118-39	20622-20628	number	_	
118-40	20629-20631	of	_	
118-41	20632-20647	microstructural	_	
118-42	20648-20655	factors	_	
118-43	20656-20661	which	_	
118-44	20662-20667	could	_	
118-45	20668-20678	contribute	_	
118-46	20679-20681	to	_	
118-47	20682-20685	the	_	
118-48	20686-20692	signal	_	
118-49	20692-20693	.	_	

#Text=Multicomponent relaxation imaging allows for a more myelin-specific quantification of the dysfunction in vivo.
119-1	20694-20708	Multicomponent	_	
119-2	20709-20719	relaxation	_	
119-3	20720-20727	imaging	_	
119-4	20728-20734	allows	_	
119-5	20735-20738	for	_	
119-6	20739-20740	a	_	
119-7	20741-20745	more	_	
119-8	20746-20761	myelin-specific	_	
119-9	20762-20776	quantification	_	
119-10	20777-20779	of	_	
119-11	20780-20783	the	_	
119-12	20784-20795	dysfunction	_	
119-13	20796-20798	in	_	
119-14	20799-20803	vivo	_	
119-15	20803-20804	.	_	

#Text=The mcDESPOT protocol is such a technique which has recently been validated pre-clinically, and to our knowledge this is the first report to use this technique in chronic patients with a diagnosis of schizophrenia, with an additional stratification by treatment response status.
120-1	20805-20808	The	_	
120-2	20809-20817	mcDESPOT	_	
120-3	20818-20826	protocol	_	
120-4	20827-20829	is	_	
120-5	20830-20834	such	_	
120-6	20835-20836	a	_	
120-7	20837-20846	technique	_	
120-8	20847-20852	which	_	
120-9	20853-20856	has	_	
120-10	20857-20865	recently	_	
120-11	20866-20870	been	_	
120-12	20871-20880	validated	_	
120-13	20881-20895	pre-clinically	_	
120-14	20895-20896	,	_	
120-15	20897-20900	and	_	
120-16	20901-20903	to	_	
120-17	20904-20907	our	_	
120-18	20908-20917	knowledge	_	
120-19	20918-20922	this	_	
120-20	20923-20925	is	_	
120-21	20926-20929	the	_	
120-22	20930-20935	first	_	
120-23	20936-20942	report	_	
120-24	20943-20945	to	_	
120-25	20946-20949	use	_	
120-26	20950-20954	this	_	
120-27	20955-20964	technique	_	
120-28	20965-20967	in	_	
120-29	20968-20975	chronic	_	
120-30	20976-20984	patients	_	
120-31	20985-20989	with	_	
120-32	20990-20991	a	_	
120-33	20992-21001	diagnosis	_	
120-34	21002-21004	of	_	
120-35	21005-21018	schizophrenia	_	
120-36	21018-21019	,	_	
120-37	21020-21024	with	_	
120-38	21025-21027	an	_	
120-39	21028-21038	additional	_	
120-40	21039-21053	stratification	_	
120-41	21054-21056	by	_	
120-42	21057-21066	treatment	_	
120-43	21067-21075	response	_	
120-44	21076-21082	status	_	
120-45	21082-21083	.	_	

#Text=The mechanisms underlying resistance to antipsychotic medication are as yet not well understood, but the lack of response despite adequate dopamine D2 receptor occupancy in TRS suggests that striatal hyperdopaminergia may not be the principal aetiology of psychotic symptoms in this patient subgroup.
121-1	21084-21087	The	_	
121-2	21088-21098	mechanisms	_	
121-3	21099-21109	underlying	_	
121-4	21110-21120	resistance	_	
121-5	21121-21123	to	_	
121-6	21124-21137	antipsychotic	_	
121-7	21138-21148	medication	_	
121-8	21149-21152	are	_	
121-9	21153-21155	as	_	
121-10	21156-21159	yet	_	
121-11	21160-21163	not	_	
121-12	21164-21168	well	_	
121-13	21169-21179	understood	_	
121-14	21179-21180	,	_	
121-15	21181-21184	but	_	
121-16	21185-21188	the	_	
121-17	21189-21193	lack	_	
121-18	21194-21196	of	_	
121-19	21197-21205	response	_	
121-20	21206-21213	despite	_	
121-21	21214-21222	adequate	_	
121-22	21223-21231	dopamine	_	
121-23	21232-21234	D2	_	
121-24	21235-21243	receptor	_	
121-25	21244-21253	occupancy	_	
121-26	21254-21256	in	_	
121-27	21257-21260	TRS	_	
121-28	21261-21269	suggests	_	
121-29	21270-21274	that	_	
121-30	21275-21283	striatal	_	
121-31	21284-21301	hyperdopaminergia	_	
121-32	21302-21305	may	_	
121-33	21306-21309	not	_	
121-34	21310-21312	be	_	
121-35	21313-21316	the	_	
121-36	21317-21326	principal	_	
121-37	21327-21336	aetiology	_	
121-38	21337-21339	of	_	
121-39	21340-21349	psychotic	_	
121-40	21350-21358	symptoms	_	
121-41	21359-21361	in	_	
121-42	21362-21366	this	_	
121-43	21367-21374	patient	_	
121-44	21375-21383	subgroup	_	
121-45	21383-21384	.	_	

#Text=One study investigating white matter microstructure found reduced fractional anisotropy and increased radial diffusivity in the corpus callosum in chronic treatment resistant patients as compared to healthy controls; however this study did not include a remitted patient group and as such the specificity of the finding to TRS is unclear.
122-1	21385-21388	One	_	
122-2	21389-21394	study	_	
122-3	21395-21408	investigating	_	
122-4	21409-21414	white	_	
122-5	21415-21421	matter	_	
122-6	21422-21436	microstructure	_	
122-7	21437-21442	found	_	
122-8	21443-21450	reduced	_	
122-9	21451-21461	fractional	_	
122-10	21462-21472	anisotropy	_	
122-11	21473-21476	and	_	
122-12	21477-21486	increased	_	
122-13	21487-21493	radial	_	
122-14	21494-21505	diffusivity	_	
122-15	21506-21508	in	_	
122-16	21509-21512	the	_	
122-17	21513-21519	corpus	_	
122-18	21520-21528	callosum	_	
122-19	21529-21531	in	_	
122-20	21532-21539	chronic	_	
122-21	21540-21549	treatment	_	
122-22	21550-21559	resistant	_	
122-23	21560-21568	patients	_	
122-24	21569-21571	as	_	
122-25	21572-21580	compared	_	
122-26	21581-21583	to	_	
122-27	21584-21591	healthy	_	
122-28	21592-21600	controls	_	
122-29	21600-21601	;	_	
122-30	21602-21609	however	_	
122-31	21610-21614	this	_	
122-32	21615-21620	study	_	
122-33	21621-21624	did	_	
122-34	21625-21628	not	_	
122-35	21629-21636	include	_	
122-36	21637-21638	a	_	
122-37	21639-21647	remitted	_	
122-38	21648-21655	patient	_	
122-39	21656-21661	group	_	
122-40	21662-21665	and	_	
122-41	21666-21668	as	_	
122-42	21669-21673	such	_	
122-43	21674-21677	the	_	
122-44	21678-21689	specificity	_	
122-45	21690-21692	of	_	
122-46	21693-21696	the	_	
122-47	21697-21704	finding	_	
122-48	21705-21707	to	_	
122-49	21708-21711	TRS	_	
122-50	21712-21714	is	_	
122-51	21715-21722	unclear	_	
122-52	21722-21723	.	_	

#Text=On a functional connectivity level, a recent report by suggested that divergent pathophysiologies of striatal resting-state connectivity are present in treatment resistant and treatment responsive schizophrenia.
123-1	21724-21726	On	_	
123-2	21727-21728	a	_	
123-3	21729-21739	functional	_	
123-4	21740-21752	connectivity	_	
123-5	21753-21758	level	_	
123-6	21758-21759	,	_	
123-7	21760-21761	a	_	
123-8	21762-21768	recent	_	
123-9	21769-21775	report	_	
123-10	21776-21778	by	_	
123-11	21779-21788	suggested	_	
123-12	21789-21793	that	_	
123-13	21794-21803	divergent	_	
123-14	21804-21821	pathophysiologies	_	
123-15	21822-21824	of	_	
123-16	21825-21833	striatal	_	
123-17	21834-21847	resting-state	_	
123-18	21848-21860	connectivity	_	
123-19	21861-21864	are	_	
123-20	21865-21872	present	_	
123-21	21873-21875	in	_	
123-22	21876-21885	treatment	_	
123-23	21886-21895	resistant	_	
123-24	21896-21899	and	_	
123-25	21900-21909	treatment	_	
123-26	21910-21920	responsive	_	
123-27	21921-21934	schizophrenia	_	
123-28	21934-21935	.	_	

#Text=In addition, Sarpal and colleagues demonstrated that functional striatal resting-state connectivity may be predictive of treatment response in first-episode psychosis patients.
124-1	21936-21938	In	_	
124-2	21939-21947	addition	_	
124-3	21947-21948	,	_	
124-4	21949-21955	Sarpal	_	
124-5	21956-21959	and	_	
124-6	21960-21970	colleagues	_	
124-7	21971-21983	demonstrated	_	
124-8	21984-21988	that	_	
124-9	21989-21999	functional	_	
124-10	22000-22008	striatal	_	
124-11	22009-22022	resting-state	_	
124-12	22023-22035	connectivity	_	
124-13	22036-22039	may	_	
124-14	22040-22042	be	_	
124-15	22043-22053	predictive	_	
124-16	22054-22056	of	_	
124-17	22057-22066	treatment	_	
124-18	22067-22075	response	_	
124-19	22076-22078	in	_	
124-20	22079-22092	first-episode	_	
124-21	22093-22102	psychosis	_	
124-22	22103-22111	patients	_	
124-23	22111-22112	.	_	

#Text=Our data suggest that these findings of functional connectivity differences are not mirrored by myelin water fraction differences.
125-1	22113-22116	Our	_	
125-2	22117-22121	data	_	
125-3	22122-22129	suggest	_	
125-4	22130-22134	that	_	
125-5	22135-22140	these	_	
125-6	22141-22149	findings	_	
125-7	22150-22152	of	_	
125-8	22153-22163	functional	_	
125-9	22164-22176	connectivity	_	
125-10	22177-22188	differences	_	
125-11	22189-22192	are	_	
125-12	22193-22196	not	_	
125-13	22197-22205	mirrored	_	
125-14	22206-22208	by	_	
125-15	22209-22215	myelin	_	
125-16	22216-22221	water	_	
125-17	22222-22230	fraction	_	
125-18	22231-22242	differences	_	
125-19	22242-22243	.	_	

#Text=In this chronic patient sample, the effects of illness chronicity and exposure to medication can by definition not be entirely disentangled from the effects of interest and therefore remain as potential confounds.
126-1	22244-22246	In	_	
126-2	22247-22251	this	_	
126-3	22252-22259	chronic	_	
126-4	22260-22267	patient	_	
126-5	22268-22274	sample	_	
126-6	22274-22275	,	_	
126-7	22276-22279	the	_	
126-8	22280-22287	effects	_	
126-9	22288-22290	of	_	
126-10	22291-22298	illness	_	
126-11	22299-22309	chronicity	_	
126-12	22310-22313	and	_	
126-13	22314-22322	exposure	_	
126-14	22323-22325	to	_	
126-15	22326-22336	medication	_	
126-16	22337-22340	can	_	
126-17	22341-22343	by	_	
126-18	22344-22354	definition	_	
126-19	22355-22358	not	_	
126-20	22359-22361	be	_	
126-21	22362-22370	entirely	_	
126-22	22371-22383	disentangled	_	
126-23	22384-22388	from	_	
126-24	22389-22392	the	_	
126-25	22393-22400	effects	_	
126-26	22401-22403	of	_	
126-27	22404-22412	interest	_	
126-28	22413-22416	and	_	
126-29	22417-22426	therefore	_	
126-30	22427-22433	remain	_	
126-31	22434-22436	as	_	
126-32	22437-22446	potential	_	
126-33	22447-22456	confounds	_	
126-34	22456-22457	.	_	

#Text=However, the absence of group difference on these variables as well as the lack of association with myelin water fraction suggest that it is unlikely that these effects are masking true differences in myelination between treatment resistant and responsive patients.
127-1	22458-22465	However	_	
127-2	22465-22466	,	_	
127-3	22467-22470	the	_	
127-4	22471-22478	absence	_	
127-5	22479-22481	of	_	
127-6	22482-22487	group	_	
127-7	22488-22498	difference	_	
127-8	22499-22501	on	_	
127-9	22502-22507	these	_	
127-10	22508-22517	variables	_	
127-11	22518-22520	as	_	
127-12	22521-22525	well	_	
127-13	22526-22528	as	_	
127-14	22529-22532	the	_	
127-15	22533-22537	lack	_	
127-16	22538-22540	of	_	
127-17	22541-22552	association	_	
127-18	22553-22557	with	_	
127-19	22558-22564	myelin	_	
127-20	22565-22570	water	_	
127-21	22571-22579	fraction	_	
127-22	22580-22587	suggest	_	
127-23	22588-22592	that	_	
127-24	22593-22595	it	_	
127-25	22596-22598	is	_	
127-26	22599-22607	unlikely	_	
127-27	22608-22612	that	_	
127-28	22613-22618	these	_	
127-29	22619-22626	effects	_	
127-30	22627-22630	are	_	
127-31	22631-22638	masking	_	
127-32	22639-22643	true	_	
127-33	22644-22655	differences	_	
127-34	22656-22658	in	_	
127-35	22659-22670	myelination	_	
127-36	22671-22678	between	_	
127-37	22679-22688	treatment	_	
127-38	22689-22698	resistant	_	
127-39	22699-22702	and	_	
127-40	22703-22713	responsive	_	
127-41	22714-22722	patients	_	
127-42	22722-22723	.	_	

#Text=Nevertheless, future research could usefully examine these issues by applying the technique to patients at an earlier stage of the illness.
128-1	22724-22736	Nevertheless	_	
128-2	22736-22737	,	_	
128-3	22738-22744	future	_	
128-4	22745-22753	research	_	
128-5	22754-22759	could	_	
128-6	22760-22768	usefully	_	
128-7	22769-22776	examine	_	
128-8	22777-22782	these	_	
128-9	22783-22789	issues	_	
128-10	22790-22792	by	_	
128-11	22793-22801	applying	_	
128-12	22802-22805	the	_	
128-13	22806-22815	technique	_	
128-14	22816-22818	to	_	
128-15	22819-22827	patients	_	
128-16	22828-22830	at	_	
128-17	22831-22833	an	_	
128-18	22834-22841	earlier	_	
128-19	22842-22847	stage	_	
128-20	22848-22850	of	_	
128-21	22851-22854	the	_	
128-22	22855-22862	illness	_	
128-23	22862-22863	.	_	

#Text=Cognitive deficits are considered a core feature of TRS, and as such we aimed to investigate whether a lack of cognitive control specifically was associated with treatment resistance.
129-1	22864-22873	Cognitive	_	
129-2	22874-22882	deficits	_	
129-3	22883-22886	are	_	
129-4	22887-22897	considered	_	
129-5	22898-22899	a	_	
129-6	22900-22904	core	_	
129-7	22905-22912	feature	_	
129-8	22913-22915	of	_	
129-9	22916-22919	TRS	_	
129-10	22919-22920	,	_	
129-11	22921-22924	and	_	
129-12	22925-22927	as	_	
129-13	22928-22932	such	_	
129-14	22933-22935	we	_	
129-15	22936-22941	aimed	_	
129-16	22942-22944	to	_	
129-17	22945-22956	investigate	_	
129-18	22957-22964	whether	_	
129-19	22965-22966	a	_	
129-20	22967-22971	lack	_	
129-21	22972-22974	of	_	
129-22	22975-22984	cognitive	_	
129-23	22985-22992	control	_	
129-24	22993-23005	specifically	_	
129-25	23006-23009	was	_	
129-26	23010-23020	associated	_	
129-27	23021-23025	with	_	
129-28	23026-23035	treatment	_	
129-29	23036-23046	resistance	_	
129-30	23046-23047	.	_	

#Text=The presence of cognitive control deficits, accompanied by abnormal activation of networks underlying cognitive control, has been widely established in schizophrenia and the extent of the dysfunction has been linked to symptom severity.
130-1	23048-23051	The	_	
130-2	23052-23060	presence	_	
130-3	23061-23063	of	_	
130-4	23064-23073	cognitive	_	
130-5	23074-23081	control	_	
130-6	23082-23090	deficits	_	
130-7	23090-23091	,	_	
130-8	23092-23103	accompanied	_	
130-9	23104-23106	by	_	
130-10	23107-23115	abnormal	_	
130-11	23116-23126	activation	_	
130-12	23127-23129	of	_	
130-13	23130-23138	networks	_	
130-14	23139-23149	underlying	_	
130-15	23150-23159	cognitive	_	
130-16	23160-23167	control	_	
130-17	23167-23168	,	_	
130-18	23169-23172	has	_	
130-19	23173-23177	been	_	
130-20	23178-23184	widely	_	
130-21	23185-23196	established	_	
130-22	23197-23199	in	_	
130-23	23200-23213	schizophrenia	_	
130-24	23214-23217	and	_	
130-25	23218-23221	the	_	
130-26	23222-23228	extent	_	
130-27	23229-23231	of	_	
130-28	23232-23235	the	_	
130-29	23236-23247	dysfunction	_	
130-30	23248-23251	has	_	
130-31	23252-23256	been	_	
130-32	23257-23263	linked	_	
130-33	23264-23266	to	_	
130-34	23267-23274	symptom	_	
130-35	23275-23283	severity	_	
130-36	23283-23284	.	_	

#Text=An exacerbated inability to exert cognitive control may thus result in the persistence of symptoms even if a subcortical dopamine dysfunction is normalised.
131-1	23285-23287	An	_	
131-2	23288-23299	exacerbated	_	
131-3	23300-23309	inability	_	
131-4	23310-23312	to	_	
131-5	23313-23318	exert	_	
131-6	23319-23328	cognitive	_	
131-7	23329-23336	control	_	
131-8	23337-23340	may	_	
131-9	23341-23345	thus	_	
131-10	23346-23352	result	_	
131-11	23353-23355	in	_	
131-12	23356-23359	the	_	
131-13	23360-23371	persistence	_	
131-14	23372-23374	of	_	
131-15	23375-23383	symptoms	_	
131-16	23384-23388	even	_	
131-17	23389-23391	if	_	
131-18	23392-23393	a	_	
131-19	23394-23405	subcortical	_	
131-20	23406-23414	dopamine	_	
131-21	23415-23426	dysfunction	_	
131-22	23427-23429	is	_	
131-23	23430-23440	normalised	_	
131-24	23440-23441	.	_	

#Text=Cognitive control further relies on intact connectivity of the underlying neural network; hence we aimed to assess how both cognitive and structural mechanisms relate to treatment response.
132-1	23442-23451	Cognitive	_	
132-2	23452-23459	control	_	
132-3	23460-23467	further	_	
132-4	23468-23474	relies	_	
132-5	23475-23477	on	_	
132-6	23478-23484	intact	_	
132-7	23485-23497	connectivity	_	
132-8	23498-23500	of	_	
132-9	23501-23504	the	_	
132-10	23505-23515	underlying	_	
132-11	23516-23522	neural	_	
132-12	23523-23530	network	_	
132-13	23530-23531	;	_	
132-14	23532-23537	hence	_	
132-15	23538-23540	we	_	
132-16	23541-23546	aimed	_	
132-17	23547-23549	to	_	
132-18	23550-23556	assess	_	
132-19	23557-23560	how	_	
132-20	23561-23565	both	_	
132-21	23566-23575	cognitive	_	
132-22	23576-23579	and	_	
132-23	23580-23590	structural	_	
132-24	23591-23601	mechanisms	_	
132-25	23602-23608	relate	_	
132-26	23609-23611	to	_	
132-27	23612-23621	treatment	_	
132-28	23622-23630	response	_	
132-29	23630-23631	.	_	

#Text=We did not observe differences in reaction time interference on the Stroop task between the two patient groups.
133-1	23632-23634	We	_	
133-2	23635-23638	did	_	
133-3	23639-23642	not	_	
133-4	23643-23650	observe	_	
133-5	23651-23662	differences	_	
133-6	23663-23665	in	_	
133-7	23666-23674	reaction	_	
133-8	23675-23679	time	_	
133-9	23680-23692	interference	_	
133-10	23693-23695	on	_	
133-11	23696-23699	the	_	
133-12	23700-23706	Stroop	_	
133-13	23707-23711	task	_	
133-14	23712-23719	between	_	
133-15	23720-23723	the	_	
133-16	23724-23727	two	_	
133-17	23728-23735	patient	_	
133-18	23736-23742	groups	_	
133-19	23742-23743	.	_	

#Text=Thus on a behavioural level, treatment resistance does not seem to be associated with exacerbated cognitive control deficits at the chronic stage of the illness.
134-1	23744-23748	Thus	_	
134-2	23749-23751	on	_	
134-3	23752-23753	a	_	
134-4	23754-23765	behavioural	_	
134-5	23766-23771	level	_	
134-6	23771-23772	,	_	
134-7	23773-23782	treatment	_	
134-8	23783-23793	resistance	_	
134-9	23794-23798	does	_	
134-10	23799-23802	not	_	
134-11	23803-23807	seem	_	
134-12	23808-23810	to	_	
134-13	23811-23813	be	_	
134-14	23814-23824	associated	_	
134-15	23825-23829	with	_	
134-16	23830-23841	exacerbated	_	
134-17	23842-23851	cognitive	_	
134-18	23852-23859	control	_	
134-19	23860-23868	deficits	_	
134-20	23869-23871	at	_	
134-21	23872-23875	the	_	
134-22	23876-23883	chronic	_	
134-23	23884-23889	stage	_	
134-24	23890-23892	of	_	
134-25	23893-23896	the	_	
134-26	23897-23904	illness	_	
134-27	23904-23905	.	_	

#Text=However, callosal myelin reductions in schizophrenia patients partially mediated performance differences compared to healthy individuals.
135-1	23906-23913	However	_	
135-2	23913-23914	,	_	
135-3	23915-23923	callosal	_	
135-4	23924-23930	myelin	_	
135-5	23931-23941	reductions	_	
135-6	23942-23944	in	_	
135-7	23945-23958	schizophrenia	_	
135-8	23959-23967	patients	_	
135-9	23968-23977	partially	_	
135-10	23978-23986	mediated	_	
135-11	23987-23998	performance	_	
135-12	23999-24010	differences	_	
135-13	24011-24019	compared	_	
135-14	24020-24022	to	_	
135-15	24023-24030	healthy	_	
135-16	24031-24042	individuals	_	
135-17	24042-24043	.	_	

#Text=Impaired white matter integrity in the corpus callosum reductions have been widely observed in the illness, but this is the first report of a direct link between a measure of callosal myelination and cognitive control function in schizophrenia.
136-1	24044-24052	Impaired	_	
136-2	24053-24058	white	_	
136-3	24059-24065	matter	_	
136-4	24066-24075	integrity	_	
136-5	24076-24078	in	_	
136-6	24079-24082	the	_	
136-7	24083-24089	corpus	_	
136-8	24090-24098	callosum	_	
136-9	24099-24109	reductions	_	
136-10	24110-24114	have	_	
136-11	24115-24119	been	_	
136-12	24120-24126	widely	_	
136-13	24127-24135	observed	_	
136-14	24136-24138	in	_	
136-15	24139-24142	the	_	
136-16	24143-24150	illness	_	
136-17	24150-24151	,	_	
136-18	24152-24155	but	_	
136-19	24156-24160	this	_	
136-20	24161-24163	is	_	
136-21	24164-24167	the	_	
136-22	24168-24173	first	_	
136-23	24174-24180	report	_	
136-24	24181-24183	of	_	
136-25	24184-24185	a	_	
136-26	24186-24192	direct	_	
136-27	24193-24197	link	_	
136-28	24198-24205	between	_	
136-29	24206-24207	a	_	
136-30	24208-24215	measure	_	
136-31	24216-24218	of	_	
136-32	24219-24227	callosal	_	
136-33	24228-24239	myelination	_	
136-34	24240-24243	and	_	
136-35	24244-24253	cognitive	_	
136-36	24254-24261	control	_	
136-37	24262-24270	function	_	
136-38	24271-24273	in	_	
136-39	24274-24287	schizophrenia	_	
136-40	24287-24288	.	_	

#Text=This study was performed in a relatively small sample.
137-1	24289-24293	This	_	
137-2	24294-24299	study	_	
137-3	24300-24303	was	_	
137-4	24304-24313	performed	_	
137-5	24314-24316	in	_	
137-6	24317-24318	a	_	
137-7	24319-24329	relatively	_	
137-8	24330-24335	small	_	
137-9	24336-24342	sample	_	
137-10	24342-24343	.	_	

#Text=Due to the risk of effect size overestimation associated with small sample sizes, the results warrant replication in future multi-centre studies with larger samples.
138-1	24344-24347	Due	_	
138-2	24348-24350	to	_	
138-3	24351-24354	the	_	
138-4	24355-24359	risk	_	
138-5	24360-24362	of	_	
138-6	24363-24369	effect	_	
138-7	24370-24374	size	_	
138-8	24375-24389	overestimation	_	
138-9	24390-24400	associated	_	
138-10	24401-24405	with	_	
138-11	24406-24411	small	_	
138-12	24412-24418	sample	_	
138-13	24419-24424	sizes	_	
138-14	24424-24425	,	_	
138-15	24426-24429	the	_	
138-16	24430-24437	results	_	
138-17	24438-24445	warrant	_	
138-18	24446-24457	replication	_	
138-19	24458-24460	in	_	
138-20	24461-24467	future	_	
138-21	24468-24480	multi-centre	_	
138-22	24481-24488	studies	_	
138-23	24489-24493	with	_	
138-24	24494-24500	larger	_	
138-25	24501-24508	samples	_	
138-26	24508-24509	.	_	

#Text=However, recruitment and neuroimaging assessment in clinical populations can be particularly challenging and typically require a large amount of resources, and as such preliminary assessments in smaller samples can be useful. recently demonstrated that effect sizes achieved with the DESPOT sequence in a calibration study on six participants was highly predictive of effect sizes observed in a large-scale multi-centre imaging study.
139-1	24510-24517	However	_	
139-2	24517-24518	,	_	
139-3	24519-24530	recruitment	_	
139-4	24531-24534	and	_	
139-5	24535-24547	neuroimaging	_	
139-6	24548-24558	assessment	_	
139-7	24559-24561	in	_	
139-8	24562-24570	clinical	_	
139-9	24571-24582	populations	_	
139-10	24583-24586	can	_	
139-11	24587-24589	be	_	
139-12	24590-24602	particularly	_	
139-13	24603-24614	challenging	_	
139-14	24615-24618	and	_	
139-15	24619-24628	typically	_	
139-16	24629-24636	require	_	
139-17	24637-24638	a	_	
139-18	24639-24644	large	_	
139-19	24645-24651	amount	_	
139-20	24652-24654	of	_	
139-21	24655-24664	resources	_	
139-22	24664-24665	,	_	
139-23	24666-24669	and	_	
139-24	24670-24672	as	_	
139-25	24673-24677	such	_	
139-26	24678-24689	preliminary	_	
139-27	24690-24701	assessments	_	
139-28	24702-24704	in	_	
139-29	24705-24712	smaller	_	
139-30	24713-24720	samples	_	
139-31	24721-24724	can	_	
139-32	24725-24727	be	_	
139-33	24728-24734	useful	_	
139-34	24734-24735	.	_	
139-35	24736-24744	recently	_	
139-36	24745-24757	demonstrated	_	
139-37	24758-24762	that	_	
139-38	24763-24769	effect	_	
139-39	24770-24775	sizes	_	
139-40	24776-24784	achieved	_	
139-41	24785-24789	with	_	
139-42	24790-24793	the	_	
139-43	24794-24800	DESPOT	_	
139-44	24801-24809	sequence	_	
139-45	24810-24812	in	_	
139-46	24813-24814	a	_	
139-47	24815-24826	calibration	_	
139-48	24827-24832	study	_	
139-49	24833-24835	on	_	
139-50	24836-24839	six	_	
139-51	24840-24852	participants	_	
139-52	24853-24856	was	_	
139-53	24857-24863	highly	_	
139-54	24864-24874	predictive	_	
139-55	24875-24877	of	_	
139-56	24878-24884	effect	_	
139-57	24885-24890	sizes	_	
139-58	24891-24899	observed	_	
139-59	24900-24902	in	_	
139-60	24903-24904	a	_	
139-61	24905-24916	large-scale	_	
139-62	24917-24929	multi-centre	_	
139-63	24930-24937	imaging	_	
139-64	24938-24943	study	_	
139-65	24943-24944	.	_	

#Text=Thus, while acknowledging the need to further validate mcDESPOT imaging as a sensitive method for studying schizophrenia, our results may be useful for supporting the design and execution of future studies.
140-1	24945-24949	Thus	_	
140-2	24949-24950	,	_	
140-3	24951-24956	while	_	
140-4	24957-24970	acknowledging	_	
140-5	24971-24974	the	_	
140-6	24975-24979	need	_	
140-7	24980-24982	to	_	
140-8	24983-24990	further	_	
140-9	24991-24999	validate	_	
140-10	25000-25008	mcDESPOT	_	
140-11	25009-25016	imaging	_	
140-12	25017-25019	as	_	
140-13	25020-25021	a	_	
140-14	25022-25031	sensitive	_	
140-15	25032-25038	method	_	
140-16	25039-25042	for	_	
140-17	25043-25051	studying	_	
140-18	25052-25065	schizophrenia	_	
140-19	25065-25066	,	_	
140-20	25067-25070	our	_	
140-21	25071-25078	results	_	
140-22	25079-25082	may	_	
140-23	25083-25085	be	_	
140-24	25086-25092	useful	_	
140-25	25093-25096	for	_	
140-26	25097-25107	supporting	_	
140-27	25108-25111	the	_	
140-28	25112-25118	design	_	
140-29	25119-25122	and	_	
140-30	25123-25132	execution	_	
140-31	25133-25135	of	_	
140-32	25136-25142	future	_	
140-33	25143-25150	studies	_	
140-34	25150-25151	.	_	

#Text=In summary, the current study demonstrates that mcDESPOT is a suitable method to detect myelin alterations in schizophrenia, clarifying the nature of the changes reported in earlier DTI studies, and this may be a relevant marker in terms of cognitive control performance in patients.
141-1	25152-25154	In	_	
141-2	25155-25162	summary	_	
141-3	25162-25163	,	_	
141-4	25164-25167	the	_	
141-5	25168-25175	current	_	
141-6	25176-25181	study	_	
141-7	25182-25194	demonstrates	_	
141-8	25195-25199	that	_	
141-9	25200-25208	mcDESPOT	_	
141-10	25209-25211	is	_	
141-11	25212-25213	a	_	
141-12	25214-25222	suitable	_	
141-13	25223-25229	method	_	
141-14	25230-25232	to	_	
141-15	25233-25239	detect	_	
141-16	25240-25246	myelin	_	
141-17	25247-25258	alterations	_	
141-18	25259-25261	in	_	
141-19	25262-25275	schizophrenia	_	
141-20	25275-25276	,	_	
141-21	25277-25287	clarifying	_	
141-22	25288-25291	the	_	
141-23	25292-25298	nature	_	
141-24	25299-25301	of	_	
141-25	25302-25305	the	_	
141-26	25306-25313	changes	_	
141-27	25314-25322	reported	_	
141-28	25323-25325	in	_	
141-29	25326-25333	earlier	_	
141-30	25334-25337	DTI	_	
141-31	25338-25345	studies	_	
141-32	25345-25346	,	_	
141-33	25347-25350	and	_	
141-34	25351-25355	this	_	
141-35	25356-25359	may	_	
141-36	25360-25362	be	_	
141-37	25363-25364	a	_	
141-38	25365-25373	relevant	_	
141-39	25374-25380	marker	_	
141-40	25381-25383	in	_	
141-41	25384-25389	terms	_	
141-42	25390-25392	of	_	
141-43	25393-25402	cognitive	_	
141-44	25403-25410	control	_	
141-45	25411-25422	performance	_	
141-46	25423-25425	in	_	
141-47	25426-25434	patients	_	
141-48	25434-25435	.	_	

#Text=However, we did not find more severe myelin abnormalities in treatment resistant patients compared to treatment responsive patients, suggesting that primary differences in treatment response and functional dysconnectivity are not driven by alterations in myelination.
142-1	25436-25443	However	_	
142-2	25443-25444	,	_	
142-3	25445-25447	we	_	
142-4	25448-25451	did	_	
142-5	25452-25455	not	_	
142-6	25456-25460	find	_	
142-7	25461-25465	more	_	
142-8	25466-25472	severe	_	
142-9	25473-25479	myelin	_	
142-10	25480-25493	abnormalities	_	
142-11	25494-25496	in	_	
142-12	25497-25506	treatment	_	
142-13	25507-25516	resistant	_	
142-14	25517-25525	patients	_	
142-15	25526-25534	compared	_	
142-16	25535-25537	to	_	
142-17	25538-25547	treatment	_	
142-18	25548-25558	responsive	_	
142-19	25559-25567	patients	_	
142-20	25567-25568	,	_	
142-21	25569-25579	suggesting	_	
142-22	25580-25584	that	_	
142-23	25585-25592	primary	_	
142-24	25593-25604	differences	_	
142-25	25605-25607	in	_	
142-26	25608-25617	treatment	_	
142-27	25618-25626	response	_	
142-28	25627-25630	and	_	
142-29	25631-25641	functional	_	
142-30	25642-25657	dysconnectivity	_	
142-31	25658-25661	are	_	
142-32	25662-25665	not	_	
142-33	25666-25672	driven	_	
142-34	25673-25675	by	_	
142-35	25676-25687	alterations	_	
142-36	25688-25690	in	_	
142-37	25691-25702	myelination	_	
142-38	25702-25703	.	_	

#Text=Further research could usefully address potential confounds of medication exposure and illness duration by studying these measures in a longitudinal setup in first-episode psychosis.
143-1	25704-25711	Further	_	
143-2	25712-25720	research	_	
143-3	25721-25726	could	_	
143-4	25727-25735	usefully	_	
143-5	25736-25743	address	_	
143-6	25744-25753	potential	_	
143-7	25754-25763	confounds	_	
143-8	25764-25766	of	_	
143-9	25767-25777	medication	_	
143-10	25778-25786	exposure	_	
143-11	25787-25790	and	_	
143-12	25791-25798	illness	_	
143-13	25799-25807	duration	_	
143-14	25808-25810	by	_	
143-15	25811-25819	studying	_	
143-16	25820-25825	these	_	
143-17	25826-25834	measures	_	
143-18	25835-25837	in	_	
143-19	25838-25839	a	_	
143-20	25840-25852	longitudinal	_	
143-21	25853-25858	setup	_	
143-22	25859-25861	in	_	
143-23	25862-25875	first-episode	_	
143-24	25876-25885	psychosis	_	
143-25	25885-25886	.	_	

#Text=References
#Text=Remission in schizophrenia: proposed criteria and rationale for consensus
#Text=The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations
#Text=Treatment-refractory schizophrenia
#Text=A selective review of structural connectivity abnormalities of schizophrenic patients at different stages of the disease
#Text=Global connectivity of prefrontal cortex predicts cognitive control and intelligence
#Text=Management of treatment resistance in schizophrenia
#Text=High central D 2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients
#Text=High-resolution T1 mapping of the brain at 3T with driven equilibrium single pulse observation of T1 with high-speed incorporation of RF field inhomogeneities (DESPOT1-HIFI)
#Text=Transverse relaxation time (T2) mapping in the brain with off-resonance correction using phase-cycled steady-state free precession imaging
#Text=One component?
144-1	25887-25897	References	_	
144-2	25898-25907	Remission	_	
144-3	25908-25910	in	_	
144-4	25911-25924	schizophrenia	_	
144-5	25924-25925	:	_	
144-6	25926-25934	proposed	_	
144-7	25935-25943	criteria	_	
144-8	25944-25947	and	_	
144-9	25948-25957	rationale	_	
144-10	25958-25961	for	_	
144-11	25962-25971	consensus	_	
144-12	25972-25975	The	_	
144-13	25976-25994	moderator-mediator	_	
144-14	25995-26003	variable	_	
144-15	26004-26015	distinction	_	
144-16	26016-26018	in	_	
144-17	26019-26025	social	_	
144-18	26026-26039	psychological	_	
144-19	26040-26048	research	_	
144-20	26048-26049	:	_	
144-21	26050-26060	conceptual	_	
144-22	26060-26061	,	_	
144-23	26062-26071	strategic	_	
144-24	26071-26072	,	_	
144-25	26073-26076	and	_	
144-26	26077-26088	statistical	_	
144-27	26089-26103	considerations	_	
144-28	26104-26124	Treatment-refractory	_	
144-29	26125-26138	schizophrenia	_	
144-30	26139-26140	A	_	
144-31	26141-26150	selective	_	
144-32	26151-26157	review	_	
144-33	26158-26160	of	_	
144-34	26161-26171	structural	_	
144-35	26172-26184	connectivity	_	
144-36	26185-26198	abnormalities	_	
144-37	26199-26201	of	_	
144-38	26202-26215	schizophrenic	_	
144-39	26216-26224	patients	_	
144-40	26225-26227	at	_	
144-41	26228-26237	different	_	
144-42	26238-26244	stages	_	
144-43	26245-26247	of	_	
144-44	26248-26251	the	_	
144-45	26252-26259	disease	_	
144-46	26260-26266	Global	_	
144-47	26267-26279	connectivity	_	
144-48	26280-26282	of	_	
144-49	26283-26293	prefrontal	_	
144-50	26294-26300	cortex	_	
144-51	26301-26309	predicts	_	
144-52	26310-26319	cognitive	_	
144-53	26320-26327	control	_	
144-54	26328-26331	and	_	
144-55	26332-26344	intelligence	_	
144-56	26345-26355	Management	_	
144-57	26356-26358	of	_	
144-58	26359-26368	treatment	_	
144-59	26369-26379	resistance	_	
144-60	26380-26382	in	_	
144-61	26383-26396	schizophrenia	_	
144-62	26397-26401	High	_	
144-63	26402-26409	central	_	
144-64	26410-26411	D	_	
144-65	26412-26413	2	_	
144-66	26413-26414	-	_	
144-67	26414-26422	dopamine	_	
144-68	26423-26431	receptor	_	
144-69	26432-26441	occupancy	_	
144-70	26442-26444	as	_	
144-71	26445-26453	assessed	_	
144-72	26454-26458	with	_	
144-73	26459-26467	positron	_	
144-74	26468-26476	emission	_	
144-75	26477-26487	tomography	_	
144-76	26488-26490	in	_	
144-77	26491-26500	medicated	_	
144-78	26501-26504	but	_	
144-79	26505-26522	therapy-resistant	_	
144-80	26523-26536	schizophrenic	_	
144-81	26537-26545	patients	_	
144-82	26546-26561	High-resolution	_	
144-83	26562-26564	T1	_	
144-84	26565-26572	mapping	_	
144-85	26573-26575	of	_	
144-86	26576-26579	the	_	
144-87	26580-26585	brain	_	
144-88	26586-26588	at	_	
144-89	26589-26591	3T	_	
144-90	26592-26596	with	_	
144-91	26597-26603	driven	_	
144-92	26604-26615	equilibrium	_	
144-93	26616-26622	single	_	
144-94	26623-26628	pulse	_	
144-95	26629-26640	observation	_	
144-96	26641-26643	of	_	
144-97	26644-26646	T1	_	
144-98	26647-26651	with	_	
144-99	26652-26662	high-speed	_	
144-100	26663-26676	incorporation	_	
144-101	26677-26679	of	_	
144-102	26680-26682	RF	_	
144-103	26683-26688	field	_	
144-104	26689-26704	inhomogeneities	_	
144-105	26705-26706	(	_	
144-106	26706-26713	DESPOT1	_	
144-107	26713-26714	-	_	
144-108	26714-26718	HIFI	_	
144-109	26718-26719	)	_	
144-110	26720-26730	Transverse	_	
144-111	26731-26741	relaxation	_	
144-112	26742-26746	time	_	
144-113	26747-26748	(	_	
144-114	26748-26750	T2	_	
144-115	26750-26751	)	_	
144-116	26752-26759	mapping	_	
144-117	26760-26762	in	_	
144-118	26763-26766	the	_	
144-119	26767-26772	brain	_	
144-120	26773-26777	with	_	
144-121	26778-26791	off-resonance	_	
144-122	26792-26802	correction	_	
144-123	26803-26808	using	_	
144-124	26809-26821	phase-cycled	_	
144-125	26822-26834	steady-state	_	
144-126	26835-26839	free	_	
144-127	26840-26850	precession	_	
144-128	26851-26858	imaging	_	
144-129	26859-26862	One	_	
144-130	26863-26872	component	_	
144-131	26872-26873	?	_	

#Text=Two components?
145-1	26874-26877	Two	_	
145-2	26878-26888	components	_	
145-3	26888-26889	?	_	

#Text=Three?
146-1	26890-26895	Three	_	
146-2	26895-26896	?	_	

#Text=The effect of including a nonexchanging “free” water component in multicomponent driven equilibrium single pulse observation of T1 and T2
#Text=Gleaning multicomponent T1 and T2 information from steady-state imaging data
#Text=Improving prefrontal cortex function in schizophrenia through focused training of cognitive control
#Text=Review of functional and anatomical brain connectivity findings in schizophrenia
#Text=General and specific functional connectivity disturbances in first-episode schizophrenia during cognitive control performance
#Text=The dysconnection hypothesis (2016)
#Text=Schizophrenia: a disconnection syndrome
#Text=Compromised myelin integrity during psychosis with repair during remission in drug-responding schizophrenia
#Text=
#Text=Altered interhemispheric and temporal lobe white matter microstructural organization in severe chronic schizophrenia
#Text=Strengthening of top-down frontal cognitive control networks underlying the development of inhibitory control: a functional magnetic resonance imaging effective connectivity study
#Text=The positive and negative syndrome scale (PANSS) for schizophrenia
#Text=White matter disruptions in schizophrenia are spatially widespread and topologically converge on brain network hubs
#Text=Evidence for white matter abnormalities in schizophrenia
#Text=A review of diffusion tensor imaging studies in schizophrenia
#Text=Myelin water imaging in multiple sclerosis: quantitative correlations with histopathology
#Text=Treatment refractory schizophrenia
#Text=Changes in cerebellar functional connectivity and anatomical connectivity in schizophrenia: a combined resting-state functional MRI and diffusion tensor imaging study
#Text=Is diffusion anisotropy an accurate monitor of myelination?
147-1	26897-26900	The	_	
147-2	26901-26907	effect	_	
147-3	26908-26910	of	_	
147-4	26911-26920	including	_	
147-5	26921-26922	a	_	
147-6	26923-26936	nonexchanging	_	
147-7	26937-26938	“	_	
147-8	26938-26942	free	_	
147-9	26942-26943	”	_	
147-10	26944-26949	water	_	
147-11	26950-26959	component	_	
147-12	26960-26962	in	_	
147-13	26963-26977	multicomponent	_	
147-14	26978-26984	driven	_	
147-15	26985-26996	equilibrium	_	
147-16	26997-27003	single	_	
147-17	27004-27009	pulse	_	
147-18	27010-27021	observation	_	
147-19	27022-27024	of	_	
147-20	27025-27027	T1	_	
147-21	27028-27031	and	_	
147-22	27032-27034	T2	_	
147-23	27035-27043	Gleaning	_	
147-24	27044-27058	multicomponent	_	
147-25	27059-27061	T1	_	
147-26	27062-27065	and	_	
147-27	27066-27068	T2	_	
147-28	27069-27080	information	_	
147-29	27081-27085	from	_	
147-30	27086-27098	steady-state	_	
147-31	27099-27106	imaging	_	
147-32	27107-27111	data	_	
147-33	27112-27121	Improving	_	
147-34	27122-27132	prefrontal	_	
147-35	27133-27139	cortex	_	
147-36	27140-27148	function	_	
147-37	27149-27151	in	_	
147-38	27152-27165	schizophrenia	_	
147-39	27166-27173	through	_	
147-40	27174-27181	focused	_	
147-41	27182-27190	training	_	
147-42	27191-27193	of	_	
147-43	27194-27203	cognitive	_	
147-44	27204-27211	control	_	
147-45	27212-27218	Review	_	
147-46	27219-27221	of	_	
147-47	27222-27232	functional	_	
147-48	27233-27236	and	_	
147-49	27237-27247	anatomical	_	
147-50	27248-27253	brain	_	
147-51	27254-27266	connectivity	_	
147-52	27267-27275	findings	_	
147-53	27276-27278	in	_	
147-54	27279-27292	schizophrenia	_	
147-55	27293-27300	General	_	
147-56	27301-27304	and	_	
147-57	27305-27313	specific	_	
147-58	27314-27324	functional	_	
147-59	27325-27337	connectivity	_	
147-60	27338-27350	disturbances	_	
147-61	27351-27353	in	_	
147-62	27354-27367	first-episode	_	
147-63	27368-27381	schizophrenia	_	
147-64	27382-27388	during	_	
147-65	27389-27398	cognitive	_	
147-66	27399-27406	control	_	
147-67	27407-27418	performance	_	
147-68	27419-27422	The	_	
147-69	27423-27436	dysconnection	_	
147-70	27437-27447	hypothesis	_	
147-71	27448-27449	(	_	
147-72	27449-27453	2016	_	
147-73	27453-27454	)	_	
147-74	27455-27468	Schizophrenia	_	
147-75	27468-27469	:	_	
147-76	27470-27471	a	_	
147-77	27472-27485	disconnection	_	
147-78	27486-27494	syndrome	_	
147-79	27495-27506	Compromised	_	
147-80	27507-27513	myelin	_	
147-81	27514-27523	integrity	_	
147-82	27524-27530	during	_	
147-83	27531-27540	psychosis	_	
147-84	27541-27545	with	_	
147-85	27546-27552	repair	_	
147-86	27553-27559	during	_	
147-87	27560-27569	remission	_	
147-88	27570-27572	in	_	
147-89	27573-27588	drug-responding	_	
147-90	27589-27602	schizophrenia	_	
147-91	27604-27611	Altered	_	
147-92	27612-27628	interhemispheric	_	
147-93	27629-27632	and	_	
147-94	27633-27641	temporal	_	
147-95	27642-27646	lobe	_	
147-96	27647-27652	white	_	
147-97	27653-27659	matter	_	
147-98	27660-27675	microstructural	_	
147-99	27676-27688	organization	_	
147-100	27689-27691	in	_	
147-101	27692-27698	severe	_	
147-102	27699-27706	chronic	_	
147-103	27707-27720	schizophrenia	_	
147-104	27721-27734	Strengthening	_	
147-105	27735-27737	of	_	
147-106	27738-27746	top-down	_	
147-107	27747-27754	frontal	_	
147-108	27755-27764	cognitive	_	
147-109	27765-27772	control	_	
147-110	27773-27781	networks	_	
147-111	27782-27792	underlying	_	
147-112	27793-27796	the	_	
147-113	27797-27808	development	_	
147-114	27809-27811	of	_	
147-115	27812-27822	inhibitory	_	
147-116	27823-27830	control	_	
147-117	27830-27831	:	_	
147-118	27832-27833	a	_	
147-119	27834-27844	functional	_	
147-120	27845-27853	magnetic	_	
147-121	27854-27863	resonance	_	
147-122	27864-27871	imaging	_	
147-123	27872-27881	effective	_	
147-124	27882-27894	connectivity	_	
147-125	27895-27900	study	_	
147-126	27901-27904	The	_	
147-127	27905-27913	positive	_	
147-128	27914-27917	and	_	
147-129	27918-27926	negative	_	
147-130	27927-27935	syndrome	_	
147-131	27936-27941	scale	_	
147-132	27942-27943	(	_	
147-133	27943-27948	PANSS	_	
147-134	27948-27949	)	_	
147-135	27950-27953	for	_	
147-136	27954-27967	schizophrenia	_	
147-137	27968-27973	White	_	
147-138	27974-27980	matter	_	
147-139	27981-27992	disruptions	_	
147-140	27993-27995	in	_	
147-141	27996-28009	schizophrenia	_	
147-142	28010-28013	are	_	
147-143	28014-28023	spatially	_	
147-144	28024-28034	widespread	_	
147-145	28035-28038	and	_	
147-146	28039-28052	topologically	_	
147-147	28053-28061	converge	_	
147-148	28062-28064	on	_	
147-149	28065-28070	brain	_	
147-150	28071-28078	network	_	
147-151	28079-28083	hubs	_	
147-152	28084-28092	Evidence	_	
147-153	28093-28096	for	_	
147-154	28097-28102	white	_	
147-155	28103-28109	matter	_	
147-156	28110-28123	abnormalities	_	
147-157	28124-28126	in	_	
147-158	28127-28140	schizophrenia	_	
147-159	28141-28142	A	_	
147-160	28143-28149	review	_	
147-161	28150-28152	of	_	
147-162	28153-28162	diffusion	_	
147-163	28163-28169	tensor	_	
147-164	28170-28177	imaging	_	
147-165	28178-28185	studies	_	
147-166	28186-28188	in	_	
147-167	28189-28202	schizophrenia	_	
147-168	28203-28209	Myelin	_	
147-169	28210-28215	water	_	
147-170	28216-28223	imaging	_	
147-171	28224-28226	in	_	
147-172	28227-28235	multiple	_	
147-173	28236-28245	sclerosis	_	
147-174	28245-28246	:	_	
147-175	28247-28259	quantitative	_	
147-176	28260-28272	correlations	_	
147-177	28273-28277	with	_	
147-178	28278-28292	histopathology	_	
147-179	28293-28302	Treatment	_	
147-180	28303-28313	refractory	_	
147-181	28314-28327	schizophrenia	_	
147-182	28328-28335	Changes	_	
147-183	28336-28338	in	_	
147-184	28339-28349	cerebellar	_	
147-185	28350-28360	functional	_	
147-186	28361-28373	connectivity	_	
147-187	28374-28377	and	_	
147-188	28378-28388	anatomical	_	
147-189	28389-28401	connectivity	_	
147-190	28402-28404	in	_	
147-191	28405-28418	schizophrenia	_	
147-192	28418-28419	:	_	
147-193	28420-28421	a	_	
147-194	28422-28430	combined	_	
147-195	28431-28444	resting-state	_	
147-196	28445-28455	functional	_	
147-197	28456-28459	MRI	_	
147-198	28460-28463	and	_	
147-199	28464-28473	diffusion	_	
147-200	28474-28480	tensor	_	
147-201	28481-28488	imaging	_	
147-202	28489-28494	study	_	
147-203	28495-28497	Is	_	
147-204	28498-28507	diffusion	_	
147-205	28508-28518	anisotropy	_	
147-206	28519-28521	an	_	
147-207	28522-28530	accurate	_	
147-208	28531-28538	monitor	_	
147-209	28539-28541	of	_	
147-210	28542-28553	myelination	_	
147-211	28553-28554	?	_	

#Text=: correlation of multicomponent T2 relaxation and diffusion tensor anisotropy in human brain
#Text=Investigation of anatomical thalamo-cortical connectivity and FMRI activation in schizophrenia
#Text=Clozapine for treatment-resistant schizophrenia: national institute of clinical excellence (NICE) guidance in the real world
#Text=Brain-imaging studies of treatment-resistant schizophrenia: a systematic review
#Text=Dysconnectivity in schizophrenia: where are we now?
148-1	28554-28555	:	_	
148-2	28556-28567	correlation	_	
148-3	28568-28570	of	_	
148-4	28571-28585	multicomponent	_	
148-5	28586-28588	T2	_	
148-6	28589-28599	relaxation	_	
148-7	28600-28603	and	_	
148-8	28604-28613	diffusion	_	
148-9	28614-28620	tensor	_	
148-10	28621-28631	anisotropy	_	
148-11	28632-28634	in	_	
148-12	28635-28640	human	_	
148-13	28641-28646	brain	_	
148-14	28647-28660	Investigation	_	
148-15	28661-28663	of	_	
148-16	28664-28674	anatomical	_	
148-17	28675-28691	thalamo-cortical	_	
148-18	28692-28704	connectivity	_	
148-19	28705-28708	and	_	
148-20	28709-28713	FMRI	_	
148-21	28714-28724	activation	_	
148-22	28725-28727	in	_	
148-23	28728-28741	schizophrenia	_	
148-24	28742-28751	Clozapine	_	
148-25	28752-28755	for	_	
148-26	28756-28775	treatment-resistant	_	
148-27	28776-28789	schizophrenia	_	
148-28	28789-28790	:	_	
148-29	28791-28799	national	_	
148-30	28800-28809	institute	_	
148-31	28810-28812	of	_	
148-32	28813-28821	clinical	_	
148-33	28822-28832	excellence	_	
148-34	28833-28834	(	_	
148-35	28834-28838	NICE	_	
148-36	28838-28839	)	_	
148-37	28840-28848	guidance	_	
148-38	28849-28851	in	_	
148-39	28852-28855	the	_	
148-40	28856-28860	real	_	
148-41	28861-28866	world	_	
148-42	28867-28880	Brain-imaging	_	
148-43	28881-28888	studies	_	
148-44	28889-28891	of	_	
148-45	28892-28911	treatment-resistant	_	
148-46	28912-28925	schizophrenia	_	
148-47	28925-28926	:	_	
148-48	28927-28928	a	_	
148-49	28929-28939	systematic	_	
148-50	28940-28946	review	_	
148-51	28947-28962	Dysconnectivity	_	
148-52	28963-28965	in	_	
148-53	28966-28979	schizophrenia	_	
148-54	28979-28980	:	_	
148-55	28981-28986	where	_	
148-56	28987-28990	are	_	
148-57	28991-28993	we	_	
148-58	28994-28997	now	_	
148-59	28997-28998	?	_	

#Text=SPSS and SAS procedures for estimating indirect effects in simple mediation models
#Text=White matter alterations in early stages of schizophrenia: a systematic review of diffusion tensor imaging studies
#Text=Baseline striatal functional connectivity as a predictor of response to antipsychotic drug treatment
#Text=Are power calculations useful?
149-1	28999-29003	SPSS	_	
149-2	29004-29007	and	_	
149-3	29008-29011	SAS	_	
149-4	29012-29022	procedures	_	
149-5	29023-29026	for	_	
149-6	29027-29037	estimating	_	
149-7	29038-29046	indirect	_	
149-8	29047-29054	effects	_	
149-9	29055-29057	in	_	
149-10	29058-29064	simple	_	
149-11	29065-29074	mediation	_	
149-12	29075-29081	models	_	
149-13	29082-29087	White	_	
149-14	29088-29094	matter	_	
149-15	29095-29106	alterations	_	
149-16	29107-29109	in	_	
149-17	29110-29115	early	_	
149-18	29116-29122	stages	_	
149-19	29123-29125	of	_	
149-20	29126-29139	schizophrenia	_	
149-21	29139-29140	:	_	
149-22	29141-29142	a	_	
149-23	29143-29153	systematic	_	
149-24	29154-29160	review	_	
149-25	29161-29163	of	_	
149-26	29164-29173	diffusion	_	
149-27	29174-29180	tensor	_	
149-28	29181-29188	imaging	_	
149-29	29189-29196	studies	_	
149-30	29197-29205	Baseline	_	
149-31	29206-29214	striatal	_	
149-32	29215-29225	functional	_	
149-33	29226-29238	connectivity	_	
149-34	29239-29241	as	_	
149-35	29242-29243	a	_	
149-36	29244-29253	predictor	_	
149-37	29254-29256	of	_	
149-38	29257-29265	response	_	
149-39	29266-29268	to	_	
149-40	29269-29282	antipsychotic	_	
149-41	29283-29287	drug	_	
149-42	29288-29297	treatment	_	
149-43	29298-29301	Are	_	
149-44	29302-29307	power	_	
149-45	29308-29320	calculations	_	
149-46	29321-29327	useful	_	
149-47	29327-29328	?	_	

#Text=A multicentre neuroimaging study
#Text=Is the magnetization transfer ratio a marker for myelin in multiple sclerosis?
150-1	29329-29330	A	_	
150-2	29331-29342	multicentre	_	
150-3	29343-29355	neuroimaging	_	
150-4	29356-29361	study	_	
150-5	29362-29364	Is	_	
150-6	29365-29368	the	_	
150-7	29369-29382	magnetization	_	
150-8	29383-29391	transfer	_	
150-9	29392-29397	ratio	_	
150-10	29398-29399	a	_	
150-11	29400-29406	marker	_	
150-12	29407-29410	for	_	
150-13	29411-29417	myelin	_	
150-14	29418-29420	in	_	
150-15	29421-29429	multiple	_	
150-16	29430-29439	sclerosis	_	
150-17	29439-29440	?	_	

#Text=Brain interactions in chronic schizophrenics under resting and activation conditions
#Text=Is multicomponent T2 a good measure of myelin content in peripheral nerve?
151-1	29441-29446	Brain	_	
151-2	29447-29459	interactions	_	
151-3	29460-29462	in	_	
151-4	29463-29470	chronic	_	
151-5	29471-29485	schizophrenics	_	
151-6	29486-29491	under	_	
151-7	29492-29499	resting	_	
151-8	29500-29503	and	_	
151-9	29504-29514	activation	_	
151-10	29515-29525	conditions	_	
151-11	29526-29528	Is	_	
151-12	29529-29543	multicomponent	_	
151-13	29544-29546	T2	_	
151-14	29547-29548	a	_	
151-15	29549-29553	good	_	
151-16	29554-29561	measure	_	
151-17	29562-29564	of	_	
151-18	29565-29571	myelin	_	
151-19	29572-29579	content	_	
151-20	29580-29582	in	_	
151-21	29583-29593	peripheral	_	
151-22	29594-29599	nerve	_	
151-23	29599-29600	?	_	

#Text=Impaired cognitive inhibition in schizophrenia: a meta-analysis of the Stroop interference effect
#Text=A review of structural neuroimaging in schizophrenia: from connectivity to connectomics
#Text=Dysfunctional striatal systems in treatment-resistant schizophrenia
#Text=Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia
#Text=
#Text=Methodological considerations regarding the association of Stroop and verbal fluency performance with the symptoms of schizophrenia
152-1	29601-29609	Impaired	_	
152-2	29610-29619	cognitive	_	
152-3	29620-29630	inhibition	_	
152-4	29631-29633	in	_	
152-5	29634-29647	schizophrenia	_	
152-6	29647-29648	:	_	
152-7	29649-29650	a	_	
152-8	29651-29664	meta-analysis	_	
152-9	29665-29667	of	_	
152-10	29668-29671	the	_	
152-11	29672-29678	Stroop	_	
152-12	29679-29691	interference	_	
152-13	29692-29698	effect	_	
152-14	29699-29700	A	_	
152-15	29701-29707	review	_	
152-16	29708-29710	of	_	
152-17	29711-29721	structural	_	
152-18	29722-29734	neuroimaging	_	
152-19	29735-29737	in	_	
152-20	29738-29751	schizophrenia	_	
152-21	29751-29752	:	_	
152-22	29753-29757	from	_	
152-23	29758-29770	connectivity	_	
152-24	29771-29773	to	_	
152-25	29774-29786	connectomics	_	
152-26	29787-29800	Dysfunctional	_	
152-27	29801-29809	striatal	_	
152-28	29810-29817	systems	_	
152-29	29818-29820	in	_	
152-30	29821-29840	treatment-resistant	_	
152-31	29841-29854	schizophrenia	_	
152-32	29855-29863	Dopamine	_	
152-33	29864-29872	blockade	_	
152-34	29873-29876	and	_	
152-35	29877-29885	clinical	_	
152-36	29886-29894	response	_	
152-37	29894-29895	:	_	
152-38	29896-29904	evidence	_	
152-39	29905-29908	for	_	
152-40	29909-29912	two	_	
152-41	29913-29923	biological	_	
152-42	29924-29933	subgroups	_	
152-43	29934-29936	of	_	
152-44	29937-29950	schizophrenia	_	
152-45	29952-29966	Methodological	_	
152-46	29967-29981	considerations	_	
152-47	29982-29991	regarding	_	
152-48	29992-29995	the	_	
152-49	29996-30007	association	_	
152-50	30008-30010	of	_	
152-51	30011-30017	Stroop	_	
152-52	30018-30021	and	_	
152-53	30022-30028	verbal	_	
152-54	30029-30036	fluency	_	
152-55	30037-30048	performance	_	
152-56	30049-30053	with	_	
152-57	30054-30057	the	_	
152-58	30058-30066	symptoms	_	
152-59	30067-30069	of	_	
152-60	30070-30083	schizophrenia	_	
